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Abstract 
Progressive loss of vascular reactivity and increased vascular tone with age are being increasingly 
recognised as significant cardiovascular disease (CVD) risk factors. The vasculature has emerged as a 
target for dietary strategies to modify these progressions. Our previous data suggest that inclusion of 
fish oil in a high-fat test meal improves postprandial vascular reactivity in healthy men. The primary 
aim of this project was to determine the individual effects of the fish oil fatty acids, eicosapentaenoic 
acid (EPA) versus docosahexaenoic acid (DHA) on post-prandial vascular reactivity and to identify 
underlying molecular mechanisms of these effects. 
In this study, the acute effects of a single dose (4.16g) of EPA, DHA and placebo oil on postprandial 
vascular reactivity were determined in men categorised as being at a 1.5 relative risk of CVD in a 
double-blind randomised crossover trial. Measures of vascular tone and function, alongside an 
endothelium dependent measure of vascular reactivity, were taken along with blood samples, at 
baseline and at 4 hours in order to coincide with the anticipated peak plasma concentration of these 
fatty acids. These blood samples were utilised for assessment of biomarkers associated with changes 
in vascular tone and postprandial whole blood culture (WBC). WBC was conducted to investigate the 
effect of changes in the postprandial lipidome, dependent on EPA and DHA consumption, on cytokine 
production. Response to intervention according to genotype was also determined retrospectively.  
We observed that DHA (p=0.04) but not EPA (p=0.06) significantly reduced Augmentation Index (AI) 
postprandially when compared to control. AI was reduced by 13.3% and 11.3% in response to DHA 
and EPA respectively. In addition, our data shows for the first time, that levels of the vasoactive n-3 
PUFA epoxide and diol metabolites are subject to large changes post consumption of physiological 
levels of EPA and DHA. Our data also suggests there is wide inter-individual variability in circulating 
levels of these compounds, which may in part explain inter-individual responsiveness to EPA and DHA. 
We were not able to observe changes in plasma nitrite or H2S levels postprandially, suggesting that 
EPA and DHA dependent changes in vascular tone may be mediated in part by their vasoactive epoxide 
and diol metabolites. However, whole Blood Culture experiments did not show a significant effect on 
any of the cytokines or growth factors investigated, before or after correction for BMI and AGE. Finally, 
our investigations of response to treatment by genotype suggested a novel interaction between the 
PPAR-ƴ rs1801282 polymorphism, DHA consumption and improvements in postprandial 
triglyceridemia. 
The findings of this thesis emphasise the differential effects of EPA and DHA in the vasculature and 
the inter-individual responsiveness to these nutrients. 
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Chapter 1: Literature Review 
1.1. Cardiovascular disease (CVD) mortality and underlying pathology 
Cardiovascular disease (CVD) remains the main cause of morbidity in the UK; in addition to this it 
claims an estimated 17.1 million lives a year worldwide (1). A central tenet of CVD is the presence of 
atherosclerotic plaque. Atherosclerosis (the process that leads to the build-up of these plaques) is 
characterised by arterial wall thickening as a result of cholesterol and other lipid build up. This process 
eventually leads to the formation of atherosclerotic atheromas - abscess like deposits of lipids, 
macrophages, calcium and fibrous connective tissue (see Figure 1.2) (2). Rupturing of the fibrous 
connective tissue, which forms a barrier between the atheroma and the blood in the artery, can induce 
a rapid platelet and clotting response. Critically, this response can cause a narrowing or occlusion of 
arteries, which may cause a loss of blood flow to organs downstream of this occlusion. This clotting 
response to rupturing of an atheroma underlies the pathology of stroke, heart attack and other related 
cardiovascular complications. 
The initial events which occur in the development of atheroma are monocyte recruitment and 
migration into the sub-endothelial space which is mediated by a number of adhesion molecules 
expressed on the surface of vascular endothelial cells. The next step is the development of fatty 
streaks. The development of these fatty streaks is a critical stage in the progression towards the 
formation of atheroma and is dependent on differentiation of monocytes to macrophages which 
“ingest” low density lipoprotein cholesterol (LDL-C) and form the foam cells. The accumulation of foam 
cells in an artery leads to the formation of these fatty streaks. The final progression towards an 
atheroma is the formation of a fibrous cap. This fibrous cap is made up of collagen, which has its 
deposition mediated by the migration of vascular smooth muscle cells towards the intima of the 
artery, and extracellular matrix proteins. These processes are detailed below in Figure 1.1. 
 
Figure 1.1 Diagrammatic representation of atherosclerosis. (Adapted from Ross 1999 (2)). 
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1.2. Vascular function and its impact on CVD pathogenesis 
 
The highest level of evidence for linking modifiable elements of diet with reduced incidences of CVD 
events are long term randomised control trials which look at hard endpoints, such as incidences or 
mortality from CVD, such as myocardial infarction or stroke, or death from CVD. However, long term 
investigations which measure end points such as cardiovascular events and CVD mortality necessitate 
investigations of prohibitively long time spans with large numbers of participants. Accordingly, it is 
increasingly common for investigators to utilise surrogate markers that are associated with changes 
in risk. These measures typically measure early events associated with changes in blood vessel 
physiology (3), such as vascular and endothelial function. Vascular function can be broadly defined as 
a capacity of blood vessels to adequately modify and control blood supply to organs and tissue as 
according to local demand. Dysfunction of the vasculature can be mediated through structural 
changes or earlier functional changes to blood vessels, which can include changes to the endothelial 
cell layer which line blood vessels. Alterations in vascular tone, or the degree of constriction of a blood 
vessel, is one of these early changes; the impact of which is increased vascular resistance to blood 
flow. These changes are increasingly recognised as a significant early stage CVD risk factor and highly 
predictive of future CVD events.  Endothelial dysfunction, which will be discussed in more detail later 
in this review, is also known as a key early step in the manifestation of overt aspects of CVD. 
 
There are a number of validated and clinically accepted measures of vascular and endothelial 
dependent vascular function and vascular tone currently available to researchers. Examples of such, 
which will be utilised in the clinical trial undertaken as part of this project, are Pulse Wave Analysis, 
Pulse Wave Velocity (PWV) and Endopat, which are used to assess vascular compliance, arterial 
stiffness and endothelial function respectively. Another key methodology utilised in this context is 
flow mediated dilation (FMD). Flow mediated dilation is considered the gold standard of endothelium 
function (4), which is typically measured by imaging of the brachial artery, before and after a 5 minute 
occlusion, with ultrasound technology. This allows the user to establish an index which is indicative of 
this conduit artery’s capacity to dilate in response to hyperaemia. FMD is noted as being prone to poor 
reproducibility unless strict guidelines are followed (5), and requires a skilled and trained user in order 
to guarantee rigorous, reliable and reproducible results. Due to this consideration, use of FMD was 
beyond the scope of this PhD, due to the length of time required to establish the technique and train 
users on the proper use this methodology. 
Endopat is a measure of endothelial function (see section 2.7.3.3) which has been shown to correlate 
with multiple known CVD risk factors, including obesity, diabetes mellitus and ratio of total to high 
 17 | P a g e  
 
density lipoprotein cholesterol (HDL-C) (6). Endopat Reactive Hyperaemic Index (RHI) measurement is 
obtained by measuring the increase in blood flow in response to the stimulus of shear stress. This 
shear stress is caused by occlusion of the brachial artery, subsequent release of the occlusion causes 
a sudden increase in blood flow to the finger tips. The amount of hyperaemia in response to this 
stimulus is indicative of the capacity of the endothelium to produce vasodilatory substances.  Endopat 
has also been shown to be predictive of cardiac death, myocardial infarction, revascularization or 
cardiac hospitalization (7). Specifically, individuals with ln(RHI)<0.4 (or RHI<1.04) had a 7 year rate of 
48% for incidences of cardiac death, myocardial infarction, revascularization or cardiac hospitalization 
compared to 28% for individuals with ln(RHI)>0.4. 
PWV is the measurement of time taken for a pulse wave to travel from one anatomical site to another, 
the current “gold standard” considered to be the carotid and femoral sites. PWV progressively 
worsens with age, with unwanted increases in PWV reflective of the progression of arterial stiffness. 
The progression of arterial stiffness typically occurs due to elastic fibres fraying due to continual 
mechanical stress and alongside other changes to the structure of blood vessels, with chronic 
modifications to endothelium produced vasodilatory compounds likely having an impact on this 
process. A meta-analysis has shown PWV to be an independent predictor of CVD risk (8), with each 
1m/s increase in PWV correlating with a 15% increase in risk of each of total CV events, CV mortality, 
and all-cause mortality. The Vicorder equipment utilised to undertake PWV measurements also allows 
several other non-invasive measurements to be taken simultaneously including augmentation index 
(AI), an indirect measure of the enhancement of central aortic pressure by reflected pulse waves. The 
Augmentation index measurement is likely to be affected by alterations of vascular smooth muscle 
tone in peripheral muscular arteries. AI has also been shown to be associated with increased European 
Society of Cardiology (ESC) risk levels (9). Based on the results of this study by Nurnerberger et al, a 
4% increase in AI would correlate to an equivalent 1% increase in CVD risk as per the ESC risk levels. 
Critically, AI has also been shown to be modified acutely upon administration of vasodilatory 
compounds, such as nitro-glycerine, and vasoconstrictory agents, such as angiotensin II (10).  
Also of consideration, is the measurement of blood pressure, which is associated with increased 
vascular tone and systematic vascular resistance and is the most widely utilised and most widely 
recognised predictor of CVD among these measures. Vascular tone alone is not the only determinant 
of blood pressure. Blood pressure is also dependent on the physiology of conduit arteries, peripheral 
arteries and the heart itself, heart rate, strength of ventricular contractions and many other factors.  
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1.3. Inflammation in CVD 
It is known that the innate inflammatory response plays a critical role in the pathogenesis of CVD (11). 
As mentioned in section 1.1, monocytes and macrophages play a key role in the pathogenesis of 
atherosclerotic plaque. A key consideration here is the infiltration of monocytes into the sub-
endothelial space by recruitment through adhesion molecule expression on endothelial cells. 
Subsequently, the accumulation of monocytes and differentiation to macrophages leads to the 
formation of foam cells, which play a central role in the formation of fatty streaks in the vasculature. 
The production of inflammatory cytokines is central to initiating, and perpetuating, the sequence of 
events that leads to the eventual formation of these fatty streaks. A key effector protein in this process 
is the redox sensitive transcription factor nuclear factor-κB (NFκB). NFκB is expressed and active in 
most cell types. In this context its activation in the endothelium is important due to its role in 
upregulating the expression of adhesion molecules, such as intercellular adhesion molecule-1 (ICAM1) 
and vascular cell adhesion molecule-1 (VCAM), which leads to the recruitment of monocytes to the 
site of expression. 
This NFκB initiated recruitment of monocytes plays a key role in the development of fatty streaks and 
ultimately, atherosclerotic plaques. Subsequently, the accumulation of monocytes and differentiation 
to macrophages leads to the formation of foam cells, which accumulate to form fatty streaks in the 
vasculature. These monocytes and macrophages contribute to local production of pro-inflammatory 
cytokines such as IL-4, IL-6, IL-8 and TNF-α which propagate the inflammatory response and in turn 
lead to recruitment of more monocytes. Dysregulation of production of IL-10, an anti-inflammatory 
cytokine, by monocytes is also an important consideration in this context and can lead to increases in 
NFκB activity (12). It is also worth considering that cytokine concentrations in the systemic circulation, 
are also likely to play a role and increased plasma concentrations can be indicative of CVD risk (13).  
Ultimately, the activation of the innate immunity response through NFκB and production of pro-
inflammatory cytokines is meant to act as an important response to cellular injury; however, in the 
context of CVD this process can become dysregulated and lead to collateral damage in the vasculature. 
This damage can manifest itself as stiffened arteries, which is a product of both mechanical fatigue 
and overexpression of matrix metalloproteinases (MMPs). These MMPs are induced as part of the 
above described cellular injury response by monocytic production of factors such as vascular 
endothelial growth factor (VEGF) (14). As mentioned previously, increased monocytic recruitment and 
the formation of fatty streaks are also a manifestation of dysregulation of the immune response and 
this plays a central role in the development of atherosclerosis.  
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1.4. An introduction to the fish-oil long chain n-3 polyunsaturated fatty 
acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) are n-3 polyunsaturated fatty acids 
(commonly referred to as omega-3 fatty acids), typified by the presence of a double carbon-carbon 
bond at the third carbon from the methyl-end of their carbon chains (or at positions 18 and 20 
respectively, as per IUPAC nomenclature, see figure 1.4). As can be seen in Figure 1.3, both are 
carboxylic acids which differ in chain length (DHA possesses a 22 carbon chain and EPA a 20 carbon 
chain), by the number of cis-double bonds (6 in DHA and 5 in EPA) and the positioning of these cis-
double bonds. The most common dietary source of these fatty acids are cold water oily fish, such as 
salmon, kipper, trout, mackerel, anchovies and sardines which have high concentrations of EPA and 
DHA in their tissues due to the algae and plankton which these fish consume. Consumption of these 
fish typically provides 1.5-3.0g of EPA and DHA per portion (15). In contrast, white fish such as cod and 
halibut, primarily store EPA and DHA in the liver, which is used to provide EPA and DHA rich cod and 
halibut liver oil.  
 
 
 
Figure 1.4. Above – EPA (eicosa-5,8,11,14,17-pentenoic acid) and below - DHA (docosa-4,7,10,13,16,19-hexa-enoic acid). 
In human metabolism, DHA can be synthesised from EPA with docosapentaenoic acid (DPA) as an 
intermediate. Synthesis via DPA occurs via an initial chain elongation to 24:5n-3 acid, which is in turn 
desaturated at position 6 to yield a 24:6n-3 acid. The chain of this 24:6n-3 acid is then shortened via 
beta-oxidation to yield DHA (16, 17). EPA can also be synthesised in human metabolism via α-linolenic 
acid. However, it has been shown that the pathways capable of converting other fatty acids (namely 
α-linolenic acid) to EPA and DHA are non-efficient (18-20) (see Figure 1.4.1 for a diagrammatic 
depiction of EPA and DHA synthesis). Accordingly, it is known that improvement in EPA and DHA status 
is best achieved through increased intakes.   
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Figure 1.4.1. Pathway for human EPA and DHA synthesis. 
Currently, the recommended level of EPA and DHA in the United Kingdom is a minimum of 450 mg per 
day (21), a recommendation which is largely based on the cardio-protective actions of EPA and DHA 
as detailed in section 1.5. The equivalent of 450mg per day of EPA and DHA can be achieved by 
consuming one portion of oily fish per week. EPA and DHA intake in adults of 19-64 years of age in the 
United Kingdom is estimated as 244mg per day, about 50% of the recommended intake (21). It is 
worth noting that this average intake is highly skewed with skewed with approximately 70% of the 
population being non-oily fish consumers, with intakes <50mg per day (22, 23). 
 21 | P a g e  
 
1.5. Impact of fish oil fatty acids on CVD risk and incidence 
 
The development of cardiovascular disease is a complex and dynamic process which is affected by a 
large number of potentially modifiable variables. Diet (24, 25) and in particular, the lipid composition 
of diet, has long been understood to be a modifiable aspect of CVD pathogenesis (25). It has been 
known for over 40 years that increased intakes of fish derived long chain n-3 fatty polyunsaturated 
fatty acids (LC n-3 PUFA) are associated with improved blood lipid profiles and also decreased 
incidences of cardiovascular disease (26). Since these initial observations, the effect of LC n-3 PUFA 
intake on CVD risk has been studied extensively. For instance, a number of large randomised control 
trials have demonstrated these CVD risk reducing effects of EPA and DHA – including the JELIS (27) 
and GISSI (28) trials. The JELIS and GISSI trials recruited 18,645 and 11,324 participants respectively. 
GISSI, a secondary prevention investigating the effects of LC n-3 PUFA (1 g/day) , vitamin E 
(300mg/day), both , or control (no treatment) for 3.5 years showed decrease in risk of cardiovascular 
death by 17% by two-way analysis and 30% by four-way analysis for LC n-3 PUFA. The JELIS trial was a 
primary prevention trial conducted in Japan, which investigated the effects of EPA ethyl esters on 
Japanese hypercholesterolemic participants. In JELIS participants were randomised either to EPA (1.8 
g/day) and statin treatment or statin treatment alone. The results showed reductions of 24% in the 
frequency of unstable anginas. Furthermore, major coronary events were reduced by 19% in the EPA 
treated group relative to the control group. It is important to note that the effects of EPA in this trial 
were evident even with concurrent statin administration and in the Japanese population, who 
habitually consume high amounts of LC n-3 PUFA (estimated as 750 mg/day on average).  
A number of other studies, summarised in pooled meta-analysis, have shown EPA and DHA intake to 
be an important modifiable aspect of diet which influences CVD risk (29-33). For instance, meta-
analysis of randomized controlled trials undertaken in populations with coronary heart disease have 
shown that polyunsaturated n-3 fatty acids (average intake of 3.8g/day) are associated with a 20% 
decreased risk of  myocardial infarction and 30% decreased risk of fatal myocardial infarction. These 
effects were accompanied by an average 20% decrease in blood triglyceride levels (30). Meta-analysis 
has also shown that studies which recruited healthy populations showed an average 37% decrease 
risk of mortality from coronary heart disease (CHD) with an average daily intake of 566 mg/d of EPA 
and DHA (33), indicating that lower doses may also decrease CVD risk. However, it is worth noting that 
there isn’t currently a consensus among clinical trials that have investigated the effect of EPA and DHA 
on CVD outcomes. A recent large scale trial, the Risk and Prevention Study, did not show an effect for 
850mg per day of EPA and DHA over 5 years on CVD morbidity or mortality in a population of 
individuals (n=6250 per group) with multiple CVD risk factors (34). However, it should be noted that 
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due to the rate of stroke and myocardial infarction being lower than expected, this study may have 
been underpowered. On a more general level, the lack of consensus in these studies may be 
attributable to variances in dosage, ratio of EPA and DHA administered, endpoints measured and 
populations investigated. Evidence in the literature suggests that EPA and DHA might be particularly 
efficacious in secondary prevention post MI (27, 28) and possibly that doses of approximately 2g per 
day, or greater than 2g per day, may be required to reduce incidences of CVD events (29, 30). 
It is likely that the positive effects seen in these randomised controlled trials are mediated by the anti-
arrhythmic (35), hypolipidemic (36-39), improved vascular function and blood pressure lowering (40), 
anti-inflammatory and plaque stabilising (41) and cholesterol profile modulating (42, 43) effects of LC 
n-3 PUFA. As previously suggested, there is considerable variation in the LC n-3 PUFA dosage needed 
to exert these effects. For example, LC n-3 PUFA intake as low as 0.5g/day may have potential anti-
arrhythmic effects (44, 45). Whereas studies have shown 4g/day of DHA but not EPA to lower both 
diastolic and systolic blood pressure (SBP) by approximately 5% in hyperlipidemic individuals. Meta-
analysis has shown a median dose of 1.68g/day of DHA to increase HDL-C by an estimated 5% (43). 
Doses in the range of 0.7g to 1.8g/day of EPA and DHA have been shown to lower fasting TAG typically 
by 10-20% (39, 46), but also as large as 50% (39); with evidence suggesting a larger effect for DHA in 
this regard (47). Accordingly, low doses of EPA and DHA (0.5g/day) mediate anti-arrhythmic effects, 
moderate doses (1-2g/day) are known to modulate lipid profiles whereas higher doses (>3/4g/day) of 
EPA or DHA may be needed to modulate vascular function and blood pressure. It should be noted that 
limited studies have been conducted to assess the effects of lower doses in this regard. 
1.6. A role for dietary fat, and EPA and DHA, in the modulation of innate 
inflammatory responses 
A number of factors can contribute to the establishment of a dysregulated inflammatory state in the 
vasculature including exposure to biological and chemical agents, genetic, diet and lifestyle factors. 
Diet in particular is a well-documented modifier of chronic inflammation in the vasculature. It is 
thought that amount and the type of dietary fat plays a role in modifying innate inflammatory status 
(48). For instance, certain common fatty acids, such as palmitic acid and oleic acid, are known to 
activate Toll-like receptor 4 (TLR4) signalling and increase inflammatory cytokine production (49). TLR-
4 plays a fundamental role in innate immunity activation in CVD (see Figure 1.6) (50), and can be 
involved as a trigger for NFκB activation. Accordingly, this mechanism is one, among many, that 
contributes to dietary fat’s capacity to modify inflammatory state in CVD progression. Another 
important consideration in this context, is that DHA and in particular EPA, have been indicated to have 
a positive effect on inflammatory status (51). This is thought to occur through the action of the 
eicosanoid metabolites, which will be discussed in further depth in section 1.9.4 of this review. 
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Figure 1.6. An overview of the interaction between TLR-4, inflammatory cytokine production and dietary saturated and 
monounsaturated fatty acids. 
Examples of EPA, and to some extent DHA’s capacity to modify inflammatory status can be seen in 
studies of monocytic cytokine production. For instance, studies on monocytic cytokine production in 
LPS stimulated whole blood culture (WBC) models have indicated that 8 weeks of fish-oil consumption 
(3.1g per day of EPA and DHA, ratio of EPA:DHA not provided) yield modest reductions in IL-6 (52). In-
vitro studies have indicated that EPA (114µM) rich media modifies TNF-α transcription through 
modification of NFκB activation in a macrophage cell line (53). Similar experiments conducted 
subsequent to this observation have indicated a similar effect when macrophage cultures are exposed 
to EPA and DHA (54). Finally, a 90 day supplementation of 6g/day of DHA in 11 healthy men has been 
shown to decrease IL-1β and TNF-α secretion in peripheral blood mononuclear cells isolated post 
intervention (55). However, the relative effects of EPA and DHA in their capacity to modify monocytic 
cytokine production have not been well described in the literature. Furthermore, the majority of 
experiments in this context have investigated the effects of longer term EPA and DHA 
supplementation (56) and it remains unknown how postprandial alterations in the lipidome may affect 
ex-vivo cytokine production. 
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1.7. EPA and DHA’s effects on vascular and endothelial function  
1.7.1. The impact of EPA and DHA on BP and vascular tone: Evidence from 
human studies. 
A number of studies are suggestive of the LC n-3 PUFA having a capacity to modulate vascular tone, 
both in response to chronic habitual consumption of these fats and in the acute state. Longer term 
studies have shown that over a 6 week intervention period DHA (4g/day) but not EPA reduced 
ambulatory blood pressure and heart rate in 59 mildly hyperlipidemic men  (40) relative to placebo. 
Specifically, the DHA intervention resulted in a significant 4.5% reduction in systolic and diastolic blood 
pressure; this equated to a 5.8/3.3mmHg decrease in systolic and diastolic blood pressure 
respectively. 
Further to this, a 6 week intervention in which hyperlipidemic obese men were randomised to receive 
either 4 g/day of purified EPA, DHA (equivalent to the n-3 fatty acid content of approximately 2 ½ 
servings of oily fish per day) or olive oil showed DHA to be more efficacious in enhancing vasodilator 
mechanisms, as measured via forearm blood flow, relative to placebo (57).  Specifically, these 
investigations showed that DHA supplementation improved vasodilatory responses to acetylcholine 
with L-NNMA and nitroprusside, suggesting that this effect is mediated in an endothelium 
independent manner. DHA supplementation also attenuated vasoconstrictory responses to 
norepinephrine but not to basal blood flow responses to L-NMMA infusion (an eNOS inhibitor). Taken 
together this evidence is suggestive of these vasodilatory effects of DHA being independent of the 
endothelium. 
With regards to current understanding of the post-prandial effects of fish-oil on vascular tone, data 
generated by our research group indicates that inclusion of fish oil (2.16g EPA and 3.24g DHA)  in a 
high-fat test meal improves postprandial endothelium independent vasodilatory responses (by 
approximately 20%) in 25 healthy men (58). The effect for endothelium dependent vasodilatory 
responses did not reach significance in this study. Other studies have suggested that inclusion of 1g of 
EPA and DHA preserves endothelial function in healthy men and women, as measure by FMD, after a 
high fat meal. Other studies on AI responses indicate that inclusion of 2.0g of EPA and 2.7g of DHA in 
a high fat meal (30g of palm oil and soybean oil in a 4:1 ratio in the control meal, with control fat being 
displaced by EPA and DHA in the test meal) improve postprandial measures of AI in healthy males and 
females (59). Finally, a study has also shown improvements in postprandial FMD response to a high 
fat meal containing EPA (2.8g) and DHA (1.2g) in diabetics at risk of CVD complications (60). However, 
these effects were also observed post consumption to a high fat MUFA control meal containing α-
linolenic acid. In short, the evidence in the literature is strongly supportive of an effect for meals 
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containing mixed doses of both EPA and DHA to improve vasodilatory responses in the postprandial 
state; however, it is not clear whether this effect is mediated by endothelium dependent or 
independent mechanisms.  
With regards the individual effects of EPA and DHA in the postprandial state, acute studies which have 
compared the effects of EPA and DHA have shown systemic vascular resistance to be decreased by 5% 
in 22 healthy males in the postprandial state during exercise, but not at rest, when preceded by 4.7g 
of DHA but not EPA (61). Furthermore, a recently published study has investigated the effects of 
inclusion of EPA and DHA (5g in a 4:3 ratio) relative to the effects of inclusion of DHA (5g) only in a 
meal high in MUFA (75g of total fat) in 16 healthy males (62). This study showed no effect for either 
the EPA and DHA meal, or the DHA meal, when compared to control on AI. A trend for greater 
decreases in Digital Volume Pulse Reflective-Index (indicative of changes in vascular tone of peripheral 
resistance arteries) was observed postprandially for the DHA meal; however, these effects did not 
reach significance.  
Accordingly, given the evidence provided from longer term studies and post-prandial studies which 
have investigated the effects of EPA and DHA on cardiovascular hemodynamics during exercise, we 
anticipate that DHA will be more efficacious than EPA in improving postprandial vascular tone. Since 
individuals tend to spend the majority of the day in the post-prandial state (63) and impaired vascular 
tone is intrinsically associated with the accelerated progression of atherosclerosis (64), it is possible 
that the impact of EPA or DHA on the postprandial response may correlate with the effects of these 
fats when habitually consumed. 
In summary, there is a growing body of evidence to suggest an effect for the LC n-3 PUFA in modulating 
vascular tone, and in turn BP. When considering both the chronic and acute data, the balance of the 
literature is suggestive of this effect being mediated in an endothelium independent manner. 
However, there is not a consensus as a number of studies have shown modulations to endothelium 
dependent measures of vascular tone. Furthermore, there remains a paucity of information on the 
individual effects of EPA and DHA on the post-prandial response in the vasculature in particular in 
individuals at risk of CVD. This thesis therefore aims to expand on these findings by comparing the 
effects of consuming a DHA rich meal to an EPA rich meal and control meal on postprandial vascular 
function and tone in a population at an increased risk of CVD. 
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1.7.2. Regulation of endothelial function by NO and H2S 
 
Endothelial dysfunction is a key step in the progression of both macro and microvascular disorders 
such as atherosclerosis, stroke and hypertension (65, 66). Endothelial dysfunction can be broadly 
defined as an imbalance in the production of vasodilatory and vasoconstrictory paracrine signalling 
molecules, however, it can also be characterised by modifications to adhesion molecule expression, 
cytokine release, and ROS production. Two vasodilatory signalling molecules whose productions are 
perturbed in endothelial dysfunction are Nitric Oxide (NO) and the novel vasodilatory signalling 
molecule, Hydrogen Sulfide (H2S). 
NO is a key mediator of vasodilation and insufficient NO production or bioavailability is known to be a 
central tenant of endothelial dysfunction. Further to this, NO also has been shown to exert important 
anti-inflammatory and anti-thrombotic properties (67). NO is released by the endothelium and 
decreased production has been indicated in the pathogenesis of cardiovascular diseases (68, 69). NO 
is produced by Nitric Oxide Synthase (NOS) which catalyses the formation of NO from L-arginine. NO 
then migrates to vascular smooth muscle cells where it acts on soluble guanylyl cyclase, which acts to 
increase the production of cyclic-guanosine monophosphate which in turn activates Protein Kinase G. 
The downstream effect of this is the closing of vascular smooth muscle cell calcium channels causing 
decreases in intra-cellular Ca2+ and accordingly, decreases in smooth muscle contraction (see Fig. 
1.7.2) Production of NO in the endothelium is mostly mediated by NOS III (eNOS), however NOS II 
(inducible-NOS or iNOS, also known as high-output NOS) is also known to contribute to NO production 
in the endothelium. However, increased  iNOS expression and activity, in contrast with that of eNOS, 
can be associated with increased inflammatory states in the vasculature (70). 
It should also be noted that hydrogen sulfide (H2S) has emerged as a novel and important endothelium 
produced vasodilator (71, 72). H2S is produced from L-cysteine by at least four separate enzymes: 
cystathionine-β-synthetase (CBS), cystathionine-γ-lyase (CSE), cysteine aminotransferase (CAT) and 
cysteine lyase (CL). CSE-mediated H2S biosynthesis is known to occur in vascular endothelial cells of 
mice (73) and in human umbilical cord vein endothelial cells (HUVECs) (74). Of these CSE and CBS 
mediated H2S production are understood the best and are thought to be the predominant producers 
of H2S in the vasculature (75). With regards H2S*CVD  interactions, it has been shown that blood levels 
of H2S are lowered in individuals with coronary heart disease, and suggested that lower H2S levels 
reflect increases in disease severity (76). Further to this, plasma H2S levels have been shown to be 
inversely associated with diastolic and systolic blood pressure in men (77). Associations between 
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adiposity  and diabetes, which are known CVD risk factors also supports a role for H2S in the modifying 
the progression of cardiovascular disease.  
H2S modulates vascular tone through stimulation of plasma membrane KATP channels in vascular 
smooth muscle cells. Stimulation of these KATP channels modulates the resting membrane potential of 
cells and this modifies the tendency of these vascular smooth muscle cells to contract, leading to net 
increases in vasorelaxation (78). It is currently unknown whether these effects are mediated directly 
or by derived species that also exist at physiological pH. Species derived from H2S include HS− and S2−. 
It is unlikely S2− mediates any of these effects, as it is primarily present at high and non-physiological 
pH ranges; however it is possible that HS- may mediate some of these effects.  As it is currently 
unknown if the H2S derived species are responsible for the observed bioactivity of H2S, ‘H2S’ is used to 
encompass the sum of H2S derived species present under physiological conditions. 
 
 
Figure 1.7.2. Endothelium-derived nitric oxide synthesis and action (on left), along with endothelial derived H2S synthesis 
(middle) and COX-1 and ET-1’s vasoconstrictor effects. 
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1.7.3. Effect of EPA and DHA on endothelium produced vasodilators 
As discussed in section 1.6, there is some evidence from clinical trials to suggest that EPA and DHA 
have beneficial effects on measures of vascular tone dependent on NO production (57, 58, 79). 
Investigations on plasma levels of markers of NO metabolism have indicated an increase in total 
plasma NOx (a surrogate marker for NO production) in response to consumption 3.24g of DHA and 
2.16g of EPA. Furthermore, ex-vivo investigations on HUVECs showed an increase in eNOS mRNA 
expression in response to exposure of triacylglycerol rich lipoproteins derived from plasma after 
consumption of 3.24g DHA and 2.16g EPA (58). However, another human study showed no effect on 
nitrite, nitrate or NOx plasma concentrations in response to consumption of 5g of a mixed EPA and 
DHA dose or 5g of DHA within a high fat meal (62). A further study investigating the effects of inclusion 
of EPA (5g) in a high fat meal showed that both control and EPA meals decreased total NOx with no 
significant difference between meals (80). 
A number of investigations in cell culture models have also investigated the effects of EPA and DHA 
on NO production via eNOS. For example, in-vitro studies on retinal microvascular endothelial cells 
have indicated that DHA (50µM) but not EPA increases NO production (81), and that this effect is 
mediated by increases in phosphorylation of the serine 1179 residue on e-NOS and also localisation 
of e-NOS away from caveolin-1 containing caveolae. Caveolin-1 is a well-recognised negative regulator 
of e-NOS; it regulates these effects by limiting calcium-calmodulin binding (82), which is known to 
effect e-NOS activity (83). Accordingly, modifications to e-NOS/caveolin-1 co-localisation or caveolin-
1 activity or expression have important implications for e-NOS activity. Other in-vitro studies have 
suggested that EPA but not DHA may be responsible for activation of eNOS in porcine coronary artery 
endothelial cells by mediating phosphorylation at serine1177 (84). Finally, a study on a permanent 
HUVEC cell line (EA.hy926) has shown that EPA (50µM) improves histamine induced eNOS activity 
whereas DHA (50µM) has a deleterious effect.  In this study, EPA (90µM) but not DHA (90µM) was 
sufficient to correct lyso-phosphatidylcholine dependent decreases in eNOS serine 1177 
phosphorylation. Neither treatment effected basal phosphorylation status in contrast to studies on 
microvascular endothelial cells. In summary, in-vitro studies seem to indicate some role for EPA and 
DHA on modulating eNOS activity. However, there is a lack of consensus, and a degree of confusion, 
within the literature with regards to the individual effects of these fats on eNOS activity and NO 
production with some studies indicating EPA to have an effect but not DHA and vice-versa. This may 
be reflective of the array of cell culture lines used in these investigations, which somewhat hampers 
comparison between studies.  
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Although, the impact of EPA and DHA on H2S production is unknown, a recent study has reported an 
activation of CSE (cystathionine-γ-lyase) in response to DHA-rich tuna-oil supplementation in lung 
tissue of Sprawgue-Dawley rats (85). Furthermore, given that CSE utilises homocysteine as a substrate 
to produce H2S (75) and that consumption of fish derived LC n-3 PUFA have been shown to be 
associated with decreases in plasma homocysteine (86), this offers a tentative link to suggest that fish 
derived n-3 fatty acids may interact with the expression or activity of CSE. To date, no human studies 
have investigated if H2S plays a role in mediating EPA or DHA dependent changes in vascular tone. 
A growing body of evidence also suggests cross-talk and involvement of H2S in the in regulation of NO 
signalling pathways  (87). Our human study will investigate the impact of EPA and DHA meals on both 
NO and H2S plasma levels to establish efficacy of these fats in modulating the concentration of these 
blood borne modulators of vascular tone.  
1.7.4. Effects of EPA and DHA on Nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH oxidase) expression and activity 
It has been proposed that an ability to modulate oxidative stress status may be responsible for EPA 
and DHA’s effects on CVD progression. This is an important consideration as oxidative stress is linked 
with the development of atherosclerotic lesions (88) and increased production of ROS is known to 
cause sequestering of vasoactive compounds such as NO. Animal models support the theory of an 
effect for the LC n-3 PUFA in modulating oxidative stress as mice models of atherosclerosis have shown 
reduced oxidative stress load in response to diets containing EPA and DHA (89). As hyperlipidemia is 
associated with increased levels of oxidative stress, it is possible that the hypolipidemic effects of EPA 
and DHA (36-38) may mediate a decrease in oxidative stress.  
These decreases may also occur via decreases in Nicotinamide adenine dinucleotide phosphate-
oxidase (NADPH oxidase) expression and activity. NADPH oxidase is the major source of the 
superoxide anion in the vasculature and a decrease in its production would be associated with 
decreased oxidative stress and also decreased NO degradation and hence, increased NO 
bioavailability. When the NADPH Oxidase p47phox component becomes phosphorylated, it’s 
translocation to the plasma membrane is promoted to form an active enzyme complex (90).  
A number of studies have shown a role for DHA and to some extent, EPA in modulating NADPH oxidase 
activity and expression. For instance, a study has shown that endothelial cells exposed to DHA (in 
concentrations up to 25µM) have decreased translocation of p47phox to the plasma membrane and 
accordingly, decreased NADPH oxidase activity (91). It is also interesting to note that work by this 
group has shown DHA’s effects to be more potent than EPA (92, 93). Evidence from studies 
investigating the effects of EPA and DHA (50µM) on micro vascular endothelial cells have also shown 
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decreased ROS production in response to EPA and DHA, with DHA having a greater effect than EPA 
(81). Expression of NOX-4 mRNA, the NADPH oxidase subunit expressed in endothelial cells, has also 
been shown to be down regulated in HUVECs exposed to triacylglycerol rich lipoproteins rich in EPA 
and DHA (9g) (58).  
In the context of EPA and DHA dependent changes in vascular tone, it is important to consider that 
any decreases in ROS production would likely lead to decreased sequestering of NO by ROS and this 
may contribute to increased net vasodilation, and possibly, decreases in systematic resistance and 
blood pressure. 
1.7.5. Summary 
The literature strongly supports an effect for EPA and DHA in modulating vascular tone in the 
postprandial state and suggests that this effect may play a part in reducing blood pressure in the longer 
term. There is evidence (mainly from chronic feeding studies) that DHA  is more efficacious in this 
regard, however, there is lack of information with regards to the individual effects of EPA and DHA in 
the postprandial state; Particularly, in individuals at increased risk of CVD. Furthermore, there is a lack 
of consensus within the literature on the mechanisms for this effect with some studies indicating that 
the effect is endothelium dependent and others suggesting otherwise. This thesis aims to address this 
by comparing the effects of an EPA rich meal, DHA rich meal and control meal on measures of 
postprandial vascular function and tone. We will also investigating EPA and DHA dependent changes 
in circulatory concentrations of vasomediators such as NO (via quantification of nitrite) and H2S using 
state of the art methodologies. 
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1.8. Mechanisms for a EPA and DHA dependent changes in vascular tone  
1.8.1. EPA and DHA as Peroxisome proliferator-activated receptor (PPAR) 
family activators 
A property of EPA and DHA which is likely to be partly responsible for part of their CVD risk reducing 
capacity is their ability to directly modify the activity and expression of the peroxisome proliferator-
activated receptor (PPAR) family of molecules. The PPAR family includes the isoforms α, β and   which 
are expressed in a number of tissues. Dysregulation of PPAR activity or expression is implicated in a 
number of complex non-communicable diseases such as CVD (94-98), Parkinson’s Disease (99, 100),  
Alzheimer’s Disease (99), type-II diabetes (101), Lupus and the associated nephritic syndrome (102). 
The PPAR family members are ligand-dependent transcription factors, which form homodimers with 
the retinoid X receptor (RXR) and bind other co-activators such as steroid receptor co-activating 
factor-1 (SRC-1) in order to bind to the peroxisome proliferator response elements (PPRE) in the 
promoter region of genes containing these PPREs (see Figure 1.5). Genes containing these PPREs are 
involved in lipid and glucose metabolism and inflammation (103, 104).  
1.8.2. Modification of PPAR family activation and expression by EPA and 
DHA 
The ligand binding domain of the PPAR family members is buried in the core of three key α-helices. 
Binding of EPA and DHA occurs through their carboxylic acid groups interacting with key histidine 
residues (H323, H473 and H449) located within this ligand binding domain (105, 106) with 
hydrophobic interactions  stabilizing this configuration (106). This interaction of EPA and DHA with the 
PPAR family has been shown to increase activity of PPAR- (107-109) , PPAR-α (110-112) and PPAR-β 
(111, 113) in a number of cell types and tissues in both in-vitro and animal model experiments. Current 
evidence suggests that this increase in activation occurs by inducing changes in conformation of a key 
activating function-2 (AF-2) helix which is important for ligand dependent transcription. Upon these 
conformational changes in AF-2 taking place, co-activator proteins such as SRC-1 may bind (105), 
allowing the PPAR family to induce expression of those target genes containing a PPRE.  
Of note is reports of increases in PPAR- mRNA in response to DHA but not EPA in 3T3-L1 adipocytes 
(114). The study also showed that both EPA and DHA increased secreted adiponectin (a hormone 
involved in glucose regulation and fatty acid catabolism) concentration relative to control (44% and 
102% respectively). Further to this incubation with a PPAR- antagonist, bisphenol-A-diglycidyl ether 
(BADGE), inhibited the observed increase in adiponectin secretion in cells which were incubated with 
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DHA but not those incubated with EPA. These results indicate that the mechanism underlying DHA’s 
affects may be more PPAR- dependent than EPA.  
It is important to consider, that members of the PPAR family do indeed bind other fatty acids (106) 
and not just EPA and DHA, but there is little evidence to suggest that other fatty acids are as potent 
activators of the PPAR family as EPA and DHA.  It has been proposed by Xu et al (106) that the carbon 
chain length and degree of unsaturation of fatty acids may be key in determining the interactions of 
fatty acids with the PPAR family. It has also been suggested that the PPAR family members only 
interact with fatty acids of a certain length due to the fact that short chain fatty acids cannot make 
the hydrophobic interactions required for stable binding, further to this they propose that excessively 
long chain fatty acids may be subject to destabilizing effects of solvent due to an inability to fit into 
the ligand binding domain. Unsaturation of long chain fatty acids also plays a key role in determining 
the ability of fatty acids to bind and activate the PPAR family members. A greater amount of double 
cis-bonds facilitates the formation of kinks in the hydrocarbon chain and accordingly, allows fatty acids 
containing greater number of cis-bonds to adopt a contorted conformation that is needed to enter 
into the ligand binding domain to bind and activate the PPAR family. Accordingly, it is likely a 
combination of optimal amounts of double cis-bonds and optimal chain length confers EPA and DHA 
with a capacity to bind and active the PPAR family members. Differential activation of these PPAR 
family members by EPA and DHA may some role in the differential effects of EPA and DHA in-vivo. 
1.8.3. Potential PPAR family dependent modulation of endothelial function  
Putative evidence exists to suggest that PPAR activation may confer part of the suggested ability of 
EPA and DHA to modulate NO production in the endothelium. PPAR- agonists have been shown to 
activate eNOS phosphorylation  (115) and increase eNOS mRNA expression in in-vitro models of 
hemodynamic conditions (116). Furthermore, PPAR-α agonists have shown to increase activity of 
eNOS via phosphorylation (117) and expression of eNOS (118). PPAR-α (117, 118) and PPAR-β (119, 
120) activation has also shown a capacity to reduce hypertension (119, 121), perhaps via increased 
NO production by the endothelium (117, 120). Taken together, given that EPA and DHA are known 
PPAR family agonists, this evidence tentatively suggests that a PPAR-α, PPAR-β and PPAR- dependent 
mechanism may play a role in any potential increases in NO production in response to EPA and DHA. 
It is interesting to note, however, that the human eNOS gene does not contain a PPRE. It is plausible, 
that events downstream from PPAR-α, PPAR-β and PPAR-γ activation may influence alterations in 
eNOS activity. These events could potentially include binding to other regions within the eNOS 
promoter or alteration of eNOS mRNA stability (122), thereby increasing eNOS expression.  It has also 
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been shown that caveolin-1 expression is modified by PPAR-γ (104). As mentioned earlier in this 
review, caveolin-1 is a known negative regulator of eNOS activity. 
PPAR- agonists have also been shown to down regulate P47phox in macrophages and monocytes (a 
major source of superoxide production in the vasculature) (123). Accordingly, DHA dependent 
activation of PPAR-ƴ may play a role in modulation of ROS production and subsequently NO 
bioavailability. Animal studies have supplied further evidence, that EPA and DHA may modulate 
superoxide production through a PPAR dependent modification in NADPH expression/activity in the 
vasculature. For instance, it has been shown that PPAR- agonists prevent ET-1 activation of pro-
inflammatory pathways (including NADPH oxidase activation) in vascular smooth muscle cells from 
normotensive and hypertensive rats (124) (see Figure 1.7.2 for an overview of ET-1’s effect on the 
vasculature). The observations that DHA is more efficacious in modulating NADPH activity than EPA 
(92, 93) could again potentially be explained by a PPAR-γ dependent model for these effects, given 
the reports indicating increases in PPAR- mRNA in response to DHA but not EPA (114).  
 
Figure 1.8.3. An overview of pathways influencing PPAR-, α and β activity. 
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1.8.4. Summary 
In summary, the observations suggesting DHA is be more efficacious in modulating NO production 
than EPA (81) could potentially be explained by a PPAR-γ dependent mechanism. It must be noted 
that at the moment these are putative links and further work must be undertaken to confirm whether 
this mechanism contributes to EPA and DHA dependent modulations to vascular tone. These 
mechanistic investigations were beyond the scope of this PhD.  Never the less, the interaction of EPA 
and DHA with the PPAR family is an important consideration in understanding the effects of EPA and 
DHA on the vasculature and on lipid metabolism and accordingly in chapter 5 genotype*treatment 
interactions for a common variant in the PPAR-γ gene were examined.  
1.9. A role for EPA and DHA metabolites in the modulation of vascular 
tone 
There is strong evidence to suggest a role for the metabolites of EPA and DHA in their ability to 
modulate vascular tone. These metabolites are produced by both discrete enzymatic and non-discrete 
enzymatic pathways, have a wide range of actions and a relatively wide range of receptors, some of 
which may yet to be described.  
EPA supplementation is known to have effects on “classical” eicosanoid production. Eicosanoids are 
autocrine and paracrine hormones produced via oxidation of the 20-carbon fatty acids - EPA, AA, and 
dihomo--linoleic acid. Eicosanoids include leukotrienes, prostanoids (prostaglandins and 
prostacyclins) and thromboxanes – all of which possess vasoconstrictory properties. It is well 
established that the production of EPA derived “classical” eicosanoids species in favour of the AA and 
dihomo--linoleic acid derived species results in the production of metabolites with decreased 
vasoconstrictory properties. For instance, fish-oil intake has been shown to modulate leukotriene 
production in-vivo with LTB5 (containing 5 double bonds) being produced in favour of LTB4 (containing 
4 double bonds) (125). Interestingly, LTB5 has been shown to have a decreased capacity to illicit 
smooth muscle contraction (126). Prostaglandin H3 (PGH3) is also derived from EPA and is formed at 
a slower rate than AA-derived Prostaglandin H2 (127). It has been shown that increased production of 
PGH3 is associated with a reduced risk of  CVD and its effect on vasoconstriction are less potent than 
its AA derived counterparts (128). The molecules derived from PGH3 such as TXA3 have also been 
shown to have less potent vasoconstrictory effects than TXA2 (derived from AA) (128). It is likely that 
some of the beneficial effects of EPA intake on vascular tone are mediated through EPA’s capacity to 
increase PGH3 and subsequently, LTB5 and TXA3 production, however, the effects of these metabolites 
alone are unlikely to explain in full the vasodilatory effects of EPA or in particular, DHA. Please see 
Figure 1.9, for an overview of the range of bioactive metabolites produced from EPA and DHA. 
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A current gap in the literature with regards to EPA and DHA’s beneficial effects on the vasculature is 
establishing the contribution of the novel EPA and DHA epoxymetabolite and resolvin/protectin 
groups to EPA and DHA’s capacity to modulate vascular tone in-vivo. There is also evidence to suggest 
genotype*nutrient interactions may influence the production of these novel and potent vasodilatory 
epoxymetabolites produced from EPA and DHA. Curiously, this area is particularly understudied in the 
context of human nutrition. The following sections will cover the bioactivity of these novel EPA and 
DHA metabolites in the vasculature.  
1.9.1. EPA and DHA derived epoxymetabolites 
The CYP450 enzymes are a large and diverse group of enzymes involved in the oxidation of organic 
compounds in phase 1 metabolism. The CYP450 enzymes were first identified as being central to the 
processing and detoxification of xenobiotics (129). It is also known that these enzymes act on fatty 
acids and other lipid compounds and of this substantial group of enzymes the 2J2, 1A1, 1A2, 4A11, 
4B1, 4F12 CYP450s, among others, act on EPA, DHA and other fatty acids as their major substrates. 
EPA and DHA are among the fatty acids that these CYP450 enzymes act upon. 
Several oxygenated metabolites generated by cytochrome P450 enzymes from EPA and DHA have 
been shown to modulate vascular muscle tone (130). It has been shown that these metabolites, 
referred to as epoxymetabolites, due to the presence of an epoxide group (a cyclic ether with a three 
atom ring), activate large Ca2+ - activated K+ channels (131).  The effect of the activation of these K+ 
channels by EPA and DHA derived epoxymetabolites is hyperpolarization and relaxation of vasculature 
smooth muscles cells  (132-134). The effects of these metabolites on vascular tone will be discussed 
in sections 1.9.2 and 1.9.3.  
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Figure 1.9. Diagram depicting the diverse range of metabolites derived from EPA, DHA and AA. 
 
 37 | P a g e  
 
1.9.2. Effect of EPA and DHA epoxymetabolites on thromboxane production 
In accordance with the evidence that suggests DHA to have more potent vasodilatory effects than 
EPA, a number of recent studies suggest CYP450 epoxide metabolites derived from DHA to be more 
potent than those derived from EPA (135). Evidence also exists to suggest that DHA derived epoxy-
docosapentaenoic acid (EpDPEs) isomers have an inhibitory effect on platelet aggregation and the 
production of the potent vasoconstrictor thromboxane A2 (135). In this study, DHA derived EpDPEs 
(19,20 EpDPE, 16,17 EpDPE, 13,14 EpDPE, 10,11 EpDPE, and 7,8 EpDPE; see Fig. 1.9.2) had IC50 values 
for inhibition of platelet aggregation in the range of 0.71 to 1.5µM and IC50 values for inhibition of 
thromboxane production in the range of 6 to 75µM. Interestingly, the epoxyeicosatetraenoic acid 
(EpETE) epoxymetabolites, derived from EPA, had IC50 values for inhibition of platelet aggregation in 
the range of 3.2 to 5.4µM, i.e. 3-4 fold higher than the DHA epoxides. This effect was mirrored in the 
EpETE capacity to reduce thromboxane production, which was approximately 33% decreased relative 
to the DHA derived epoxides, with IC50 values in the range of 9.7 to >100µM. Accordingly, when 
considering the effects of DHA and EPA epoxy-metabolites on platelet function DHA epoxy-
metabolites are likely to be the more efficacious than EPA. This effect on platelet function is likely to 
mitigate some effect on vascular tone through thromboxane A2, a potent vasoconstrictor which acts 
through the G-protein couple thromboxane receptors. This evidence once again suggests that DHA is 
potentially more efficacious than EPA in beneficially modulating vascular tone. 
 
Figure 1.9.2. The DHA derived epoxymetabolites. 
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1.9.3. Direct effects of EPA and DHA epoxymetabolites on vascular smooth 
muscle tone 
It has also been shown that 19, 20 EpDPE has potent direct effects on vascular smooth muscle tone 
(131). In this study pulmonary arteries were treated with 0.01-100µM MAG-DHA or 19, 20-EpDPE 
(0.001–10µM). Experiments revealed a concentration dependent effect for MAG-DHA on arterial 
relaxation in arteries challenged with U-44619 (30nM), a thromboxane A2 agonist which induces 
vasoconstriction. These experiments were then repeated with 19, 20-EpDPE which showed a similar 
concentration dependent relationship for decreases in vascular tone. These experiments also showed 
that when treated with U-44619 the arteries had enhanced Ca2+ sensitivity (increasing vascular tone) 
and that pre-treatment with MAG-DHA caused a marked inhibition of this effect. Interestingly, 
experiments conducted in order to establish if MAG-DHA had effects on Ca2+ sensitivity in non-
challenge arteries showed non-significant results. These results suggest that the metabolites of DHA 
offer a protective effect for arterial reactivity when the arteries are subject to non-optimal conditions, 
but they do not improve vascular reactivity beyond normal baseline levels. 
In these experiments significant reductions in RhoA activity were also observed in response to both 
3µM and 30µM MAG-DHA. Western-blotting revealed that phosphorylation of MLC and myosin 
phosphatase targeting protein (MYPT) was increased in response to U-44619 and reduced in response 
to pre-treatment with MAG-DHA. RhoA protein is known to activate Rho kinase, which leads to 
inhibition of myosin light chain phosphatase (MLC-phosphatase). When myosin light chains are 
phosphorylated they actively contract. Accordingly, the net effect of these reductions in RhoA is 
decreased contraction of vascular smooth muscle cells via RhoA dependent increases in MLC-
phosphatase activity. Finally, this study (131) also investigated the effect of the selective CYP-450 
epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide (MS-PPOH) on 
MAG-DHA’s ability to modulate vascular reactivity in these in-vitro pulmonary arteries. It was shown 
during the course of these experiments that MS-PPOH treatment alongside MAG-DHA resulted in an 
approximately 75% decrease in MAG-DHA’s ability to modulate vascular tone. This data provides 
further evidence that DHA’s ability to modulate vascular tone in-vitro is dependent on the production 
of these epoxymetabolites, such as 19, 20 EpDPE, which are produced by CYP450 epoxygenases. 
 
In-vitro studies of animal blood vessels also indicate DHA derived epoxymetabolites to be particularly 
efficacious in eliciting vasodilation. Some studies have suggested these DHA metabolites to be up to 
2-3 orders of magnitude more potent than the arachidonic acid derived epoxymetabolites and 1-2 
orders of magnitude more potent than the EPA derived epoxymetabolites (EpETEs) with regard to 
their ability to modulate BK channels in porcine coronary arterioles (134). In-vitro studies of human 
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PMA have shown IC50 values for the vasodilatory effects of the EPA epoxymetabolite, 17, 18-EpETE 
to be in the low µM range (132) in human PMA pre-contracted by methacholine (1µM). Experiments 
with the DHA epoxymetabolite 19,20 EpDPE showed an IC50 for its vasodilatory effects in human 
PMA’s to be of one order of magnitude lower than that of 17,18-EpETE (approximately 0.1µM) (131). 
It should be noted that in the 19, 20 EpDPE experiments the arteries were challenged with U-46619 
(30nM), whereas methacholine (1µM) was used in the previous study, and this inconsistency makes it 
difficult to directly compare the results; however, this does suggest that the DHA derived 
epoxymetabolites have greater vasodilatory capacity than their EPA counterparts. Consideration 
should be given to the fact that blood flow is regulated differentially in different vascular beds and the 
effects of these compounds in pulmonary arteries is likely to differ in peripheral arteries and large 
conduit arteries. It is also worth noting that  studies in porcine coronary arteries have shown IC50 
values for the DHA epoxymetabolites to be in the pM to nM range (134), but it should be noted that 
it may not be advisable to extrapolate these results from animal in-vitro blood vessel models to those 
from human blood vessels models.   
 
Further work is warranted to establish if the effects shown for these epoxymetabolites in these in-
vitro studies contribute to the effects of EPA and DHA to modulate vascular tone. Furthermore, further 
mechanistic work is warranted to establish the relative bioactivity of the EPA and DHA derived epoxy 
metabolites on vascular reactivity. Although data from clinical studies have shown a potential for 
circulatory concentrations of these compounds to be modulated after a 4 week supplementary period 
(136), in-vivo studies documenting their contributions to the improvements in vascular tone in 
response to either acute or chronic interventions are non-existent. Furthermore, the only 
demonstration in the literature of short term modulation of the concentration of these compounds is 
in response to a dosage of 22g of DHA and 3g of EPA and DHA, consumption of this amount of DHA 
and EPA through diet would require consumption of 1.5kg of salmon. Accordingly, given the potential 
impact of these compounds on human health further research is required on the modulation of these 
compounds to physiological consumption of EPA and DHA, the inter-individual variability in the 
production of these compounds and the determinants of any variability in the production of these 
compounds. 
 
Specifically, given that allelic variants of the CYP450 enzymes which produce these metabolites have 
been shown to produce differential epoxymetabolite profiles from EPA (137), it is possible that  
genotype*nutrient interactions may also influence an individual’s capacity to produce these 
epoxymetabolites and this may have an impact on the chronic and acute vascular response to EPA and 
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DHA. Given the health benefits of EPA and DHA, the diversity in the bioactive lipids produced from 
these n-3 PUFA and the heterogeneity of the response to EPA and DHA (138) establishment of the 
aetiology of the variability in response to intake is of wide public health interest.  
1.9.4. An introduction to the resolvins and protectins 
Resolvins are a group of bioactive compounds derived from EPA (E-series resolvins) and DHA (D-series 
resolvins) by the cyclooxegenase-2 (COX-2) pathway and lipoxygenase enzymes (see Fig. 1.9.4), which 
have been shown to modulate inflammation in the vasculature (139). The resolvins were first 
identified in in-vivo experiments of murine dorsal air pouches treated with aspirin (most widely known 
for exerting its anti-inflammatory effects via the COX-2 pathway) and EPA or DHA.  
 
 
Figure. 1.9.4. Generation of E and D-series resolvins and protectin D1. 
The E-series resolvins are generated from 18R-hydroxyeicosapentanoic acid (18 R-HEPE). 18 R-HEPE 
has been shown to be generated in endothelial cells with upregulated COX-2 expression treated with 
aspirin. This generation of 18 R-HEPE has been shown to be blocked in response to COX-2 inhibition, 
indicating the critical role COX-2 plays in the generation of the resolvins (140). 18 R-HEPE can then be 
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released by endothelial cells to be acted upon by leukocytes which convert 18 RHEPE to Resolvin E1 
(RvE1) or Resolvin E2 (RvE2) by 5-LOX via an intermediate possessing a 5(6) epoxide group (140, 141). 
D-series resolvins, such as aspirin-triggered RvD1 (AT-RvD1) and RvD1 are synthesised via a pathway 
involving sequential oxygenations. AT-RvD1 production is initiated by aspirin-acetylated COX-2 and 
RvD1 production is initiated by 15-LOX in the microvascular. In a similar manner to the E-series 
resolvins, 5-LOX present in leukocytes plays a role in the generation of the D-series resolvins. 
DHA can also generate protectins (PDs). These PDs are synthesised enzymatically by 15-LOX which 
generates a 17S-hydroperoxide containing intermediate, which is rapidly converted by human 
leukocytes into a 16(17)-epoxide. This 16(17) epoxide is then enzymatically converted to a 10, 17-
dihydroxy-containing compound, such as protectin D1 (PD1 (142).  
1.9.4.1. Bioactivity of resolvins and protectins 
To date, studies on the bioactivity of the resolvins have focused mainly on their anti-inflammatory 
effects. For example, studies have shown RvE1 to inhibit trans-endothelial migration of 
polymorphonuclear neutrophils (PMNs) (140). These PMNs play a role in the atherogenesis through 
their capacity to produce cytokines which help induce and maintain the inflammatory state associated 
with atherosclerosis. PMNs are also likely to have involvement in this process through their production 
of the superoxide ion, which concurrently decreases NO bioavailability, and mediates their capacity to 
oxidise LDL (143).  
Another plausible mechanism by which these neutrophils may contribute to a pro-atherogenic state 
is through induction of CD36 expression in macrophages via IL-4. Induction of CD36 expression results 
in increased oxLDL uptake and it has been shown that increased levels of CD36 are present in 
individuals with advanced atherosclerosis. It is likely that the RvE1’s effects are mediated through the 
orphan G-protein couple receptor (GPCR) – ChemR23 (144). Activation of ChemR23 down-regulates 
the activity of NF-κB and also activates signalling pathways involved in initiating mitogen-activated 
protein kinase (MAPK). Critically, it has been shown that this GPCR is expressed on endothelial cells 
(145) and that it’s activation is likely to induce production of NO (146). It has also been shown that 
RvE1 protects against ox-LDL induced injury in HUVECs and that this effect is inhibited by the PI3K 
inhibitor wortmanin (147). This would suggest that some of the beneficial effects of RvE1 on the 
vasculature are likely to be mediated through the PI3K-AKT signalling pathway. RvE1 has also shown 
to modulate PDGF-receptor activation and the chemotaxis in in-vitro vascular smooth muscles cells 
(148). This PDGF-receptor activation and chemotaxis is associated with vascular cell migration in the 
formation of atheromas. Interestingly RvD1 was shown to be less efficacious in exerting these effects. 
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Less is known regarding the mechanisms through which RvE2 may act but it has been shown to have 
similar actions as RvE1 on PMNs (131). The receptor which RvE2 binds to has yet to be established, 
since RvE2 effects have been shown to be additive to RvE1 (149), it has been hypothesised that it acts 
on a distinct receptor. 
The D-series resolvins have been shown to act in a similar manner to the E-series resolvins, in 
particular with reference to their effects on neutrophil migration (150, 151). RvD1, like RvE1, has also 
shown to modulate leukotriene B4 signalling. This modulation of leukotriene B4 signalling reduces the 
pro-inflammatory response to increased cytokine production and blocks the function of the β-2 
integrin adhesion molecules which play a role in neutrophil adhesion (152). It is interesting to note 
that both RvE1 and RvD1 have been shown to have no effect on PPAR-α, PPAR-β or PPAR- in PMN at 
nano-molar concentrations indicating that the effects of these EPA and DHA metabolites are likely to 
be independent of the PPAR family (152). 
 As illustrated in Figure. 1.9.4, DHA also acts a precursor for PD1. PD1 has also shown that it may offer 
some capacity to resolve the inflammation associated with oxidative stress and the atherogenic 
phenotype. This likely occurs through modulation of neutrophil migration and increasing macrophage 
ingestion of apoptotic PMNs (150).  
Direct contribution of these compounds to EPA and DHA changes in vascular tone have not been 
documented in the literature and it is unknown if the concentrations of these compounds are modified 
in the acute state.  The quantification of the resolvins and protectins profile in response to EPA and 
DHA rich test meals was beyond the scope of this PhD, due to a lack of in-house capacity. However, 
this may be undertaken retrospectively. 
1.9.5. Summary 
A broad range of bioactive compounds are derived from EPA and DHA and these compounds are 
thought to account for some of EPA and DHA’s beneficial effects in the vasculature.  
With specific reference to potential modulation of vascular tone, a robust mechanism for DHA and 
EPA dependent changes in vascular tone has emerged through investigations of the effects of CYP450 
generated epoxide metabolites on in-vitro whole artery models with evidence suggesting that the DHA 
derived epoxymetabolites are more active than their EPA counterparts. In-vitro experiments have 
suggested that 19, 20-EpDPE accounts for approximately 75% of DHA’s capacity to induce changes in 
vascular tone in in-vitro experiments in human pulmonary arteries.  It is important to consider that 
the bioavailability of these compounds is thought to be low and it is unknown if circulatory 
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concentrations of these compounds changes acutely in response to physiological dosages of EPA and 
DHA. Furthermore, demonstrations of changes in the circulatory concentrations of these compounds 
in-vivo alongside demonstrations of changes in vascular tone have not been demonstrated. Finally, it 
has been shown that allelic variants of the CYP450 enzymes that produce these metabolites impact 
the epoxymetabolite profiles from EPA (137). It is possible that genotype*nutrient interactions may 
influence an individual’s capacity to produce these epoxymetabolites and this may have an impact on 
the chronic and acute vascular response to EPA and DHA. This may in part contribute to the 
heterogeneity in response to EPA and DHA (138). Although the effects of the EPA and DHA derived 
resolvins and protectins have been well described and likely contribute to EPA and DHA’s longer term 
effects in the vasculature, a strong line of evidence on their effects on vascular tone does not emerge 
in the literature. Accordingly, these compounds were not a main focus of this project. 
We hypothesise that these epoxide compounds may contribute to EPA and DHA’s capacity to 
modulate vascular tone in the postprandial state. Accordingly, our study will investigate the 
production of these novel metabolites in response to physiological doses of EPA and DHA for the first 
time. Given the bioactivity of these compounds, it is of critical importance to establish their 
bioavailability post consumption and also to generate data regarding inter individual variation in the 
capacity to produce these compounds. 
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1.10. Hypothesis and objectives 
There is evidence from a number of avenues of research which indicate that DHA may be more 
efficacious than EPA in modulating vascular tone. Longer term chronic feeding clinical trials have 
indicated DHA to be more efficacious in modulating fasting vascular tone (40, 57) and this has been 
supported more recently by a single acute feeding studies which investigate the impact of EPA and 
DHA on cardiac and vascular function during exercise (61). A current research gap is establishing the 
relative efficacy of EPA and DHA to modulate post-prandial vascular tone in at risk populations. We 
hypothesise that DHA may be more efficacious than EPA in modulating vascular tone and a primary 
aim of this project will be to elucidate the relative impact of EPA versus DHA on postprandial vascular 
tone in a population at an increased risk of CVD. 
Further to this, although it is known that LC n-3 PUFA modulate vascular tone, the mechanisms 
mediating these effects have not been fully elucidated. Investigations on how these effects are 
exerted are another novel aim of this project. It is interesting to note that studies which give insight 
into potential mechanisms of these effects suggest DHA to be more efficacious than EPA in modulating 
vascular tone. Finally, it is evident that a significant contribution to EPA and DHA’s beneficial effects 
on the vasculature are mediated by their metabolites. Current knowledge indicates that the epoxy 
metabolites generated by the CYP450 enzymes act directly on vascular smooth muscle cells to elicit 
dilatation via activation of large Ca2+ - activated K+ channels (131), with the DHA derived epoxy-
metabolites known to be particularly potent (132-134). Our study will investigate a broad range of 
blood borne vasomediators via state of the art methodology in order to compare the capacity of EPA 
and DHA to influence the concentration of vasoactive compounds in the postprandial state. 
Our study will also investigate the impact of meal dependent changes to the postprandial blood fat 
profile on innate inflammatory responses by utilisation of an LPS stimulated WBC model. Previous 
investigations using this model have shown that a 6 week fish-oil intervention has been shown to alter 
production of IL-6 in LPS stimulated WBC (52). We will investigate the impact of our EPA and DHA 
interventions compared to control on LPS stimulated WBC responses from blood drawn 
postprandially. We hypothesise that EPA and DHA may have differential effects in this regard. 
Furthermore, information on the impact of post meal alterations to the whole lipidome on monocytic 
cytokine production haven’t been described in the literature and our study will allow us to address 
this consideration. 
Finally, we will investigate the interactions between meal fat content, a select number of candidate 
genes and vascular and triglyceride responses as a pilot study. These candidate genes include SNPs in 
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the genes coding for PPAR-γ, NAPDH oxidase and eNOS. An introduction to these candidate genes is 
provided in Section 5.1. 
In summary, to date, the characterisation and comparison of the individual effects of EPA and DHA on 
postprandial responses has been insufficiently described in the literature.  Given the evidence 
suggesting a role for the LC n-3 PUFAs in modulating CVD risk, establishing the relative efficacy of EPA 
and DHA to modulate postprandial responses are important given that most individuals spend the 
majority of the day in the postprandial state. It is possible that such day to day “acute” changes to 
postprandial responses, when habitually repeated, have implications for long term vascular health and 
CVD risk. Our study aims to address these considerations by investigating the effects of EPA and DHA 
rich meals, when compared to a high-fat control meal, on vascular and inflammatory responses.  
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Chapter 2 
A clinical investigation of the impact of fish-oil fatty acids on postprandial vascular reactivity – Trial 
design and methodology 
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Chapter 2: A clinical investigation of the impact of fish-oil 
fatty acids on postprandial vascular reactivity – Trial design 
and methodology 
2.1. Introduction 
 
The primary aim of this study, which will be hence forth referred to as the (F.O.F.A) Fish Oil Fatty Acid 
Study, was to determine the impact of the fish oil fatty acids, eicosapentaenoic acid (EPA) versus 
docosahexaenoic acid (DHA) on vascular reactivity and to identify underlying physiological and 
molecular mechanism of any observed effects in a group of males aged 35-55 years (Chapter 3). In 
addition, LPS stimulated WBC was undertaken on blood drawn postprandially to compare the effect 
of EPA and DHA consumption on WBC responses (Chapter 4). Response to intervention according to 
genotype was also determined retrospectively (see Chapter 5). The following chapter details the 
protocol of this human intervention study. 
2.2. Approach 
 
In this study the ability of EPA and DHA to acutely affect PWV, AI and Endopat RHI was tested in men 
estimated to be at a 1.5 increased relative risk of developing CVD. Further to this, the effect of EPA 
and DHA inclusion in meals on whole blood culture of blood drawn postprandially was investigated. 
To this end, a randomised controlled acute study, with 3 arms, was designed to test the relative 
efficacy of a single dose of EPA and DHA (4.16g) provided in a milkshake form; see Table 2.6.1 for meal 
design. This dosage was chosen on the basis of results indicating that similar doses of EPA and DHA 
modulate vascular tone in human intervention studies (40, 57, 58). 
Subjects were randomised to one of the three study groups 1 to 3 outlined below, and consumed a 
single dose of each of the following treatments in random order:  
1) High fat meal containing 4.2g EPA  
2) High fat meal containing 4.2g DHA 
3) High fat meal containing placebo fat  
Each test meal was assessed separately (3 study days in total) at the Clinical Research and Trials Unit 
at the University of East Anglia, which is an embedded NHS facility under the auspices of the Norfolk 
and Norwich University Hospital (NNUH). A 4 week wash-out period between each visit to the unit 
was observed. This 4 week wash out period between treatments is consistent with other acute phase 
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studies with fish-oil (153). Clearance of test fats from circulation was confirmed by quantification of 
the fatty acid profile at baseline at each visit (see section 3.3.2.5). An overview of the enrolment and 
assessment process is detailed in Figure 2.2.1 and 2.2.2. 
 
Figure 2.2.1. Overview of schedule of participant recruitment, screening and randomisation to the acute intervention. 
 
 
 
Figure 2.2.2. Order of meal and assessments on study days – including pre-study day restrictions. 
 
In brief, participants attended each assessment visit in a fasted state, with blood samples and vascular 
measurements taken before administration of the test food. All measurements were then repeated 
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at 4 hour postprandially. This time point was chosen as 4 hours postprandially is the point at which 
exogenous lipids reach their peak in plasma post consumption (154) and also the point at which 
postprandial reductions in vascular reactivity tend to occur after consumption of a high fat meal (155).   
Prior to the visit participants were asked to fast for 10 hours and to consume a standardised meal as 
the last meal before their visit to the clinic. Furthermore, for 24 hours before each assessment visit, 
participants abstained from consuming specific EPA and DHA rich foods, alcohol and caffeinated 
products. A list of dietary restrictions and alternative foods that were freely consumed are provided 
in Annex 2. Participants also consumed a standardised low fat meal (<10g total fat) the night before 
each assessment. For instance, for 48hr prior to each assessment, participants also refrained from 
strenuous exercise and moderated the intake of nitrate and nitrite rich foods (including leafy green 
vegetables, broccoli, beetroot, radishes, carrots, sausages, other processed, cured meats, bottled 
waters (excluding Buxton bottled water, which contains <0.1mg/L nitrate) and sulphite and sulphate 
rich foods (such as onions, garlic, wine, dried fruits or meats, nut/trail mixes, shredded coconut,  
brussel sprouts, cabbage, broccoli, red peppers). This was undertaken as these dietary components 
could potentially affect our measures of blood H2S, NO and NO oxidation products.  
Ethics submission, recruitment, screening, clinical measures and all aspects of protocol compliance in 
this study were the responsibility of Seán McManus. Phlebotomy was performed by staff at the 
University of East Clinical Trials and Research Unit. 
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2.3. Study population 
 
In order to recruit a population at a relative risk of developing CVD, males aged 35-55 years, who 
had one of the following risk factors for CVD were recruited through local advertisement: 
 Total cholesterol  6mmol/L 
 High density lipoprotein cholesterol (HDLC)  1.0mmol/L 
 Systolic blood pressure > 140 mmHg 
 Diastolic blood pressure > 90 mmHg 
 Waist circumference > 102cm 
 
The rationale for these selection criteria was based on evidence suggesting that individuals with these 
measures are at 1.5 relative risk of developing cardiovascular disease relative to other adult males of 
the same age. This approach was utilised in order to select for a study population with an increased 
relative risk of CVD complications who were otherwise healthy and whose cardiovascular status was 
otherwise considered pre-clinical. The rationale for this was two fold; we reasoned that we would be 
unlikely to observe any nutrient dependent changes in vascular tone in individuals with poor vascular 
reactivity, such as would be expected in individuals with clinically diagnosed CVD. Furthermore, it was 
reasoned that the study would be more clinically relevant if undertaken in a population with pre-
clinical risk factors for CVD. Accordingly, the above described approach was utilised. 
Based on power calculations of Endopat and Pulse Wave Velocity (measures of vascular tone) a target 
of 25 participants was required to complete the study (see section 2.4). Individuals matching the 
following criteria were deemed ineligible for the study: 
 A history of clinically diagnosed vascular or circulatory disease, diabetes, systemic lupus 
erythematosus, hepatic, renal, digestive, haematological, neurological, cancer or thyroidal 
disease. 
 Allergy to intervention foods (dairy or fish products) 
 Individuals unprepared or unable to adhere to dietary restrictions during the 3 days preceding 
each assessment visit. 
 Current smokers, or ex-smokers ceasing <3 months before screening 
 Prescribed medication that could affect lipoprotein metabolism, liver enzyme function, blood 
clotting or blood pressure. Including vasodilators such as Viagra (see Annex 1) 
 Had taken antibiotics or vaccinations within 3 months of enrolment into the study. 
 Taking dietary fish-oil supplements (>1g of EPA and DHA per day) or high dose of anti-oxidant 
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vitamins (>800µg vitamin A, 60mg of vitamin C, 50 µg selenium,10mg of vitamin E or 400µg β-
carotene). 
 Heavy drinkers (>30 units of alcohol per week). 
 Individuals with a sustained BP ≥160/100 mmHg at screening. 
 Individuals with a Body Mass Index (BMI) >30kg/m2. 
 Parallel participation in another research project which involves concurrent dietary 
intervention and/or sampling of biological fluids/material. 
 Habitual consumption of more than one portion of oily fish per week (as defined as 140g of 
any oil fish, including salmon, trout, mackerel, sardines, pilchards, herring, kipper, eel, 
whitebait, etc). 
 
Screening methodology is detailed in full in section 2.8. 
2.4. Sample size considerations 
 
Sample size calculations were undertaken with a power of 0.80 to detect clinically relevant changes at 
the 5% significance level for 2 assessments in the trial, the measurement of endothelial function by 
Endopat (primary outcome) and Pulse Wave Velocity (secondary outcome). The calculations assumed 
no correlation between baseline and end of the intervention. For Endopat, given a standard deviation 
of 0.4 (156), a clinically relevant difference of 0.25 between treatments would be detectable in 21 
subjects per treatment group. For Pulse Wave Velocity, given a standard deviation of 1.2m/sec (157), 
a clinically relevant difference of 1.5m/sec would be detectable with a sample size of 11 participants 
per treatment group. For Augmentation Index (secondary outcome), a clinically relevant 4% decrease 
in AI would be detectable in a population of 13 individuals, assuming a populational standard deviation 
of 5% in AI. As the sample size needed to detect a clinically relevant difference for Endopat was greater 
than that for Pulse Wave Velocity or AI, we aimed to recruit 25 participants. This number was chosen 
to allow for a potential drop-out rate of 15% and to allow for 21 participants to complete the study. 
2.5. Volunteer randomisation 
 
The treatment order for assessment days 1 to 3 was randomised for each participant by use of an 
internet based random number generator by an independent member of staff not involved with the 
data analysis or data generation (Dr. Peter Curtis). The details of the treatment order were provided 
(by Dr. Peter Curtis) to staff who were assigned the duty of preparing the treatment foods. In order to 
ensure no bias was introduced the staff assigned the responsibility of preparing the treatment foods 
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were not involved in data collection or analysis. The coding of the treatment order was only broken at 
the analysis stage of the study. 
2.6. Test meal composition 
 
The test meal was designed in order to fulfil the following conditions: 
1. The test meal was to be composed in such a manner to reduce inter-individual variations in 
absorbance as much as possible. 
2. The test meals were designed so as to deliver a total dose of either 4.16g EPA, DHA or 
control fat. 
3. The test meals were designed to have a high fat content and so that the non-EPA and DHA 
portion of this fat would be broadly representative of the fat composition of the UK diet. 
4. The test meal was to be designed in such a way so as to mask the smell and flavour of the 
EPA and DHA oils. 
To meet these criteria, it was decided to administer the intervention materials in a liquid form in order 
to ensure homogeneity in absorption. It was decided to administer our test fats in this matrix in 
preference to capsulation, due to the inherent difficulty in encapsulating our control fat mixture which 
exists in a semi-solid state at room temperature. A peppermint oil extract was also included in the test 
meal in order to mask the flavour and smell of the fish-oils and ensure both the participants and 
research scientists were blinded to the treatment order. 
Justification for dosage was on the basis of previous studies showing doses in the range of 4-5g to be 
sufficient to modify vascular tone  (40, 57, 58). 
Justification for meal fat composition was on the basis that the non-n-3 fatty acid fat composition of 
this meal closely reflects that of the fat composition of the UK diet and also that this meal fat 
composition has been previously shown to induce postprandial increases in vascular tone (58). As 
high-fat meals are associated with impairment of vascular tone when compared to low fat meals, and 
inclusion of fish-oil fatty acids in high fat-meals is known to have a protective effect on vascular tone, 
we deemed that this meal design was optimal to investigate any differences exist between EPA and 
DHA’s efficacy in contributing to this effect. 
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Table. 2.6.1. The intervention meal design. 
*All intervention materials given to volunteers with toasted white bread (73g) and jam (30g). 
 
 
Nutritional content  Control meal EPA meal DHA meal 
Protein 
 
Fat 
of which SFA 
of which MUFA 
of which PUFA 
Carbohydrates 
of which sugars 
Sodium 
Vitamin A 
Vitamin C 
Vitamin E 
Fibre 
Total calories 
17.8g 
 
42.4g 
15.1g 
17.3g 
10.0g 
73.8g 
45.0g 
832mg 
1.5µg 
2mg 
12mg 
1.56g 
747.6kcal 
17.8g 
 
42.4g 
12.9g 
15.4g 
14.1g 
73.8g 
45.0g 
832mg 
1.5µg 
2mg 
30mg 
1.56g 
747.6kcal 
17.8g 
 
42.4g 
12.5g 
15.3g 
14.6g 
73.8g 
45.0g 
832mg 
1.5µg 
2mg 
30mg 
1.56g 
747.6kcal 
        Table 2.6.2. Meal nutritional information. 
 
 
Treatment Meal composition 
Control 
40g palm oil/soybean oil (4:1) made up in a milkshake form (skimmed milk 
(150g), Nesquik chocolate flavoured powder (25g), Skimmed milk powder (15g)), 
2g Peppermint Oil Extract 
EPA 
  33.06g palm oil/soybean oil mixture (4:1) + 6.94g of EPA rich oil made up in a 
milkshake form (skimmed milk (150g), Nesquik chocolate flavoured powder 
(25g), Skimmed milk powder (15g)), 2g Peppermint Oil Extract 
DHA 
31.67 g palm oil/soybean oil mixture (4:1) + 8.33g of DHA rich oil  made up in a 
milkshake form (skimmed milk (150g), Nesquik chocolate flavoured powder 
(25g), Skimmed milk powder (15g)), 2g Peppermint Oil Extract 
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Fatty acid  Control meal (%) EPA meal (%) DHA meal (%) 
Palmitic acid  
C16:0 
32.15 27.36 26.49 
Palmitoleic acid C16:1 n/a 0.46 0.76 
Stearic acid 
C18:0 
3.62 3.02 2.90 
Oleic acid 
C18:1 
40.47 35.32 34.87 
Linoleic acid 
C18:2 
22.27 18.40 17.63 
α-Linoleic acid 
C18:3 
1.35 1.58 1.84 
Stearidonic acid 
C18:4 
n/a 0.46 0.76 
Arachidic acid 
C20:0 
0.13 0.11 0.11 
 
Gondoic acid 
C20:1 
n/a 0.46 0.55 
Arachidonic acid 
C20:4 
n/a 0.46 0.76 
EPA 
C20:5 
n/a 9.82 1.96 
Heneicosapentaenoic acid 
C21:5 
n/a 0.46 0.76 
DPA 
C22:5 
n/a 0.46 0.76 
DHA 
C22:6 
n/a 1.64 9.82 
Table 2.6.3. Estimated fatty acid composition of meal as derived from manufacturers data. 
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2.7. Recruitment strategy 
 
Individuals matching the characteristics of our target population (see 2.3) were identified through 
open and targeted recruitment through local advertising, media calls and targeted web based social 
network advertising. 
2.7.1. Assessment visits 
 
Assessment visits were undertaken after an overnight fast, beginning at 7.30am and finishing at 
2.30pm. Participants were asked to consume a standardised meal before the visit in order to ensure 
that variance in pre-assessment dietary intake did not impact individual response to the intervention. 
At the start of each assessment a medical check and recall of diet over the preceding 24 hours was 
taken to ensure adherence to the dietary restrictions (as detailed in Annex 1 and Annex 2). It was also 
ensured that participants had not taken any medication on the prohibited medications list including 
non-prescribed non-steroidal anti-inflammatory medications. 
Subsequent to these checks, baseline vascular measures (see Section 2.9) and blood draws (see 
section 2.10.2) were taken. Participants were then asked to consume one of the intervention meals, 
which were composed daily by a third party researcher who was not involved in study design or 
analysis. Accordingly, both participants and study researchers were blinded to meal identity. 4 hours 
post meal consumption postprandial vascular measures and blood draws were taken. 
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2.8. Screening methodology  
2.8.1. Introduction 
 
All participants were screened in order to determine that they fell within the study population criteria 
defined in section 2.3. Screening visits were undertaken after a 10 hour fast. At the screening, 
questionnaires on medical history and dietary habits were taken in order to establish if any of the 
potential participants were to be excluded on the basis of fitting the exclusion criteria detailed in 
section 2.3. Those individuals who were not excluded on these criteria then had their blood pressure 
taken by an automated blood pressure measuring device (Omron 705 CP-II). Blood pressure measures 
were taken 3 minutes apart and in triplicate after a 15 minute resting period. Subsequent to blood 
pressure measurements, a blood draw was taken via a standard butterfly gauge needle and 
subsequently centrifuged at 3300rpm at 4°C for 10 minutes. Serum samples were then stored in 
monitored -80°C until analysis. Serum isolated at screening was analysed within 2 weeks for total 
cholesterol and HDL-cholesterol via an automated I-Lab 3000 Clinical Chemistry analyser. These 
methods, which are based on spectrophotometric methodologies, are detailed in Section 2.8.2.2.  
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2.8.2. Materials 
 
All Materials for screening analysis were obtained from Instrumentation Laboratories (Warrington, 
UK) unless noted otherwise. 
2.8.3. Methods 
2.8.3.1. Screening sample analysis 
 
Samples generated at screening were taken via venous puncture through a standard butterfly gauge 
needle and subsequently centrifuged at 3300rpm at 4°C for 10 minutes. Blood was then stored in a 
monitored -80°C until analysis. 
2.8.3.2. Serum total cholesterol and HDL-C analysis at screening 
 
Total cholesterol was determined in serum samples generated at screening via spectrophotometric 
analysis in an ILAB 650 (Instrumentation Laboratory UK Ltd). The analysis is based on the utilisation 
of an enzymatic pathway (see Figure 2.8.2.2) facilitating the production of quinoneimine dyes. 
 
Figure 2.8.2.2. As described above 1 molecule of Quinoneimine is produced for every 2 cholesterol esters. 
HDL-C was determined in serum samples in a similar fashion. HDL-C quantification was based on the 
principal of anti-human β-lipoprotein binding to all lipoproteins other than HDL. The antigen-antibody 
complexes that form block enzyme reactions with these lipoproteins. Upon addition of cholesterol 
esterase and cholesterol oxidase there will be selective reaction with HDL-C. Accordingly, allowing one 
to quantify the levels of HDL-C in a sample in the range of 40-994 mg/dL. 
The above reactions allowed the quantification of total cholesterol and HDL-C levels due to the fact 
that quinoneimine production is proportional to the levels of total cholesterol and HDL-C in the sample 
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(1 mole of quinoneimine to every 2 moles of cholesterol). The primary and secondary wavelengths at 
which the samples were measured were 510nm and 700nm respectively as quinoneimine absorption 
peaks at these wavelengths. 
The ILAB 600 was calibrated every 14 days, or in the cases where an analysis fell greater than 14 days 
after the previous calibration, before analysis. Calibration for total cholesterol measurement was 
undertaken via utilisation of a Referr IL G Calibrator (Instrumentation Laboratory UK Ltd). The Referr 
Il G Calibrator is a multicomponent calibrator for which total cholesterol values had been pre-
established by the supplier.   Calibration for HDL-C measurement was undertaken via utilisation of a 
Referr IL HDL-C Calibrator (Instrumentation Laboratory UK Ltd). Total cholesterol values were pre-
established against a human serum reference which had an assigned value obtained via the Abell-
Kendall method (158) in a laboratory which participates in the Cholesterol Reference Method 
Laboratory Network.  
 
Serachem Control Level 1 and Serachem Control Level 2 (instrumentation Laboratory UK Ltd) were 
utilised as quality controls in order to ensure the accuracy and precision of the analysis. Serachem 
controls were constituted from lyophilized bovine serum with cholesterol concentrations lower 
(Serachem Control Level 1) and higher (Serachem Control Level 2) than observed concentrations in 
serum isolated at screening. Accordingly, these quality controls allowed us to ensure the 
concentrations established for the screening samples were within the range of linearity for this 
analysis. 
 
Calibration and quality controls were established and the coefficient of variation was confirmed to be 
below 2.5% for both analyses. Subsequent to addition of samples cuvettes, total cholesterol levels 
were quantified by measuring absorption at 510nm and 700nm, whereas HDL-C levels were quantified 
by measuring absorption at 600nm and 700nm. Differences in wavelength measured in these two 
techniques are due to the presence of a phenolic component in the total cholesterol measure. 
Previously established standard curves were utilised to establish concentration from absorption 
values for both analysis. 
2.8.3.3. Screening blood pressure measurement 
 
As detailed in section 2.8.1, blood pressure was measured at screening visits via an automated blood 
pressure measuring device (Omron 705 CP-II). Blood pressure measures were taken 3 minutes apart 
and in triplicate after a 15 minute resting period. 
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2.9. Clinical vascular measures 
2.9.1. Introduction 
A battery of vascular measures was taken at 0H and 4H postprandially in a temperature controlled 
(21 to 22°C) room. These measures were all chosen based on a selection criteria described below: 
 must have a sound physiological and mechanistic basis that links it to atherosclerotic risk. 
 must be reproducible and easily standardized. 
 an improvement in the test should predict an improvement of subsequent cardiovascular 
risk, likewise, a worsening in the test should correlate to increased cardiovascular risk. 
 must be variable over the course of 4-5 hours dependent on the production of vasoactive 
mediators. 
 must be non-invasive. 
 capable of measuring either endothelium dependent or endothelium independent vascular 
tone. 
 
The vascular measures taken included the following measures, the physiological basis for these 
methods are introduced in full in the following sub-sections, whereas methods are described in full in 
section 2.9.2. 
 Blood pressure measurements 
 Augmentation index  
 Pulse wave velocity (PWV) 
 Reactive hyperaemia index via Endopat 
 Reactive hyperaemia index in response to 400µg nitroglycerine administration 
2.9.1.1. Augmentation Index 
Augmentation Index (AI) is a non-invasive method which utilises the pulse profile as a proximal 
measure of arterial stiffness and acute vascular tone. Specifically, a 10 second snapshot is taken at the 
radial artery via a tonometer probe. This snapshot is subsequently utilised to glean information on the 
extent of resistance against which the heart has to pump. Contributions to this resistance include 
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arterial and acute vascular tone. In addition to this measure, the system provides details of central 
blood pressure, aortic augmentation index, ejection duration and sub-endocardial viability ratio.  
Critically, the AI outcome is dependent on the elastic effects of the entire arterial tree. Changes in 
these elastic effects is one of the causes of increasing blood pressure with advancing age and occurs 
in other diseases states that increase arterial stiffness prematurely. The AI has also been shown to 
decrease acutely upon administration of vasodilatory compounds such as nitroglycerin and increase 
upon administration of compounds with vasoconstrictive effects, such as angiotensin II (10). 
Accordingly, it is known that this measure is sensitive to acute changes in vascular tone mediated by 
blood borne vasoactive components.  
 
The mathematical calculation of AI is detailed below, in Figure 2.9.1.1, with diagrammatic aid. In short, 
AI is calculated from the pulse wave by expressing augmentation pressure as a percentage of total 
pulse pressure. This gives an indication of the degree by which systolic blood pressure is augmented 
by late reflected waves in the peripheral arterial tree. Late reflected waves tend to result in extra left 
ventricular load due to blood returning to the left ventricular in timing that is out of sync with left 
ventricular ejection; this in turn acts to increase systolic blood pressure. As mentioned, this measure 
is affected by both arterial stiffness, which does not change acutely, and changes in peripheral artery 
tone which is affected acutely by blood borne vascular mediators, such as NO, H2S, thromboxane and 
the EET, ETE and EpDPE family of molecules, among others. Critically, AI has been shown to be 
associated with increased CVD risk (9). 
 
 
 
Figure 2.9.1.1. Diagrammatic representation of pulse wave form showing pulse pressure and augmentation 
pressure. 
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2.9.1.2. Pulse Wave Velocity 
 
Pulse wave velocity (PWV) is a non-invasive method to measure arterial stiffness. Arterial stiffness can 
occur due to aging as elastic fibres made from elastin begin to fray due to continual mechanical stress. 
Critically, PWV has been shown to be an independent predictor of CVD risk (8). 
Specifically PWV, measures the time for the pulse wave to travel from one site on the body to another. 
The gold standard for anatomical measurement sites is considered to be from the carotid to femoral 
artery. The calculation of PWV is depicted below in Figure 2.9.1.2. 
 
Figure 2.9.1.2. Diagrammatic representation of carotid artery and femoral artery wave form and calculation of 
PWV 
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2.9.1.3. Endopat 
Endopat is a measure of endothelial function which has been shown to be associated with multiple 
known CVD risk factors (6) and to be predictive of future cardiovascular events (7). The Endopat 
Reactive Hyperaemic Index (RHI) measurement is obtained by measuring the increase in blood flow in 
response to the stimulus of shear stress. This shear stress is caused by occluding the brachial artery 
for 5 minutes, and subsequent releasing of the occlusion, causing sudden increase in blood flow to the 
finger tips. The relative amount of hyperaemia is then measured by pneumatic sensors placed on the 
fingers in order to establish a RHI measurement. This RHI measurement is indicative of the capacity of 
the endothelium to produce vasodilatory substances, in particular NO. 
A measurement of RHI was also undertaken postprandially in response to 400µg nitroglycerine 
administration at the postprandial timepoint. This was undertaken in order to utilise nitroglycerine’s 
capacity as NO donor. Effectively, this procedure allowed us to measure RHI in a state in which the 
relative contribution of NO at the postprandial timepoint for each treatment was normalized. 
Accordingly, any changes in this measure dependent on treatment would suggest the contribution of 
vasoactive factors other than NO.  
 
Figure 2.7.4.3. A diagrammatic representation of the Endopat RHI measurement. The letters, A, B, C and D represent the 
mean amplitude of the peripheral arterial tone measurements in the control arm (probe 2) and test arm (probe 1). 
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2.9.2. Methods 
2.9.2.1. Measurement of Augmentation index and Pulse wave velocity 
AI and PWV measurements were both taken in triplicate via a Vicorder device (Skidmore Medical). 
Before the beginning of the measures the measurements were explained in full to participants. 
Participants were then asked to lie down in a supine position for period of 15 minutes in order to 
ensure the measures were taken at rest and to allow full acclimatization to room temperature (21 to 
22°C). Subsequent to this 15 minute resting period, resting blood pressure measurements were taken 
via an Omron 750 CP-II blood pressure measuring device. The Vicorder arm cuff was then attached 
half way between the elbow and the shoulder over the brachial artery in order to take the measure 
of augmentation index. AI was calculated via the Vicorder software by analysis of the blood pressure 
wave form. Specifically, Augmentation Index was calculated from the ratio of augmentation pressure 
to pulse pressure, as detailed in section 2.9.1. The measures were repeated in triplicate with a 1 
minute interlude between each measure. 
Subsequent to the Augmentation Index measures, measures of PWV were taken via placement of two 
blood pressure cuffs at the carotid artery (neck) and at the femoral artery (thigh) respectively. To 
ensure adequate recording of the pressure wave form at the carotid artery, volunteers were first asked 
to sit up and to turn to face the opposite side of the room as the PWV measurer so as to expose the 
carotid artery for optimal placement of the carotid artery pressure cuff. Volunteers were then asked 
to lie down in a supine position and to bend the knee on the same side as the carotid artery cuff 
placement. The femoral artery cuff was then placed as close to the hip as possible. A measurement of 
length was then taken from the upper sternal notch to the mid-point of the femoral artery cuff in 
order to approximate the difference in length by which the pulse wave would have to travel. 
Participants were then asked to lie down and to breathe gently for the period of measurement. These 
measurements were taken 3 times with the average of the three measures used as the PWV input. 
This average measure of length was then utilised by the Vicorder software to output the PWV 
measurement. PWV measurements were taken in triplicate with a 1 minute interlude between each 
measure. 
2.9.2.2. Measurement of Endopat Reactive Hyperaemia Index 
Endopat Reactive Hyperaemia Index (RHI) was measured by arterial tonometry via an Endopat device 
(Itamar Medical Ltd).  
The RHI measurement was taken subsequent to the PWA and PWV measurements. Participants once 
again remained in a supine position for this measurement. In brief it was explained to participants in 
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lay terms that the measurement would take 15 minutes in total, with 5 minutes at rest, 5 minutes with 
a brachial occlusion cuff inflated and subsequently another 5 minutes at rest. It was explained to 
participants that the brachial occlusion cuff would be quite tight and that they might feel some 
numbness or tingling akin to “pins and needles” and that this sensation would subside once the cuff 
was removed. Participants were also reminded to remain as still as possible during the duration of the 
measurement. 
Before the measurement, participant’s index fingers were checked in order to ensure that their 
fingernails did not protrude more than 1mm beyond the tip of their finger. Once this had been 
confirmed finger tips were checked to ensure they were dry and free of any dirt. If this was not the 
case fingertips were washed and dried with wet and dry paper cloth prior to the measurement. Once 
these checks were completed, participants were asked to insert their index fingers into the uninflated 
Endopat finger probes which were inserted into a probe place holder. An occlusion cuff was then 
attached to the participant’s left upper arm. Once the measuring apparatus was fully prepared the 
measure was started by inflating the Endopat finger probes. The participant was then asked to remove 
their index fingers from the probe place holder, the place holder was then slid back so as to allow 
participants to rest their index fingers freely over the edge of the of the place holder (as seen below 
in Figure 2.9.2.2).  
 
Figure 2.9.2.2. Depiction of the correct positioning of arm at rest during Endopat measurement. 
Once fingers were placed at rest and proper probe placement was checked, the participant was 
informed that the 15 minute measurement period was to commence. At the 5 minute mark the 
brachial occlusion cuff was inflated to either 200mmHg or 60mmHg above resting systolic blood 
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pressure for 5 minutes. Preference was given to the higher of these two pressures. After a period of 5 
minutes the brachial occlusion cuff pressure was release and the arterial tonometry measure was 
taken for a further 5 minutes. Once completed the fingers probes and occlusion cuffs were removed 
and the participant was informed that the measurement period was completed. 
2.9.2.3. Measurement of post prandial Endopat RHI measurement in 
response to nitroglycerin administration 
During the battery of vascular measurements at the 4 hour postprandial time point an additional 
measurement of RHI in response to nitroglycerin administration was taken. This measure was taken 
as described in Section 2.9.2.2, with the exception that a 400µg dose of a standard nitroglycerine spray 
was administered by trained nursing staff immediately prior to the measurement. Nitroglycerine (a 
NO donor) was administered in order to blind any effect of endogenously produced NO so that we 
could investigate any NO independent differences in the RHI measure in response to treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 66 | P a g e  
 
2.10. Biochemical analysis of biological samples at baseline and in 
response to intervention 
2.10.1. Materials 
All materials were obtained from Sigma (Dorset, UK) unless noted otherwise. 
2.10.2. Methods 
2.10.3.1. Blood sample processing at assessment visits 
 
Blood draws were taken at baseline (0H) and at 4 hours postprandially on study days. These blood 
draws were taken immediately following the barrage of vascular measurements and were always 
undertaken on the left arm. An overview of the order of these blood draws and the various plasma 
and blood treatments utilised immediately following the blood draw are detailed in Table 2.10.3.1. 
Vacutainer order Treatment 
#1 – Lithium Heparin 
(Ice Cold) 
The vacutainer was spun at 3300rpm at 4°C for 10 minutes. 30µL of plasma was 
then removed and mixed with 70 μl of Tris–HCl (100 mM, pH 9.5, 0.1 mM DTPA), 
and 50 μl of MBB solution (10 mM, in CH3CN) for analysis of plasma H2S levels. 
Samples were stored at -80°C until analysis. 
#2 - Lithium Heparin 
(Ice Cold) 
The vacutainer was spun at 3300rpm at 4°C for 10 minutes. Plasma was then 
alliquoted into labelled tubes for analysis of biomarkers pertaining to vascular 
function. Alliquots for the analysis of labile biomarkers (such as NO and its 
oxidation products) were snap frozen and placed in the dark immediately. 
Samples were stored at -80°C until analysis. 
#3 and 4 - Lithium 
Heparin 
The vacutainer were spun at 3300rpm at 4°C for 10 minutes and plasma stored 
at -80°C until analysis. 
#5 and 6 - Serum The vacutainer was left to sit at room temperature for 30 minutes in order to 
facilitate coagulation of blood. The vacutainer was then spun at 3300rpm at 4°C 
for 10 minutes. Samples were stored at -80°C until analysis. 
#7, 8, 9 and 10 – EDTA These vacutainer was spun at 3300rpm at 4°C for 10 minutes. Plasma was then 
alliquoted into labelled tubes for analysis of biomarkers pertaining to vascular 
function. Aliquots for the analysis of potentially labile biomarkers were snap 
frozen and placed in the dark immediately. Samples were stored at -80°C until 
analysis. 
#11 – Lithium Heparin 
(only taken 
postprandially) 
1ml of whole blood was utilised for whole blood culture as detailed in Chapter 4. 
Table 2.10.3.1. Blood draw treatment details. 
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2.10.3.2. Serum Triglyceride and NEFA quantification at baseline and in 
response to intervention 
 
Serum triglyceride and NEFA levels were determined in plasma samples generated during the 
intervention period via spectrophotometric analysis in an ILAB 650 (Instrumentation Laboratory UK 
Ltd). Both analyses are based on the formation of quinoneimine from Hydrogen Peroxide whose 
production is coupled in these assays to the presence of triglycerides and NEFA. Quinoneimine is 
measured in this assay at 510nm and 700nm and the absorbance at these wavelengths is proportional 
to the amount of Hydrogen Peroxide produced, which in turn is dependent on the amount of 
triglycerides and NEFA present. Accordingly, these assays allowed us to measure the concentration of 
triglycerides and NEFAs in our samples. 
 
The ILAB 600 was calibrated every 14 days, or in the cases where an analysis fell greater than 14 days 
after the previous calibration, before analysis. Calibration was undertaken via utilisation of a Referr IL 
G Calibrator (Instrumentation Laboratory UK Ltd). The Referr Il G Calibrator is a multicomponent 
calibrator for which triacylglycerol values had been pre-established by the supplier.  
 
Serachem Control Level 1 and Serachem Control Level 2 (instrumentation Laboratory UK Ltd) were 
utilised as quality controls in order to ensure the accuracy and precision of the analysis. Serachem 
controls were constituted from lyophilized bovine serum with triacylglycerol concentrations lower 
(Serachem Control Level 1) and higher (Serachem Control Level 2) than observed concentrations in 
serum isolated at screening. Accordingly, these quality controls allowed us to ensure the 
concentrations established for the screening samples were within the range of linearity for this 
analysis. 
 
Once calibration and quality controls were established and the coefficient of variation was confirmed 
to be under 2.5% samples were added to cuvettes for quantification of total cholesterol by measuring 
absorption at 510nm and 700nm and correlating this against a standard curve previously established 
during calibration. 
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2.10.3.3. Serum Glucose analysis at baseline and in response to 
intervention 
 
Serum triacylglycerol levels were determined in serums samples generated during the intervention 
period via spectrophotometric analysis in an ILAB 650 (Instrumentation Laboratory UK Ltd). The 
quantification of Glucose was based on an endpoint, bichromatic hexokinase based methodology. 
Specifically, hexokinase catalyzes the phosphorylation of hexoses including glucose and subsequently 
glucose-6-phosphate dehydrogenase catalyses the formation of 6-phosphogluconate, NADH and a 
lone proton from Glucose-6-Phosphate and NAD+. The production of NADH, which has an absorbance 
peak at 340nm, is dependent and directly proportional to the concentration of glucose in a 1:1 ratio. 
Accordingly, the quantification of glucose in serum was based on an increase in absorbance at 340nm. 
 
The ILAB 600 was calibrated every 14 days, or in the cases where an analysis fell greater than 14 days 
after the previous calibration, before analysis. Calibration was undertaken via utilisation of a Referr IL 
G Calibrator (Instrumentation Laboratory UK Ltd). The Referr Il G Calibrator is a multicomponent 
calibrator for which triacylglycerol values had been pre-established by the supplier. 
 
Serachem Control Level 1 and Serachem Control Level 2 (instrumentation Laboratory UK Ltd) were 
utilised as quality controls in order to ensure the accuracy and precision of the analysis. Serachem 
controls were constituted from lyophilized bovine serum with glucose concentrations lower 
(Serachem Control Level 1) and higher (Serachem Control Level 2) than observed concentrations in 
serum isolated at screening. Accordingly, these quality controls allowed us to ensure the 
concentrations established for the screening samples were within the range of linearity for this 
analysis. 
 
Once calibration and quality controls were established and the coefficient of variation was confirmed 
to be under 2.5% samples were added to cuvettes for quantification of total cholesterol by measuring 
absorption at 510nm and 700nm and correlating this against a standard curve previously established 
during calibration. 
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2.10.3.4. Plasma nitrite analysis at baseline and in response to intervention 
 
Plasma nitrite levels were determined using a chemiluminescence detector (CLD88), designed to 
measure levels of nitric oxide in an inert carrier gas. This detector was utilised by injecting plasma 
samples into a purge vessel containing reductive solutions, designed to reduce nitrite (NO2−), nitrate 
(NO3−) and other oxidative by products of nitric oxide, back to nitric oxide for measurement. It is known 
that both nitrite and nitrate can be reduced in-vivo to produce nitric oxide. Accordingly, due to the 
short lived nature of nitric oxide, measurement of nitrite, nitrate and other oxidation products can be 
utilised as a good proximal measure of in-vivo nitric oxide production.  
For measurement of nitrite, a triiodide solution was utilised. Specifically, a 45mM solution of I- and 
10mM solution of I2 was dissolved in a 93% glacial acetic acid as per Freelisch (159). Nitrogen gas was 
passed through the reductive solution to carry nitric oxide through to a scrubbing bottle containing 
sodium hydroxide (1M at 0°C) and finally, through a sampling probe and the detector. The scrubbing 
bottle was utilised in order to trap traces of acid and iodine before transfer into the detector. To 
maintain consistent results at trace level range nitrogen ﬂow was kept constant throughout the entire 
measurement cycle. This was achieved by utilisation of a pressure gauge to ensure flow rates between 
the scrubbing bottle and sampling probe remained constant. 
A standard curve (R2>0.99) was established by integration of peaks generated after injection of 
solutions of Sodium Nitrite ranging from 100nM to 0nM. Once coefficient of variation for standards, 
and plasma quality controls was confirmed to be under 10%, standards were run with duplicate 
injections. The triiodide solution was replaced every 40 injections, under our conditions this yielded 
optimal reproducibility for peaks derived from both standards and samples. Plasma nitrite 
concentrations in samples were generated via utilisation of standard curves. A representative 
standard curve is shown in Annex 4, Figure B. 
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2.10.3.5. Plasma Hydrogen sulfide analysis at baseline and in response to 
intervention 
 
Plasma H2S concentrations were determined via utilisation of monobromobimane (MBB) to derivitise 
Hydrogen Sulfide to sulphide dibimane (SDB). This protocol was adapted from publications from 
Winter et al (160) and Shen et al (161) and was developed and validated as part of this PhD project. 
Specifically, this methodology utilises the reaction between MBB and hydrogen sulfide under basic 
conditions at room temperature to produce SDB. SDB contains two bimane cores, and due to bimane 
being hydrophobic, SDB is more hydrophobic than most physiological thiols. This characteristic allows 
SDB to be separated by reversed phase-HPLC with a gradient elution. Subsequently, SDB can be 
quantified via flouresence detection.  
 
On each study day, free plasma H2S was derivitised to SDB immediately after centrifugation and 
separation of the plasma. In short, 30µL of plasma was added to 70µL of Tris-HCl (100 mM, pH 9.5, 
0.1mM DTPA) and 50µL of MBB solution (10 mM, in CH3CN) in an eppendorf tube wrapped in tin foil, 
as bromobimanes are sensitive to photolysis. The solution was incubated for 30 minutes at room 
temperature, before addition of 50µL of ice cold sulfosalicylic acid (200mM). Sulfosalicylic acid was 
added to stop the reaction and to precipitate any protein. The mixture was then placed on ice for ten 
minutes before centrifugation at 12,000 rpm at 4 °C for 10. Supernatant was removed and stored at -
80°C until analysis. At analysis, standards and samples were run in an Agilent C:18 4.6x250mm column 
(particle size, 5µm) under the conditions detailed in Figure 2.10.2.4. 
 
 
Figure 2.10.2.4. Mobile phase gradient for the quantification of H2S derivitised SDB. Phase A was made up of 99.9% H20 + 
0.1% TFA (v/v). Phase B was made up of 99.9% CH3CN + 0.1% TFA (v/v). 
SDB was synthesised in our laboratory by reaction of MBB with excess Sodium Sulfide. SDB was 
subsequently purified by extraction in ethyl acetate, evaporation under nitrogen stream and 
subsequent re-constitution in HPLC grade water, as described by Shen et al (161). Purity of SDB was 
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subsequently assessed by qualification of a single absorbance peak between 300 and 800nm at 380nm 
consistent with reports by Shen et al. Under the conditions described in Figure 2.10.2.4, purified SDB 
in HPLC grade water eluted at 11.6 minutes. We confirmed no matrix effect on retention times by 
spiking purified SDB in plasma, to qualify SDB elution in plasma samples at 11.6 minutes. SDB 
concentration in our samples was subsequently calculated from a standard curve, generated from 
reaction of known quantities of Sodium Sulfide with MBB. Quantification of plasma H2S concentrations 
was undertaken using a standard curve with R2 values greater than 0.99. A standard curve is shown in 
Annex 4, Figure C. A weakness of the analysis is that the range for the standard curve utilized extended 
beyond the biological range of plasma H2S concentrations. Previous work utilizing this method to 
quantify circulating H2S concentrations has utilized standard curves of similar range, which have 
shown to be linear (160). Although the graph utilized in our study had R2 values greater than 0.99, the 
possibility remains that a standard curve generated specifically within the biological range of our 
analysis may have differing slope than the standard curve utilized in our analysis. It should be noted 
that this is a weakness of the current analysis which should be addressed in future analyses. 
 
Limit of detection for analysis was below 0.2µM as previously reported by Wintner et al (160). Inter 
assay and intra assay coefficient of variation for spiked samples and standards was below 10%. 
2.10.3.6. Plasma fatty acid analysis 
 
Total lipids were extracted from 500µl of plasma with chloroform/methanol (2:1 v/v) containing 0.01% 
butylated hydroxytoluene (BHT) as antioxidant (162). The organic solvent was evaporated under a 
stream of nitrogen and the lipid content was determined gravimetrically. Total lipid fraction (TL) was 
subjected to acid-catalyzed transmethylation for 16 h at 50 ºC, using 1 ml of toluene and 2 ml of 1% 
sulphuric acid (v/v) in methanol. The resultant fatty acid methyl esters (FAME) were purified by thin 
layer chromatography (TLC), and visualised under spraying with 1% iodine in chloroform. After elution, 
FAME were separated and quantified by gas-liquid chromatography using a Hewlett Packard 5890 GC 
and a SGE BPX70 capillary GC column (30 m x 0.22 mm I.D.; SGE UK Ltd) with helium as carrier gas and 
using on-column injection. The temperature gradient started at 115 °C for 3 min, then went to 200 °C 
at 2 °C/min,  2 minutes at 200 °C, and then to 240 °C at 60 °C/min. After 5 minutes at 240°C, it cooled 
to 115 °C and equilibrated for 3 minutes before the next injection.  Individual methyl esters were 
identified by reference to authentic standards and to well-characterized fish oil (PUFA-3 from 
menhaden oil, SUPELCO, Supelco Park, Bellefonte, USA). Data were collected and processed using GC 
Chemstation (version B04-02). 
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2.10.3.7. Plasma analysis of fatty acid epoxides and diols at baseline and in 
response to intervention 
 
Plasma samples were spiked with the corresponding deuterated internal standards (Cayman Europe, 
Tallinn, Estonia) and lipid epoxide and diol derivatives were extracted twice into ethyl acetate (0.5 ml). 
After evaporation of the solvent in a vacuum block under a gentle stream of nitrogen, samples were 
reconstituted with 50μl of methanol-water (1:1, vol/vol). Lipid concentrations were subsequently 
determined with a Sciex API4000 mass spectrometer operating in the multiple reaction monitoring 
mode (163, 164). For the chromatographic separation a Gemini NX C18 column and precolumn were 
used (150 mm × 2 mm i.d, 5μm particle size and 110Å pore size (Phenomenex Aschaffenburg, 
Germany). A linear gradient was employed at a flow rate of 0.5 ml/min mobile phase with a run time 
of 18.5 minutes. Mobile phase A was water/ammonia (100:0.05, v/v) and B acetonitrile/ammonia 
(100:0.05, v/v). The gradient started from 85% A to 10% within 12 min. This was held for another 1 
min at 10% A. Within 0.5 min the mobile phase shifted back to 85% A and was held for 4.5 min to 
equilibrate the column for the next sample. The injection volume of samples was 20μl. Quantification 
was performed with Analyst Software V 1.4.2 (Applied Biosystems, Darmstadt, Germany) employing 
the internal standard method (isotope-dilution mass spectrometry). Ratios of analyte peak area and 
internal standard area (y-axis) were plotted against concentration (x-axis) and calibration curves were 
calculated by least square regression with 1/concentration2 weighting. For each lipid a calibration 
curve from 0.5 to 2500 ng/mL was constructed.  
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Chapter 3 – Screening and clinical results from the Fish Oil 
Fatty Acid (F.O.F.A) Study and insights into the biochemical 
basis of LC n-3 PUFA dependent changes in postprandial 
vascular reactivity 
3.1. Screening of the study population in the F.O.F.A Study 
3.1.1. Introduction 
 
In this study we investigated postprandial modifications in vascular tone in response to EPA or DHA 
consumption in a population estimated to be at a 1.5 relative risk of developing CVD. This population 
was selected according to the inclusion (and exclusion) criteria detailed in section 2.3 (page 50). This 
approach was utilised as we reasoned that any EPA or DHA dependent modifications to vascular tone 
would be of more clinical relevance if observed in a population at an increased risk of cardiovascular 
disease.  
The following section details the results of the screening process employed in the study and 
subsequent discussion on the results of this screening criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 75 | P a g e  
 
3.1.2. Screening results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.1.2.1. Consort diagram detailing trial enrolment, allocation, randomisation of treatments and data included in 
analysis. 
Assessed for eligibility (n=77) 
Excluded (n=49) 
   Not meeting inclusion criteria (n=47) 
   Did not complete screening, due to 
sustained blood pressure greater 
than 150/100mmHg (n=2) 
Analysed  (n=26) 
 n=2, excluded from analysis (did 
not complete all treatments) 
Allocation 
Analysis 
Randomized (n=28) 
Enrollment 
Allocated to consume  
Control fat meal at first visit  
(n=10), (n=1 dropout, no show for  
scheduled visit*) 
 
Allocated to consume DHA rich  
meal at first visit (n=11) 
 
Allocated to consume EPA  
rich meal at first visit (n=7) 
Allocated to consume  
Control fat meal at second  
visit (n=9), (n=1  
dropout due to inability to adhere  
to restrictions**) 
** 
 
Allocated to consume DHA  
rich meal at second visit 
(n=12) 
 
 
Allocated to consume EPA  
rich meal at second visit,  
(n=9)* 
 
Allocated to consume  
Control fat meal at third visit  
(n=9) 
 
Allocated to consume DHA  
rich meal at third visit (n=5) * 
 
Allocated to consume EPA  
rich meal at third visit  
(n=12)** 
 
 
1st visit 
2nd visit 
3rd visit 
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Total cholesterol and HDL-cholesterol screening results 
Median total cholesterol levels are presented below (Figure 3.1.2.2) for all individuals screened, 
volunteers deemed non-eligible and our study population. The average total cholesterol 
concentration of the study participants (5.95mmol/L) was 11% higher than that for all individuals 
screened (5.36mmol/L) and 19% higher than the average for individuals who were deemed ineligible 
(4.99mmol/L).  
Median HDL-cholesterol levels are also presented below (Figure 3.1.2.2) for all individuals screened, 
volunteers deemed non-eligible and our study population. HDL-cholesterol levels were 5% and 3% 
lower in our study participants when compared to the mean for non-eligible individuals and the entire 
group who were screened.  
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Figure 3.1.2.2. Box-plots of 5th and 95th percentiles showing median values and outliers (<5th percentile or >95th percentile) 
for total cholesterol and HDL-cholesterol (high density lipoprotein cholesterol) in non-eligible (n=47), all individuals 
screened who proceeded for blood cholesterol tests (n=75) and eligible participants (n=26). Data for n=2 dropouts is not 
presented. 
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Screening blood pressure values 
Median systolic blood pressure values are shown below (Figure 3.1.2.3) for all individuals screened, 
volunteers deemed non-eligible and our study population. The average systolic blood pressure values 
at screening for the study population was 136mmHg, which was 5.3% and 10.0% higher relative to the 
average for all individuals screened and ineligible individuals respectively. 
Median diastolic blood pressure values are also shown below (Figure 3.1.2.3) for all individuals 
screened, volunteers deemed non-eligible and our study population. The average diastolic blood 
pressure values in our study population was 86mmHg, which was 5.5% and 10.5% higher relative to 
averages for all individuals screened and ineligible individuals. 
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Figure 3.1.2.3. Box-plot of 5th and 95th percentiles showing median values and outliers (<5th percentile or >95th percentile) 
for systolic and diastolic blood pressure in non-eligible (n=47), all screened (n=77) and study population (n=26). Data for n=2 
dropouts is not presented. 
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Table 3.1.2. Study population characteristics with range. Data are presented as mean±SEM.  
3.1.3. Discussion 
The aim of the screening exercise in this study was two-fold; to select study participants that were at 
an increased relative risk of cardiovascular disease relative to the general population and to exclude 
individuals with conditions or lifestyle practices that might interfere with accurately establishing 
nutrient dependent changes in vascular tone. Our rationale for these inclusion criteria was that the 
clinical significance of any nutrient dependent changes in vascular tone would be greater in a 
population with pre-clinical risk factors for CVD. 
When compared to the average population values for total cholesterol in males in the UK, our study 
participant’s average total cholesterol levels were 8.1% higher.  
With reference to HDL-cholesterol results presented in Figure 3.1.2.2, we were successful in selecting 
for a population with lower HDL-C levels relative to the full screening population. The average study 
population HDL-C concentrations did not fall below 1mmol/L and accordingly, it is unlikely that the 
HDL-C values in this population were low enough to deem the population to be at an increased relative 
risk of CVD on the basis of their HDL-C values alone.  
As can be seen in figures 3.1.2.2 and 3.1.2.3, both systolic and diastolic blood pressure measures were 
higher in our study group relative to the excluded individuals and the whole screening population. For 
SBP, the average value was 135mmHg. When compared to average population values for males 
between the ages of 19-64 years in the UK, average systolic blood pressure values in our study 
population were 6.1% higher (165). Similarly, average diastolic blood pressure values of 86mmHg in 
our study population were 14.9% higher than the expected average populational levels for males 
between the ages of 19 and 64 the UK. Accordingly, when viewed together it can be deemed that our 
screening criteria was successful in selecting a population with clinically significant increases in three 
of the most well established traditional cardiovascular risk factors (total cholesterol, systolic blood 
pressure and diastolic blood pressure), but without overt health complications.  
Study population characteristics 
Age 
Total cholesterol (mmol/L) 
HDL-cholesterol (mmol/L) 
Systolic Blood pressure (mmHg) 
Diastolic Blood pressure (mmHg) 
Weight (kg) 
BMI ( kg/m2) 
Waist circumference 
45 +/- 5 (36 - 54) 
5.84 +/- 0.90 (3.8-7.3) 
1.42 +/- 0.28 (0.86 – 2.32) 
136 +/- 10 (101-150) 
86 +/- 7 (67.33 – 104) 
87.07 +/- 11.51 (73.5 - 129.4) 
27.4 +/- 3.3 (20.4 – 39.9 
95.5 +/- 10.4 (76.8 – 128.0) 
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3.2. Vascular measures at baseline and in response to intervention 
3.2.1. Introduction 
 
As detailed in Chapter 1, the effect of LC n-3 PUFA intake on CVD risk has been studied extensively. 
Evidence exists to suggest anti-arrhythmic (35), hypolipidemic (36-39), anti-inflammatory and plaque 
stabilising (41) and cholesterol profile modulating (42, 43) effects for the LC n-3 PUFA. One weakness 
in these investigations is that, due to the lack of availability of pure sources of EPA and DHA, EPA and 
DHA have traditionally been grouped together in investigations of their effects on human health. 
Evidence is beginning to emerge that these two dietary fats may have differential effects on human 
health, with specific reference to their effects on vascular tone and blood pressure. Specifically, 
chronic intervention studies have suggested a potential hypertensive effect for DHA but not EPA (40),  
which corresponds with a capacity for DHA, but not EPA, to modulate fasting vascular tone (57).  
A number of studies have also investigated the effect of EPA and DHA on postprandial vascular tone. 
As mentioned previously, the postprandial state is of particular physiological relevance due to the fact 
that individuals spend the majority of the day in the postprandial state. Recent studies in this context 
have shown that mixed doses of EPA and DHA beneficially modulate postprandial vascular tone (58-
60) and that DHA but not EPA reduces systemic vascular resistance in the postprandial state (61). 
A current research gap is establishing the relative efficacy of EPA and DHA to modulate post-prandial 
vascular tone in at risk populations. We hypothesise that DHA may be more efficacious than EPA in 
modulating postprandial vascular tone. Accordingly, a primary aim of this project was to elucidate the 
relative impact of EPA versus DHA on postprandial vascular tone in a population at an increased risk 
of CVD. 
As mentioned in Chapter 2 and as detailed in Section 2.9.1, a number of vascular measures were 
chosen in order to investigate the effects of EPA and DHA meals on vascular tone and function in our 
study. These measures included Augmentation index, Pulse Wave Velocity, Endopat and 
Endopat*GTN methodologies. 
This section details the results of these investigations on the effects of high fat meals containing EPA 
and DHA on vascular tone. 
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3.2.2. Statistical Analysis 
 
All data are presented as mean +/- standard error of the mean. Statistical analysis was undertaken 
using the SPSS statistical software (version 22; Chicago, Illinois, USA). Prior to analysis all datasets were 
checked for normality via visual inspection of normal Q-Q Plots. Outliers were identified by analysis of 
normal Q-Q Plots and variance in values greater than +/- two standard deviations. Repeated measures 
ANOVA was utilised in order to quantify the significance level for time, treatment and time*treatment 
interactions for measures. For Repeated Measures ANOVA, assumptions of sphericity were assessed 
via Mauchly’s Test of Sphericity. In cases where the assumptions of sphericity were not met a 
Greenhouse-Geisser correction was applied. In cases where significance was reached via initial 
Repeated measures ANOVA, subsequent post-hoc analysis was undertaken in order to investigate 
treatment dependent changes from baseline using repeated measure ANOVA and Bonferroni 
adjustment on change scores. 
For Endopat*GTN investigations a reduced sample size of n=20 was utilised due to loss of data due to 
electricity cuts (n=1), patient discomfort in response to nitroglycerine treatment (n=2) and errors in 
Endopat software reporting output in response to GTN stimulus for some individuals (n=3).  
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3.2.3. Results 
3.2.3.1. Pulse Wave Analysis results 
Analysis showed that the DHA meal significantly improved AI when compared to control.  
Specifically, repeated measures ANOVA showed a significant treatment*time interaction (p=0.005, 
F(2, 50) = 5.88, partial η2 = 0.19), time (p<0.01, F(1, 25) =40.63, partial η2 = 0.62) but not treatment 
(p=0.81, F(2, 50) = 0.21, partial η2 = 0.00) effect. 
Subsequent post-hoc analysis on change from baseline showed that the DHA meal significantly 
decreased mean AI measures by 3.19% when compared to the Control meal (95% CI, 0.03 to 6.35%, 
p=.047). AI is itself measured in percentage and accordingly, the noted 3.19% change is equivalent to 
a 13.3% improvement for the DHA treatment when compared to control. The EPA treatment did not 
significantly decrease mean AI when compared to the control meal (95% CI, -.119 to 5.986%, p=.063). 
Likewise, there were no significant differences between EPA and DHA treatments (95% CI, -2.435to 
1.927%, p=1.000).  
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Figure 3.2.3.1. Mean Augmentation Index values (in %) measured at baseline (0 hours) and 4 hours postprandially in 
response to intervention. Asterisks indicates a significant difference (* p<0.05) in change from baseline in Augmentation 
Index relative to control. Data are presented as mean±SEM. 
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3.2.3.2. Pulse Wave Velocity results 
 
Intervention had no effect on PWV. In this analysis, the assumption of sphericity for the 
treatment*time interaction was violated, as assessed by Mauchly's Test of Sphericity, χ2(2) = 7.362, p 
= 0.025, accordingly a Greenhouse-Geisser correction was applied (ε = 0.791). 
Analysis showed no significant treatment*time interaction, (p=0.32, F(1.58, 39.58) = 1.15, partial η2 = 
0.04), treatment (p=0.15, F(2, 50) = 1.98, partial η2 = 0.07) or time (p=0.85, F(1, 25) = 0.04, partial η2 = 
0.00) effect. 
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Figure 3.2.3.2. Mean Pulse Wave Velocity values (in m/s) measured at baseline (0H) and 4 hours postprandially in response 
to intervention. Data are presented as mean±SEM. 
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3.2.3.3. Endopat results 
None of the intervention meals impacted the Endopat RHI measure. 
Specifically, repeated measures ANOVA showed no significant treatment*time interaction for the RHI 
measure (p=0.92, F(2, 48) = .082, partial η2 = 0.003), or time (p=0.75 , F(1, 24) = 0.10, partial η2 = 0.00) 
or treatment (p=0.56, F(2, 48) =0.59, partial η2 = 0.02) effect. 
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Figure 3.2.3.3. Mean Reactive Hyperaemia values measured at baseline (0H) and 4 hours postprandially in response to 
intervention. Data are presented as mean±SEM. 
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3.2.3.4. Endopat*GTN results 
 
Repeated Measures ANOVA showed no significant effect for treatment (p=0.59, F(2, 38)=0.55, 
partial η2 = 0.03), accordingly post-hoc analysis was not undertaken. 
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Figure 3.2.3.4. Mean Reactive Hyperaemia values measured in response to nitrogylcerine (400µg) administration at 4 
hours postprandially. Data are presented as mean±SEM. 
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3.2.3.5. Blood pressure results 
 
Interventions had no effect on systolic or diastolic blood pressure. 
In this analysis, the assumption of sphericity was violated for the treatment effect for systolic and 
treatment*time interaction for diastolic blood pressure. Accordingly, Green-Geisser corrections were 
applied (ε = 0.79 and 0.76 respectively). 
Analysis showed no significant treatment*time interaction (p=0.38, F(2, 50) = 0.98, partial η2 = 0.04), 
treatment (p=0.09, F(2, 50) = 2.54, partial η2 = 0.09) or time (p=0.93, F(1, 25) =0.08, partial η2 = 0.00) 
effect for systolic blood pressure. Similarly, analysis showed no significant treatment*time interaction 
(p=0.15, F(1.51, 37.82) = 2.05, partial η2 = 0.076), time (p=0.25, F(1, 25) = 1.38, partial η2 = 0.05) or 
treatment (p=0.35, F(2, 50) =1.07, partial η2 = 0.04) effect for diastolic blood pressure. 
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Figure 3.2.3.5. Mean diastolic blood and systolic blood pressure values measured at baseline and in response to intervention. 
Data are presented as mean±SEM. 
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3.2.4. Discussion 
 
Our results indicate that although EPA and DHA both improve AI measures postprandially, this effect 
only reaches significance for DHA and this is reflective of a greater effect size for DHA (13.3% when 
accounting for changes in response to control meal) when compared to EPA (11.3% when accounting 
for changes in response to control meal). We did not observe an effect for any of our treatments on 
PWV, Endopat RHI, Endopat RHI in response to GTN, SBP or DBP. These results are discussed in depth 
in the following sub-sections. 
3.2.4.1. Discussion of Pulse Wave Analysis results 
 
As shown in Figure 3.2.3.1, Augmentation Index measures decreased postprandially in each 
treatment. Analysis, showed a significant treatment*time interaction. Accordingly, subsequent post-
hoc analysis was undertaken in order to investigate treatment dependent changes from baseline using 
repeated measure ANOVA and Bonferroni adjustment. Testing revealed that the DHA meal 
significantly improved mean AI measures by 13.3% when compared to the Control meal. Although 
there was a trend towards an improvement in mean AI measures in response to EPA treatment when 
compared to the control meal, this effect did not reach statistical significance (p=0.06). It is also worth 
noting that there were no significant differences between EPA and DHA treatment. 
As mentioned in section 2.7.4, the Augmentation Index outcome is dependent on the elastic effects 
of the entire arterial tree. Changes in these elastic effects is one of the causes of increasing blood 
pressure with advancing age and in diseases states that increase arterial stiffness prematurely. 
Augmentation Index has also been shown to decrease acutely upon administration of vasodilatory 
compounds such as nitroglycerin and increase upon administration of compounds with 
vasoconstrictive effects, such as angiotensin II (10). Accordingly, it is known that this measure is 
sensitive to acute changes in vascular tone.  
  
Taken as a whole, this evidence suggests that the inclusion of DHA in a high fat meal improves 
postprandial vascular reactivity. DHA’s bioactivity in this regard is consistent with investigations on 
the impact of chronic DHA supplementation on fasting vascular tone (166). For example a 6 week 
intervention of DHA (4g/day) but not EPA (4g/day) enhances vasodilation in the fasting state (57). 
Specifically, these investigations showed that DHA supplementation improved endothelium 
independent vasodilatory response as measured by forearm blood flow in response to a number of 
 87 | P a g e  
 
agonists and antogonists of vascular tone, including acteylcholine+L-NNMA, nitroprusside and 
norepinephrine but not L-NNMA alone. 
 
Our evidence corroborates the results in our group’s previously published paper that showed inclusion 
of fish oil containing both EPA and DHA in a high fat meal had a positive effect on microvascular tone 
as assessed by Laser Doppler Iontophoresis (58). Furthermore, our study corroborates investigations 
by Chong et al (59), which have reported that inclusion of EPA (2.0g) and DHA (2.7g) in a high fat meal 
(30g of palm oil and soy bean oil in a 4:1 ratio) improves AI and Digital Volume Pulse-stiffness index in 
both males and females. Our findings are also in part consistent with those of Rontoyanni et al, who 
showed that the  consumption of DHA (4.7g) but not EPA (4.7g) in a high fat meal impacts exercise 
induced changes in systemic vascular resistance (SVR), but does not impact changes to SVR at rest 5 
hours postprandially (61). In this study a finger arterial BP monitor, namely the Finometer, was used 
to estimate SVR from mean arterial pressure divided by cardiac output. Finometer strength lies in its 
capacity to accurately measure of blood pressure during exercise (167). However, it has been noted 
that arterial pressure waveforms distort between brachial and finger arteries and accordingly, 
correction, through utilisation of a waveform filter, is required to improve systolic blood pressure 
tracking with this method. Accordingly, in this context AI can be considered more sensitive in the 
information it yields on changes to vascular tone and wave reflection. Further to this, AI has been 
shown to be associated with increased European Society of Cardiology (ESC) risk levels (9). However, 
it should be noted that AI as measured in our study, in contrast to Finometer measurement of SVR, is 
not an appropriate methodology for use in the context of exercise. 
 
It should also be noted that our results contrast somewhat with a recently published paper by Purcell 
et al (62), which has indicated that neither inclusion of EPA and DHA (5g in a 4:3 ratio) or inclusion of 
DHA (5g) in a meal high in MUFA (75g of total fat) impacted AI significantly when compared to a high 
MUFA reference meal in 16 healthy males (62). This study showed no effect for either the EPA and 
DHA meal, or the DHA meal, when compared to the reference high MUFA meal on AI. A trend for 
greater decreases in Digital Volume Pulse-Reflective Index (indicative of changes in vascular tone of 
peripheral resistance arteries) was observed postprandially for the DHA meal, however, these effects 
did not reach significance. Our investigations differed somewhat in study design which may account 
for some of the discrepancy between these results. These studies differed with specific reference to 
sample size (n=14 in the study by Purcell et al for the AI analysis as compared to n=26 in our study), 
study population and meal design. Of these considerations study population and meal design are 
probably of the most relevance although the impact of study power may also have played a part. 
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Specifically, as detailed in section 3.1, our study population was comprised of individuals estimated to 
be at a 1.5 increased relative risk of CVD based on fitting into a profile of being either pre-
hypertensive/hypertensive, having central obesity or possessing pre-clinical cholesterolemia, as 
compared to the study population in the study by Purcell et al who were not an “at risk” population 
but did have increased fasting triglyceride levels relative to our study population (mean SBP, DBP, 
triglyceride and total cholesterol values were 122 mmHG, 80 mmHg, 1.88mM and 5.25mM 
respectively in the study by Purcell et al). In addition, meal design differed significantly between these 
studies. This study by Purcell et al utilised a meal which contained 75g total fat in each meal, 92.8 g 
carbohydrate, and 14.4 g protein. This compared to 42.4 g total fat, 73.75g carbohydrate and 17.75 g 
protein in our study. With regards to meal fat composition, the reference meal in the above cited 
study contained primarily oleic acid (18:1) whereas our control meal fat content composed of primarily 
oleic acid, palmitic acid (16:0) and linoleic acid (18:2 n6) (please see Table 2.6.3). Interestingly in the 
study by Purcell et al, a fourth meal high in linoleic acid (18:2 n6) seemed to have a negative effect on 
postprandial AI when compared to the mixed EPA and DHA, DHA and reference MUFA meal. These 
results might be suggestive of the presence of a relatively high amount of linoleic acid (22.3% of total 
fat) in our control meal contributing to the significant differences seen between DHA and control 
meals in our study. As mentioned previously, previous reports in the literature (59) have shown a 
capacity for a mixed dose of EPA (2.0g) and DHA (2.7g) in a high fat meal (30g of palm oil and soybean 
oil in 4:1 ratio) to improve postprandial AI in a high fat meal. Our study corroborates these reports, 
and suggests that DHA is slightly more efficacious than EPA in its capacity to positively influence 
postprandial vascular tone. When taken as a whole, the differences in these studies might suggest 
that individuals may respond differentially dependent on basal blood pressure status and potentially, 
that the n-6 fatty acids may play a role in increasing postprandial vascular tone. This consideration 
warrants further attention in future studies. 
 
Our knowledge of arterial constitution and function suggests that the effects of DHA on AI are 
mediated in small arteries and arterioles, which tend to exert a greater effect in determining systemic 
resistance in the arterial tree. If this was to be investigated in the future, direct imaging of arteries via 
ultrasound techniques, such as FMD, may yield further detail on where these changes on wave 
reflections and Augmentation Index are physiologically determined in the arterial tree.  
 
From a clinical stand point, a habitual 13.3% improvement of AI score would be considered clinically 
significant. Based on previous studies which have investigated associations between AI and European 
Society of Cardiology risk levels (9) a 13.3% habitual improvement in this measure would equate 
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approximately to a decrease in 10 year relative risk of CVD from 3.25% to 2.83%. It is important to 
consider that this improvement in AI, likely mediated by decreased vascular tone and accordingly, 
decreased systematic resistance in the arterial tree, is also indicative of decreased left ventricular load. 
Indications suggest that modifications to left ventricular load dependent on microvascular tone are 
associated with the development of left ventricular hypertrophy and the pathogenesis of ischemic 
heart disease (168). Accordingly, overtime a habitual 13.3% improvement in AI would not only be 
indicative of improved vascular tone, but may also correlate with decreased instances of left 
ventricular hypertrophy. Insights from the Framingham Study suggest that cardiac hypertrophy, in 
particular left ventricular hypertrophy, is a particularly strong predictor of congestive heart failure and 
is an “ominous harbinger” of this condition (169).   
 
It could be hypothesised, on the basis of these results that long term DHA consumption might be 
slightly more efficacious in improving vascular tone than EPA and this in turn, might correlate with 
decreased cardiovascular risk in individuals who habitually consume greater amounts of DHA. This 
finding adds to the body of evidence which suggests that establishing the individual long term effects 
of DHA and EPA, as distinct dietary fats, on CVD outcomes is warranted. 
3.2.4.2. Discussion of Pulse Wave Velocity Results 
 
Our results did not indicate an effect for meal fat composition on changes on changes to PWV 
postprandially. Our finding is similar to other previous investigations which have also shown that PWV 
does not change acutely dependent on the composition of meal fat (170). Specifically this study 
investigated whether replacement of a stearic acid rich fat source by an oleic acid rich fat source 
impacted measures of vascular function, including PWV. However, it is possible that long-term 
consumption of DHA or EPA might slow the increase of PWV with age. A cohort study looking at 
differences in PWV in age matched individuals from fishing and farming villages in Japan has suggested 
that this may be the case (171). Meta-analysis of ten LC n-3 PUFA trials (with a pooled sample size of 
n=550), defined as chronic to sub-chronic in length, is also supportive of such an effect for EPA and 
DHA on PWV (172).  However, it remains unknown what the exact contributions of EPA and DHA are. 
As previously discussed in Section 2.7.4, the Pulse Wave Velocity measure is a proximal measure of 
gross arterial stiffness determined by the speed at which pulse wave travels through the arterial tree. 
As arteries are exposed to mechanical and chemical stress as we age, the elastic fibres in the arteries 
tend to fray and stiffen. This has a number of implications for cardiovascular disease, with regards to 
its impact on the Pulse Wave Velocity measure, the increase in arterial stiffness tends to increase the 
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speed at which ejected pulse waves travel throughout the arterial tree (173). In turn, these changes 
in pulse wave velocity have a tendency to negatively augment the arrival of reflected waves to the 
heart leading to a positive contribution to central SBP, which in turns increases the force needed for 
the left ventricle to maintain adequate coronary blood flow. Viewed broadly, increases in PWV can be 
considered an intrinsic part of the pathogenesis of myocardial infarction. 
 
With regards to potential acute changes to PWV, the Moens-Korteweg equation that defines PWV, 
which is shown below in Figure 3.2.4.2, indicates that arterial radius does contribute to PWV. 
Furthermore, arterial radius is intrinsically linked to vascular tone. However, it should be noted that 
as according to the Moens-Korteweg equation any decrease in radius (R) as a result of an increase in 
vascular tone will be counterbalanced by an increase in arterial thickness (h) and an intrinsic alteration 
of the elasticity of the vessel (E).  
 
Figure 3.2.4.2. The formula for PWV.  
On the basis of these findings, it can be reasonably deducted that EPA and DHA consumption, or 
indeed meal fat content, do not impact PWV acutely, however, this does not necessarily correlate with 
their efficacy in modulating vascular tone of peripheral conduit arteries, small arteries and arterioles, 
whose tone, do not tend to impact PWV acutely. As mentioned, the possibility of differential effects 
of EPA and DHA on PWV in the longer term should not be discounted and warrants further 
investigation. 
3.2.4.3. Discussion of Endopat and Endopat*GTN Results 
 
We were not able to detect any changes from baseline in response to meal fat dependent on time, 
treatment effects or treatment*time interactions (see Figure 3.2.3.3). Previous research in this 
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context has yielded mixed results, one study has shown that inclusion of EPA and DHA (0.07g/kg 
bodyweight, 1:9.5 ratio) in a saturated fat meal (0.45g/kg bodyweight) improves postprandial 
endothelium dependent vascular reactivity, as measured by FMD, relative to a saturated fat control 
meal (0.52g/kg) (174). Previous studies by our group suggest no effect for EPA and DHA consumption 
on postprandial endothelium dependent vascular reactivity as measured by Laser Doppler 
Iontophoresis in response to acetycholine (58). Other studies have observed that chronic responses 
to DHA (1.6g/day for 16 weeks) do not impact fasting FMD measures (175).  Finally a study comparing 
the effects of 4/g day of either EPA or DHA or olive oil showed that DHA improved fasting endothelium 
independent forearm blood flow responses but not fasting endothelium dependent forearm blood 
flow responses (57). Due to the broad array of methodologies employed in these studies a proper 
comparison of these effects requires careful attention to the methodologies employed. 
 
With regards specific considerations for the Endopat RHI measure utilised in our study, previous 
investigation of the Endopat RHI output has indicated that it correlates with the gold standard 
measurement of endothelial function FMD (176). Furthermore, it is reasonably operator independent. 
However, it should be noted that during our use of the technique a number of challenges were 
encountered. In this study we observed high intra-individual variance between individuals at baseline, 
which were consistent with reports from other vascular studies undertaken in parallel at the University 
of East Anglia. As noted in the methods section, our measures were undertaken in a temperature 
controlled environment and individuals were given a period to rest and adjust to room temperature 
before measurement. These considerations were taken into account to control for any potential 
effects of temperature on the cutaneous vascular beds, which is a weakness of the Endopat technique, 
although perhaps not a weakness specific to Endopat as FMD and the Laser Doppler iontophoresis 
technique are also subject to temperature dependent changes in their outputs. Critically, other 
indications have since emerged in the literature which suggest that Endopat is not sufficiently sensitive 
to assess changes in endothelial function in early stage clinical pharmacological interventions (177). 
Specifically, this study indicated that Endopat is not able to detect changes in endothelial function in 
renally impaired and type-II diabetics, when compared to a healthy population. Furthermore, Endopat 
was not able to detect changes in endothelial function in robust interventions in healthy populations, 
including investigations on glucose load and smoking. This information, when taken into consideration 
with the findings of our study, is suggestive that the Endopat measure may be suited towards 
qualitatively establishing the presence of endothelial dysfunction, but may not be ideally designed for 
the quantitative measurement of endothelial function, in particular in the context of measuring acute, 
non-chronic subtle responses to intervention.  
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In short, taken on face value, our data suggests that neither EPA nor DHA meals in our study impacted 
postprandial endothelial dependent vascular tone. This is broadly in line with other indications in the 
literature but it should be noted that there isn’t a clear consensus in this regard, as discussed in this 
section and section 1.7.1. Furthermore, we suggest caution in interpretation of this result due to 
differences in methodologies employed, with specific reference to the methodological considerations 
for Endopat described above.  
 
We were also unable to detect any changes in response to Endopat in response to nitroglycerine 
administration dependent on treatment (see Figure 3.2.3.4). This experimental approach was 
developed in order to estimate contributions independent of NO production on the RHI response. It 
should be noted that we did observe an increase in amplitude of the peripheral arterial tone 
measurement used to calculate the Endopat RHI output in response to nitroglycerine administration 
(400mg) as expected. This  is indicative of the peripheral arterial tone measurement in Endopat being 
dependent on circulating NO and corroborates the suggestions that the increase in  peripheral arterial 
tone in the Endopat measure in response to brachial artery occlusion is dependent on increased NO 
production.  
 
In summary, we were not able to pick up changes in vascular tone via the Endopat measure for EPA, 
DHA or control meals. We feel that that although the Endopat measure, from a theoretical perspective, 
is based on sound physiological principles, it may not be sensitive enough to pick up on acute 
physiological changes in endothelial function. As mentioned, previous indications in the literature 
suggest that this may be the case (177). We further suggest that Endopat’s utility in measuring acute 
changes in endothelial function should be evaluated carefully. 
3.2.4.4. Discussion of blood pressure results 
Our results did not indicate any changes in systolic or diastolic blood pressure dependent on time, 
treatment or treatment*time effects (see Figure 3.2.3.5). Furthermore, we did not observe any 
significant differences in the baseline measures between the 3 visits. It is however worth noting, that 
we did observe a modest decrease in both diastolic and systolic blood pressure at the assessment 
visits when compared to screening visits. This effect was likely due to habituation to the surroundings 
of the clinic and the patients being more comfortable at follow up visits, given that blood pressure 
measurement protocol was kept consistent across visits. However, it is not implausible that dietary 
restrictions in the lead up to assessment visits, which prohibited caffeine consumption, impacted 
these measurements favourably due to caffeine’s capacity to raise blood pressure acutely (178). 
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Our observations are corroborative of previous intervention studies of similar design which have 
indicated neither mixed doses of EPA and DHA (1g total, ratio not disclosed) (79),  or 4.7g of EPA or 
DHA within a high fat meal effects  postprandial measures of blood pressure (61). However, it should 
be noted that the previous study by Rontoyanni et al, suggests an effect for DHA in modulating 
diastolic BP response to exercise in the postprandial state (61), which was not assessed in our study. 
Another recently published study by Purcell et al (62), has also indicated that neither inclusion of EPA 
and DHA (5g in a 4:3 ratio) or inclusion of DHA (5g) in a meal high in MUFA (75g of total fat) impacted 
SBP or DBP 16 healthy males (62).  
3.2.4.5. Summary 
 
In summary, our data indicates that although EPA and DHA both improve AI measures postprandially, 
this effect only reaches significance for DHA (p=0.04) and this is reflective of a slightly greater effect 
size for DHA when compared to EPA. These effect sizes equated to a 13.3% and 11.3% improvement 
in AI relative to control for DHA and EPA respectively. As mentioned previously, it is known that 
increases in AI correlate with increases in CVD risk (9). A  habitual 13.3% improvement in this measure 
would equate approximately to a decrease in 10 year relative risk of CVD from 3.25% to 2.83% 
according to previously established correlations between the European Society of Cardiology Risk 
Levels and AI (9). Our findings suggest for the first time, that DHA is more efficacious than EPA in 
modulating resting postprandial vascular tone. Furthermore, when considering the impact of these 
effects in the longterm, these findings are suggestive of DHA having a greater capacity to chronically 
improve vascular function and associated health conditions. These findings should be considered in 
the context of potential therapeutic uses of these fatty acids, and further inform us of the unique 
properties of these individual dietary nutrients. 
Given that individuals tend to spend the majority of the day in the postprandial state, these changes 
in postprandial vascular reactivity are likely to correlate with the chronic effects of EPA and DHA on 
vascular function, when habitually consumed. Also it should be noted, that measurement of fasting 
vascular tone in response to dietary intervention, although useful in part for standardisation purposes, 
cannot be considered to correlate fully with the normal physiological state of the average individual; 
who tends to spend 16 to 18 hours of the day in the postprandial state.  
With regards to potential mechanisms, this effect on AI is likely indicative of the activity of blood borne 
vasoactive factors in the small peripheral arteries and arterioles of the arterial tree, as these tend to 
more reactive to changes in vascular tone. We also know that AI tends to be sensitive to changes in 
vascular tone in this part of the arterial tree. The following section (3.3) of this chapter, describes our 
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investigations on the blood borne vasoactive factors which may be involved in mediating these effects 
in the peripheral arterial tree. 
We did not detect any changes in PWV or blood pressure in this acute study. We were also unable to 
detect changes in the Endopat RHI measure. As mentioned in Section 4.2.5.3, although the 
physiological basis of Endopat seems sound, there are indications that it may not be sufficiently 
sensitive to pick up on acute or early changes in endothelial function and its use in this context 
warrants further investigation.  
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3.3. Biochemical analysis of biological samples at baseline and in 
response to intervention 
3.3.1. Introduction 
Although a number of studies have investigated modifications to blood borne vasomediators in 
response to EPA and DHA consumption, the literature has failed to come to a consensus on how EPA 
and DHA dependent changes in vascular tone are mediated. Some investigations have observed 
postprandial changes to total NOx in response to a mixed dose of EPA and DHA (58), however there 
has not been a consensus in this regard with some other studies showing no effect on NOx, nitrite or 
nitrate (62, 80). This is similarly reflected in a lack of consensus of whether changes in vascular tone 
dependent on EPA and DHA are mediated in an endothelium dependent or endothelium independent 
manner with some studies suggesting the former (60, 174) and others suggesting the latter (57, 58).  
 We opted to investigate NO, via quantification of plasma nitrite levels in our study via 
chemiluminescent reaction with O3, which is thought to be the most sensitive clinically feasible 
measure of changes in NO. Quantification of plasma nitrite has been shown to be the most reliable 
measure of NO production and to correlate more reliably than NOx or nitrate with changes in vascular 
tone (179). Furthermore, given that studies have shown links between DHA and tissue levels of CSE 
(an enzymatic producer of H2S) in Sprawgue-Dawley rats, and reports of potential modifications to 
cysteine metabolism dependent on LC n-3 PUFA (86), we investigated changes In plasma levels of H2S 
in response to EPA and DHA consumption. This was undertaken to investigate if H2S may play a role in 
mediating EPA or DHA’s capacity to modulate vascular tone. Finally given that the LC n-3 PUFA epoxide 
metabolites have been shown to robustly and efficaciously directly modify vascular tone in in-vitro 
whole blood vessel models (131-134), we hypothesised that these compounds may contribute, or 
potentially be responsible for, EPA and DHA dependent changes in vascular tone. To the best of our 
knowledge, our study is the first to examine the production of these compounds in the postprandial 
state in response to physiological consumption of EPA and DHA. Furthermore, our study is the first to 
compare changes in the profile of these LC n-3 PUFA epoxides and diols in response to EPA and DHA 
rich meals.  
Serum triglyceride, NEFA and glucose concentrations were also established at baseline and in response 
to meal consumption to investigate how meal composition affected triglyceride, NEFA and glucose 
metabolism at 0h and 4h postprandially. 
The following section details the biochemical analysis conducted on blood samples generated at 
baseline and at 4 hours postprandially (i.e. in response to intervention) during the F.O.F.A study.  
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3.3.2. Statistical Analysis 
 
All data are presented as mean +/- standard error of the mean. Statistical analysis was undertaken 
using the SPSS statistical software (version 22; Chicago, Illinois, USA). Prior to analysis all datasets were 
checked for normality via visual inspection of normal Q-Q Plots. Outliers were identified by analysis of 
normal Q-Q Plots and confirmed due to variance +/- two standard deviations. Repeated measures 
ANOVA was utilised in order to quantify the significance level for time, treatment and time*treatment 
interactions for measures. For Repeated Measures ANOVA, assumptions of sphericity were assessed 
via Mauchly’s Test of Sphericity. In cases where the assumptions of sphericity were not met a 
Greenhouse-Geisser correction was applied. In cases where significance was reached via initial 
Repeated measures ANOVA, subsequent post-hoc analysis was undertaken in order to investigate 
treatment dependent changes from baseline using repeated measure ANOVA and Bonferroni 
adjustment on change scores. 
For serum glucose analysis and plasma H2S analysis n=1 and n=2 samples were lost during analysis 
respectively. For serum triglyceride analysis data for n=3 individuals was omitted on the basis of 
variance in values +/- 2 standard deviations. For plasma H2S analysis and nitrite analysis data for n=2 
and n=4 individuals were omitted due to variance greater than 2 standard deviations at baseline. 
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3.3.3. Results 
3.3.3.1. Serum triglyceride and NEFA results at baseline and in response to 
intervention 
 
Analysis showed no significant differences between treatments on serum triglyceride concentrations.  
Specifically, analysis showed no significant treatment*time interaction for serum triglycerides, p=0.36, 
F(1, 22) = 59.14, partial η2 = 0.04. Accordingly, no further investigation was undertaken for 
treatment*time effects. Analysis showed significant differences dependent on time as expected, 
p<0.001, F(2, 44) = 1.01, partial η2 = 0.73, with 40% higher levels at 4h vs 0h, but no significant effect 
of treatment alone, p=0.36, F(2, 44)=1.12, partial η2=0.05. 
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Figure 3.3.3.1.1. Mean serum triacylglycerol concentration measured at baseline and in response to treatment. Data are 
presented as mean ± SEM. 
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Analysis showed no significant difference between treatments on serum NEFA concentrations at 4 
hours postprandially. 
Specifically, repeated measures ANOVA showed no significant treatment*time interaction for NEFA 
concentration (p=0.90, F(2, 50) = 0.11, partial η2 = 0.004) or treatment (p=0.47, F(2, 50) = 0.76, partial 
η2 = 0.03). As expected, we saw a significant effect for time (p=0.02, F(1, 25) = 5.75, partial η2 = 0.19). 
Average concentrations (for 3 treatment groups combined) were 0.33 mM and 0.38 mM at 0h and 4h 
respectively. 
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Figure 3.3.3.1.2. Mean serum NEFA concentration measured at baseline and in response to treatment. Data are presented 
as mean ± SEM. 
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3.3.3.2. Serum glucose results at baseline and in response to intervention 
 
Analysis showed no difference between treatments on serum glucose concentrations at 4 hours 
postprandially. 
Analysis showed no significant effect for treatment*time interaction (p=0.49, F(2, 48) = 0.73, partial 
η2 = 0.03) or for treatment (p=0.22, F(1, 24) = 1.55, partial η2 = 0.06). There was a significant effect for 
time (p<0.001, F(1, 24) = 27.37, partial η2 = 0.53), with glucose concentrations decreasing by 9% 
postprandially. 
 
 
 
 
 
Figure 3.3.3.2. Mean serum glucose concentration measured at baseline and in response to treatment. Data are presented 
as mean ± SEM. 
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3.3.3.3. Plasma Hydrogen sulphide analysis at baseline and in response to 
intervention 
 
Analysis showed no effect of meal consumption or any significant differences between meals on 
plasma H2S concentrations. 
Specifically, Repeated Measures Anova showed no significant effect for the treatment*time 
interaction for plasma H2S concentrations, (p=0.35, F(2, 42) = 1.08, partial η2 = 0.05), treatment 
(p=0.80, F(2, 42)=0.23, partial η2 = 0.01) or time effects (p=0.76, F(1, 21)=0.10, partial η2 = 0.01). 
Accordingly, differences in meal fat content had no significant effect on postprandial H2S 
concentration and no further post-hoc analysis was undertaken. 
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Figure 3.3.3.3. Mean plasma H2S concentration measured at baseline and in response to treatment. Data are presented as 
mean ± SEM. 
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3.3.3.4. Plasma nitrite levels at baseline and in response to treatment 
 
Analysis showed no effect of meal consumption or any significant differences between meals on 
plasma nitrite concentrations. 
Specifically, Repeated Measures Anova showed no significant effect for the treatment*time 
interaction for plasma nitrite concentrations, (p=0.46, F(2, 42) = 0.78, partial η2 = 0.04), treatment 
(p=0.76, F(2, 42)=0.28, partial η2 = 0.01) or time effects (p=0.37 F(1, 21)=0.89, partial η2 = 0.04). 
Accordingly, differences in meal fat content had no significant effect on postprandial nitrite 
concentrations and no further post-hoc analysis was undertaken. 
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Figure 3.3.3.4. Mean plasma nitrite concentration measured at baseline and in response to treatment. Data are presented 
as mean ± SEM. 
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3.3.3.5. Plasma fatty acid analysis 
The fatty acid data was expressed in both % of total fatty acid (see supplementary Annex 4, Table A) 
and concentration (μg/ml plasma) terms. Here in the main text the data is given in concentration, 
which is a more physiologically meaningful way of considering the data in the current context, where 
absolute amounts are likely to provide a better insight into the association of plasma fatty acids and 
vascular tone. 
 
Plasma fatty acid concentrations at baseline and in response to treatment 
 
Table 3.3.3.5. Plasma fatty acid concentration at baseline and in response to treatment. Data presented as mean±SEM. 
1Indicates significant effect for time by Repeated Measures Anova, 2Indicates significant effect for treatment by Repeated 
Measures Anova, 3Indicates significant effect for time*treatment effect by Repeated Measures Anova. *Indicates a 
significant difference in change from baseline when compared to control. 
 
 
 
 
Fatty acid Control meal 
(0h) 
Control meal 
(4h) 
EPA meal 
(0h) 
EPA meal 
(4h) 
DHA meal 
(0h) 
DHA meal 
(4h) 
16:0  
(µg/ml) 
87.01±14.93 89.89±7.81 89.87±8.35 90.58±7.65 86.54±10.00 91.72±7.89 
16:1  
(µg/ml) 
8.68±2.05 7.12±0.57 8.71±0.93 7.84±0.85 7.80±1.01 7.57±0.80 
18:0 
 (µg/ml) 
28.30±4.78 29.30±2.65 28.48±2.80 27.33±2.25 27.92±3.36 28.11±2.36 
18:1  
(µg/ml) 
94.98±4.78 98.27±6.88 95.66±10.03 95.31±8.72 95.17±10.89 102.62±9.01 
18:2n6 
(µg/ml) 
105.92±19.43 103.48±8.33 101.97±10.63 99.46±8.76 95.30±7.94 100.66±8.29 
18:3n3 
(µg/ml) 
2.50±0.39 2.88±0.23 2.24±0.31 2.94±0.33 2.84±0.62 3.07±0.33 
18:3n6 
(µg/ml) 
1.64±0.22 1.70±0.20 1.66±0.20 1.81±0.20 2.17±0.48 1.78±0.20 
20:3n6 
(µg/ml) 
6.35±1.28 5.83±0.57 6.44±0.69 5.97±0.49 5.90±0.66 5.90±0.53 
20:4n6 
(µg/ml) 
24.79±3.50 24.17±2.23 25.45±3.03 23.72±2.29 23.90±3.57 24.07±2.40 
20:5n3123 
(µg/ml) 
3.00±0.41 3.49±0.62 3.31±0.38 8.49±1.46* 3.66±0.74 5.08±0.64 
22:5n33 
(µg/ml) 
0.88±0.14 1.04±0.15 1.07±0.16 0.74±0.12 0.80±0.12 0.92±0.13 
22:6n3123 
(µg/ml) 
6.59±1.28 6.44±0.66 6.70±0.78 7.54±0.83 6.44±0.91 12.00±1.28* 
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Figure 3.3.3.5. Graph showing plasma fatty acid  concentrations of minor plasma fatty acids (<10% of total fatty acids) at 
baseline and in response to treatment. Data are presented as mean±SEM.  
 
 
 
Figure 3.3.3.5.1. Graph showing plasma fatty acid  concentrations of major plasma fatty acids (>10% of total fatty acids) at 
baseline and in response to treatment. Data presented as mean±SEM.  
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No significant effect of time, treatment or  a time*treatment interactions was evident for C16:0, C16:1, 
C18:0, C18:1, C18:6n6, C18:3n3, C20:3n6, C20:4n6 (Table 3.3.4.5). 
20:5 n3 (EPA) 
Analysis showed significant treatment*time interactions (p=0.008, F(2, 50)=5.32, partial η2 = 0.18). 
Analysis also showed significant differences dependent on treatment (p=0.004, F(2, 50 )=6.10, partial 
η2 = 0.20) and time (p<0.001, F(1, 25)=17.61, partial η2=0.41). 
Post-hoc analysis revealed that the EPA meal significantly increased mean EPA concentrations (by 
156%) when compared to the control meal (95% CI, 0.44 to 8.94, p=0.03) but not the DHA meal (95% 
CI, -0.58 to 8.10, p=0.10). Although a 58% increase in EPA from baseline was evident, the DHA meal 
did not significantly change EPA concentrations when compared to the control meal (95% CI, -2.05 to 
3.91, p=1.00).  
22:5 n3 (DPA) 
Analysis showed significance for treatment*time interactions (p=0.02, F(2, 50)=4.03, partial η2 = 0.14) 
but no significant differences dependent on treatment alone (p=0.66, F(2, 50 )=0.42, partial η2 = 0.02) 
or time (p=0.86, F(1, 25)=0.03, partial η2=0.00). 
Post-hoc analysis revealed that after bonferonni correction, no treatment had a significant impact on 
changes in DPA concentration from baseline. P=0.07 for the control meal and EPA meal comparison, 
p=1.00 for the control meal and DHA meal comparison and p=0.12 for the DHA meal and EPA 
comparison. No further analysis analysis was undertaken and it was concluded that meal fat content 
did not impact plasma DPA concentrations significantly. 
22:6 n3 (DHA) 
Analysis showed significant treatment*time interactions (p=0.007, F(2, 50)=5.412, partial η2 = 0.18). 
Analysis also showed significant differences dependent on treatment (p=.005, F(2, 50 )=5.89, partial 
η2 = 0.19) and time (p=0.006, F(1, 25)=9.19, partial η2=0.27). 
Post-hoc analysis revealed that the DHA meal significantly increased mean DHA concentrations (by 
100%) when compared to the control meal (95% CI, -0.03 to 11.46, p=0.05) and to the EPA meal (95% 
CI, 0.35 to 9.11, p=.03). Although there was an increase of 12% the EPA meal did not significantly 
change DHA concentrations when compared to the control meal (95% CI, -4.97 to 3.00, p=1.00).  
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3.3.3.6. Plasma epoxide and diol metabolites at baseline and in response 
to treatment 
A repeated measures ANOVA was conducted to determine the significance of treatment and time 
effects and treatment*time interactions for all epoxide and diol metabolite concentrations.  
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Figure 3.3.3.6. Mean plasma n-3 PUFA epoxide and diol concentrations at baseline and in response to treatment. Data are 
presented as mean±SEM. 
 
Table 3.3.3.6. Mean plasma n-3 PUFA epoxide and diol concentration measured at baseline and in response to treatment. 
Data are presented as mean±SEM. 1Indicates significant effect for time by Repeated Measures Anova, 2Indicates significant 
effect for treatment by Repeated Measures Anova, 3Indicates significant effect for time*treatment effect by Repeated 
Measures Anova. *Indicates a significant difference in change from baseline when compared to control. 
 
 Control meal 
(0h) 
Control meal 
(4h) 
EPA meal 
(0h) 
EPA meal 
(4h) 
DHA meal 
(0h) 
DHA meal 
(4h) 
14, 15-EpETE2,3 
(pg/ml) 
0.60±0.29 0.00±0.00 0.45±0.27 2.89±0.78* 0.39±0.21 0.48±0.13 
14, 15-DiHETE1,2,3 
(pg/ml) 
1.54±0.10 
 
1.54±0.03 1.66±0.14 3.22±0.35* 1.56±0.04 2.16±0.10* 
17, 18-EpETE1,2,3 
(pg/ml) 
0.88±0.50 0.45±0.03 0.65±0.25 9.90±1.81* 0.74±0.26 2.62±0.42* 
17, 18-DiHETE1,2,3 
(pg/ml) 
2.99±0.47 2.65±0.19 2.87±0.28 9.7±1.00* 2.83±0.17 6.00±0.44* 
15S-HEPE1,2,3 
(pg/ml) 
0.20±0.09 0.07±0.02 0.80±0.48 2.57±0.67* 0.40±0.22 0.89±0.26 
18S-HEPE1,2 
(pg/ml) 
0.55±0.23 0.21±0.06 1.80±1.00 6.47±2.29 0.52±0.33 3.75±1.61 
19, 20-
DiHDPA1,2,3 
(pg/ml) 
0.94±0.05 1.11±0.08 0.84±0.07 1.27±0.11 0.91±0.06 2.07±0.17* 
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Analysis showed that post EPA meal consumption increases in 14,15-EpETE, 14,15-DiHETE, 17,18-
EpETE, 17, 18-DiHETE and 15S-HEPE concentrations reached statistical significance when compared to 
control. Further to this, increases in 14,15-EpETE, 14,15-DiHETE, 17,18-EpETE, 17,18-DiHETE, 15S-
HEPE but not 18S-HEPE post consumption of EPA meal reached statistical significance when compared 
to the DHA meal. 
Post consumption of the DHA meal 19,20-DiHDPA, 14,15-DiHETE, 17,18-EpETE, 17,18-DiHETE 
increased significantly compared to control the meal. 19, 20-DiHDPA also increased significantly post 
consumption of the DHA meal when compared to the EPA meal. 
14, 15-EpETE 
Analysis showed significant treatment*time interactions (p=0.001, F(2, 50)=8.09, partial η2 = 0.24). 
Analysis also showed a significant effect of treatment (p<0.001, F(2, 50 )=9.21, partial η2 = 0.27), but 
not time (p=0.06, F(1, 25)=4.04, partial η2=0.14). 
Post-hoc analysis revealed that the EPA meal significantly increased mean 14, 15-EpETE when 
compared to the control meal (95% CI, 0.57 to 5.529, p=.012) and the DHA meal (95% CI, 0.107 to 
4.589, p=.038). The DHA treatment did not significantly change 14, 15-EpETE when compared to the 
control meal (95% CI, -0.187 to .433, p=0.38). Likewise, there were no significant differences between 
EPA and DHA treatments (95% CI, -2.435 to 1.927, p=1.000). See table 3.3.4.5 for mean concentrations 
by timepoint and treatment. 
14, 15-DiHETE 
Analysis showed a significant treatment*time interaction (p<0.001, F(1.24, 30.96)=11.15 , partial η2 = 
0.31), treatment effect (p<0.0001, F(1.24, 30.91)=13.34, partial η2 = 0.35) and time effect (p<0.001, 
F(1, 25)=25.66, partial η2 =0.51). 
Post-hoc analysis revealed that the EPA (95% CI, 0.532 to 2.57, p<0.005) and DHA (95% CI, 0.193 to 
0.99, p<0.005) meals significantly increased 14, 15-DiHETE by 94% and 38% from baseline, as 
compared to the control meal in which 15-15-DiHETE did not change from baseline. The EPA treatment 
did not significantly increase 14, 15-DiHETE when compared to the DHA meal (95% CI, -0.026 to 1.951, 
p=0.06). See table 3.3.4.5 for mean concentrations by timepoint and treatment. 
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17, 18-EpETE 
Analysis showed significant treatment*time interactions (p<0.001, F(1.21, 30.24)=18.665, partial η2 = 
0.427), treatment effects (p<0.001, (F(1.24, 30.95)=18.79, partial η2=0.43 and time effects (p<0.001, 
F(1, 25)=28.2, partial η2=.053). 
Post-hoc analysis revealed that the EPA meal significantly increased mean 17, 18 EpETE when 
compared to the control meal (95% CI, 4.584 to 14.798, p<0.0005) and when compared to the DHA 
meal (95% CI, 2.409 to 12.334) p<0.005). Mean 17, 18-EpETE concentrations increased 15 fold and 3.5 
fold post EPA and DHA meals respectively, whereas mean 17, 18-EpETE concentrations decreased 
from 0.88ng/ml to 0.45ng/ml post control meal. The DHA treatment also significantly increased 17, 18 
EpETE when compared to the control meal (95% CI, 0.452 to 4.19, p=0.01).  See table 3.3.4.5 for mean 
concentrations by timepoint and treatment. 
17, 18-DiHETE 
Analysis showed a significant treatment*time interaction (p<0.001, F(1.59, 39.78)=27.86 , partial η2 = 
0.527), treatment effect (p<0.001, F(1.46, 36.37)=25.49 , partial η2 = 0.51) and time effect (p<0.001, 
F(1.59, 39.78)=27.86 , partial η2 = 0.527).  
Posthoc analysis revealed that the EPA meal (95% CI, 4.357 to 9.97, p<0.0005) and DHA meal (95% CI, 
1.776 to 5.245) significantly increased mean 17, 18-DiHETE by approximately 3 and 2 fold when 
compared to the control meal. 17, 18-DiHETE values were also significantly higher following the EPA 
vs. DHA meal (95% CI, 0.948 to 6.356, p<0.05). See table 3.3.4.5 for mean concentrations by timepoint 
and treatment. 
15S-HEPE 
Analysis showed significant effects for the treatment*time interaction (p=0.03, F(1.221, 
30.528)=4.617 , partial η2 = 0.156), treatment  (p=0.001, F(1.19, 29.65)=11.77, partial η2 = 0.32) and 
time (p=0.05, F(1, 25)=4.15 , partial η2 = 0.14). 
Post-hoc analysis revealed, that the EPA meal increased mean 15S-HEPE when compared to the 
control (95% CI, 0.213 to 3.599), p=0.029) and when compared to the DHA meal. (95% CI, -0.084 to 
2.639, p=0.07). The DHA treatment also increased 15S-HEPE when compared to the control meal but 
this effect did not reach significance. See table 3.3.4.5 for mean concentrations by timepoint and 
treatment. 
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18S-HEPE 
Analysis, showed no significant treatment*time interaction, (p=0.07, F(2, 50) = 2.75, partial η2 = 0.1), 
but a significant effect for treatment (p=0.007, F(1.40, 35.06)=5.55, partial η2 = 0.18) and time (p=0.02, 
F(1, 25)=6.69, partial η2 = 0.21). See table 3.3.4.5 for mean concentrations by timepoint and treatment. 
19, 20-DiHDPA 
Analysis, showed a significant effects for the treatment*time interaction (p<0.001, F(2, 50) = 22.599, 
partial η2 = 0.475), treatment (p<0.001, F(1.58, 39.42)=17.70, partial η2 = 0.42 and time (p<0.001 F(1, 
25)=37.06, partial η2 = 0.60). 
Testing revealed that the DHA meal significantly increased mean 19, 20-DiHDPA when compared to 
the control meal (95% CI, 0.589 to 1.376, p<0.0005) and the EPA meal (95% CI, 0.282 to 1.180, 
p=0.001). Specifically, the DHA meal increased 19, 20-DiHDPA concentrations from baseline by 127%. 
The EPA treatment also increased 19, 20-DiHDPA when compared to the control meal but this effect 
did not reach significance. See table 3.3.4.5 for mean concentrations by timepoint and treatment. 
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3.3.3.7. Bivariate correlations between EPA and DHA epoxide and diol 
concentrations and Augmentation Index 
 
Correlations between AI values (at baseline and postprandial time points) with concentrations of EPA 
and DHA epoxides and diols were investigated via 1-tailed bivariate correlations.  AI was chosen as the 
vascular measure of interest as it is the main vascular measure influenced by treatment. Results 
showed that associations between plasma nitrite, H2S, 17,18-DiHETE, 19,20-DiHDPA, EPA and DHA and 
AI reached statistical significance. In order of decreasing magnitude, Nitrite, H2S, 17,18-DiHETE and 
19,20-DiHDPA emerged as being the most strongly associated with improved AI measures. 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 3.3.3.7.Pearson correlation of EPA and DHA epoxide and diol concentrations with Augmentation Index (AI). *marks 
significance at the p≤0.05 level, **marks significance at the p≤0.01 level. 1As per nitrite analysis in section 3.3.3.4, four 
outliers were omitted in this analysis.2As per H2S analysis in section 3.3.3.3, two outliers were omitted in this analysis. 
 
 
 
 
 
 Pearson correlation with AI P-value 
14, 15-EpETE 0.001 0.48 
14, 15-DiHETE 0.03 0.357 
17, 18-EpETE -0.05 0.279 
17, 18-DiHETE -0.22** 0.003 
15S-HEPE 0.01 0.477 
18S-HEPE 0.01 0.425 
19, 20-DiHDPA -0.20* 0.006 
H2S2 -0.21** 0.008 
Nitrite1 -0.33** <0.001 
EPA -0.16* 0.02 
DHA -0.16* 0.025 
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3.3.4. Discussion 
3.3.4.1. Quantification of serum markers of metabolic state 
 
There were no significant differences in serum NEFA, triglycerides or glucose at baseline between 
study days (see Figures 3.3.3.1.1, 3.3.3.1.2 and 3.3.3.2). Compared to baseline there was significant 
increase in triglycerides postprandially for all treatments, with an overall 40% increase from baseline. 
This results was as expected, as the 4h time point was chosen to approximately coincide with peak 
lipaemia and concentration of meal derived fatty acids in the plasma. Similar increases of 70% from 
baseline have been observed in other postprandial studies of comparable design (58).  There was a 
non-significant trend towards a decrease in serum glucose levels postprandially, likely due to the fact 
that sampling was not concordant with the postprandial glucose peak, typically 60-120 minutes after 
a mixed high-fat/carbohydrate meal. Serum NEFA concentrations also significantly increased 
postprandially, however there were no differences between treatments. A previous study of similar 
meal and intervention design showed no significant differences between treatment group effects on 
these markers in response to a combined 5.4g dose of DHA and EPA (in a ratio of 3:2) compared to a 
mixed oil control meal (58). One study has shown similar results for changes in glucose and triglyceride 
concentration in response to a mixed meal with or without EPA inclusion (5g) (80). Another study 
which compared the effects of 4.7g EPA or 4.7g DHA in a high fat meal had consistent results with our 
study for the postprandial NEFA, triglyceride and glucose response (61). It should be noted that in this 
study individuals were considerably younger (average 23 years of age) and the postprandial measures 
were taken at 5 hours as opposed to 4 hours.  
 
In summary, in this study neither EPA nor DHA inclusion influenced gross markers of postprandial 
lipaemia in our whole study population and this is consistent with previous observations in the 
literature. Of note, indications in the literature have suggested that genotype may play a role in the 
postprandial lipaemic response to meal fat content and this is explored in the context of PPAR-γ 
genotype in Chapter 6. 
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3.3.4.2. Plasma Hydrogen sulphide analysis at baseline and in response to 
intervention 
 
As discussed in section 1.7.3, there have been indications of CSE activation by DHA. Given that H2S 
acts as a vasodilator in the vasculature, we hypothesised, that changes in H2S concentration 
dependent on CSE activation may contribute to DHA’s capacity to elicit vasodilation. To this end we 
investigated if H2S concentrations change acutely and according to meal fat content. This investigation 
is the first to investigate H2S in the context of the postprandial state. 
Our results suggest modest increases in H2S concentrations after consumption of the high fat control 
meal (11%) and modest decreases in response to EPA (7.5%) but not DHA (see Figure 3.3.3.3). However, 
the time*treatment interaction and time and treatment effects in this analysis did not reach statistical 
significance. It is worth noting that the modest increases following intake of the control high fat meal 
although non-significant were not consistent with our hypothesis. Evidence is emerging that indicates 
H2S production can be increased in response to high fat diets and that H2S may play a role in signalling 
for reduction in the rate of lipolysis (180, 181). It is possible that the slightly increased H2S 
concentrations observed in this study in response to the high fat meal are in response to a postprandial 
hyper-lipaemic state and may be involved in signalling for inhibition of lipolysis.  It is also possible that 
these modest non-significant increases are attributable to normal biological variance. 
With regards potential interactions between EPA or DHA and H2S production, although never 
examined in the context of postprandial lipaemia, a study has demonstrated an activation of CSE 
(cystathionine-γ-lyase) in response to DHA-rich tuna-oil supplementation in lung tissue of Sprawgue-
Dawley rat (85). With regards to our findings, within the context of the postprandial state, our data 
did not support the hypothesis that EPA or DHA modified H2S production significantly. 
In summary, we were not able to detect any statistically significant differences in plasma H2S in 
response to treatment in this study. Accordingly, it is unclear whether H2S is involved as a secondary 
messenger in the response to either n-3 fatty acids or the hyper-lipaemic state. Further work may be 
warranted to qualify these interactions. 
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3.3.4.3. Plasma nitrite analysis at baseline and in response to intervention 
In our investigations we did not observe changes in plasma nitrite concentrations dependent on time, 
treatment or time*treatment effects. This observation is not consistent with our previous study 
investigating inclusion of a mixed dosage of DHA and EPA (5.2g total in a ratio of 3:2) in a high fat meal 
(58). In the absence of other data it is difficult to come to a definitive conclusion on what may be 
driving the discrepancy between these studies. The two most notable difference in study design, in 
these investigations of NO production in response to EPA and DHA consumption, are the different 
proximal measures of NO production quantified nitrite vs NOx (nitrite + nitrate), the methodologies 
used to measure the nitrite/NOx and the utilisation of a 3:2 ratio of DHA:EPA in the previous study. 
The previous study utilised a modified Griess reaction which also incorporated a reduction of nitrate 
to nitrite in order include nitrate’s contribution as a potential marker of NO production. The most 
likely explanation is that the additional contribution from nitrate explains the discrepancy between 
these studies. The final consideration in the comparison of these studies is that EPA and DHA 
consumption have an additive effect and the ratio of EPA:DHA has an important role in this effect. 
Given that we did not show any change from baseline in plasma nitrite concentration post EPA and 
DHA meals in our current study it is more likely that the discrepancy between these observations are 
described by methodological considerations described above.  
In summary, our study of these suggested changes in NO production in response to EPA and DHA 
consumption is novel in its use of methodology that accurately reflects changes to eNOS activity and 
in its comparison of the relative efficacy of EPA vs DHA. In these studies we were not able to observe 
postprandial changes in plasma nitrite concentrations in response to EPA or DHA inclusion in a high 
fat meal.  
3.3.4.4. Plasma fatty acid analysis at baseline and in response to 
intervention 
Analysis of plasma samples revealed that that the only plasma fatty acids to change markedly in 
concentration in response to treatment were EPA and DHA (see table 3.3.3.5 and figure 3.3.3.5). We 
also saw increases in DPA for all treatments. Analysis of fatty acids as a percentage of total lipid weight 
revealed that the relative percentage of palmitoleic acid (16:1), dihomo-gamma-linoleic acid (20:3 n6) 
and arachidonic acid (20:4 n6) decreased postprandially (see Table 3.3.4.5.1) but this was not 
reflective of significant changes in their concentrations. 
Somewhat unexpectedly we did not observe marked increases in the concentration of other fatty acids 
measured. Palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1), alpha (18:3 n3) and gamma-linoleic 
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acid (18:3 n6) all tended to increase but we were not able to observe significance for these effects in 
our analysis.  
In our analysis, EPA concentrations increased 2.6 fold in response to the EPA meal and DHA 
concentrations increased nearly 2 fold in response to the DHA meal. These effect sizes are broadly in 
line with previous investigation which investigated the effects of comparable doses of EPA and DHA 
on the postprandial response to high fat meals which have shown approximately 4 fold increases 
postprandially (61, 80). Specifically these previous studies investigated the effects of inclusion of EPA 
(5g) in a high fat meal in health male volunteers (80) and inclusion of 4.7g of EPA or DHA within a high 
fat meal in healthy male volunteers (61). Differences in effect sizes may be in part due to smaller EPA 
and DHA (4.16g) doses in our study or possibly the effect of meal matrix. 
3.3.4.5. Plasma epoxide and diol metabolite response and associations 
with vascular tone 
As discussed in section 1.9, it is known that vascular reactivity is directly affected by metabolites 
derived from EPA and DHA and therefore the concentration of these metabolites is more likely to 
provide mechanistic insight into the impact of meal fatty acid composition on vascular tone compared 
to the parent fats. These metabolites are produced by both discrete and non-discrete enzymatic 
pathways. Examples of these metabolites in the literature include the eicosanoid family. It is well 
documented in the literature that production of EPA derived eicosanoids in favour of the AA and 
dihomo-ƴ-linoleic derived eicosanoids can beneficially modulate excessive inflammatory states, and 
may also beneficially influence vascular tone through the generation of thromboxane A3 over the A2 
AA derivative which has greater vasoconstrictory capacity. However, there are still gaps in our 
knowledge with regards how the full array of EPA and DHA derived metabolites contribute to the 
effects of the lipidome in influencing vascular and metabolic health. As noted in section 1.9, there are 
several EPA and DHA metabolites derived from the CYP450 enzymes which are known to be potent 
modulators of vascular tone (131, 132, 182). Curiously, these metabolites have been understudied in 
the context of human health and their potential effects on vascular health and function in-vivo in 
human subjects have not been documented either in response to chronic EPA and DHA consumption 
or in the postprandial state.  
Interestingly, it has been previously shown that high fat meals alter circulating concentrations of 
certain oxylipins in the postprandial state (183). This previous study investigated postprandial changes 
in a broad range of circulating oxylipins in response to a very high fat SFA meal, MUFA meal and n-3 
PUFA meal. Specifically, the intervention meals were comprised of SFA (95g Palm Oil), MUFA (95g of 
oleic acid rich sunflower oil) and n-3 PUFA (55g of fish oil equivalent to 22g of DHA and 3g of EPA 
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alongside 40g of palm oil) respectively in a milkshake form. In the context of normal human diets, the 
dosage of DHA used in this study can be considered supra-physiological; an equivalent dosage 
achieved through consumption of an oily fish, such as salmon, would require consumption of 1.5kg of 
salmon. Furthermore, it should be noted that anecdotal evidence 1  suggests that long term 
consumption of this amount of EPA and DHA causes disaggregation of platelets and spontaneous 
internal haemorrhaging. Accordingly, although these results demonstrate a novel postprandial 
modulation of this compartment of the lipidome, they are of limited value in terms of translatability 
and there remains a need to investigate modulation of this compartment of the lipidome in response 
to physiological doses of EPA and DHA.  
We hypothesised that the epoxide metabolites derived from the CYP450 enzymes might in part 
explain the impact of EPA and DHA on postprandial vascular reactivity (58, 61) and that a more 
physiologically relevant dosage (4.16g) may be sufficient to significantly alter the concentration of 
these compounds acutely. Accordingly, we opted to investigate the profile of epoxide metabolites and 
their diol derivatives in order to qualify if a more physiological dose of EPA and DHA (4.16g) would be 
sufficient to alter this portion of the oxylipin profile. Our data is the first to investigate postprandial 
changes in the concentration of these metabolites in response to physiological EPA vs DHA dosage. 
In our investigations, we showed that the concentration of epoxides and diols in plasma change 
profoundly in the postprandial state in response to high but physiological relevant doses of EPA and 
DHA. Of note, we showed highly significant increases in the vasoactive epoxides derived from EPA in 
response to the EPA meal (see Figure and Table 3.3.3.6). Specifically, we saw a 6.5 fold increase in 14, 
15 EpETE concentration and a 15 fold increase in 17, 18 EpETE concentration in response to the EPA 
meal. These effects were not observed for the DHA or control meal indicating that changes in the 
concentration of these epoxides is highly dependent on meal fat consumption. We also observed that 
the concentration of these compounds decreased in response to the control meal. This is likely 
explained by the epoxide profile shifting to be more reflective of the presence of n-6 fatty acids in the 
control meal. Given the reported increased capacity of these EPA metabolites relative to their n-6 
counterparts to induce vasodilation these changes in concentration may in part explain the 
improvement in AI measures we saw in response to EPA meal when compared to control meal. These 
decreases in n-3 epoxide concentrations in response to the control meal may also play a role in the 
postprandial decline in vascular tone which have previously been shown in response to this control 
meal (58). It is also worth noting that post consumption of the DHA meal we saw 3.5 fold increases 17, 
18 EpETE concentrations. This effect was modest when compared to the EPA meal and is likely 
                                                          
1 This evidence stems from the unpublished “inuit diet” self-experimentation of Dr. Hugh Sinclair, documented in “Fine Wines and Fish Oil: 
The Life of Hugh Mc Donald Sinclair”. 
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explained by the inclusion of small amounts of EPA in the DHA meal and also possible retroconversion 
of DHA to EPA (see table 2.6.2). 
We also saw significant concurrent increases in the diol derivatives of the EPA epoxides, 17, 18 DiHETE 
and 14, 15 DiHETE. Specifically, we observed 3.4 fold increase in concentration of 17, 18 DiHETE and 
a 1.94 fold increase in concentration of 14, 15 DiHETE in response to the EPA meal. Both of these 
increases were highly significant when compared to the control meal. We also saw modest increases 
in the concentration of these compounds in response to the DHA meal. This effect reached significance 
for 17, 18 DiHETE and 14, 15 DiHETE when the DHA meal was compared to control. Curiously, little is 
known about the bioactivity of these diols compounds although it seems that they play a role in both 
the excretion of EPA and DHA (184) and may play a role in angiogenesis and immune function (185). 
However, there is no evidence to suggest these compounds contribute to vascular tone and 
accordingly, it is unlikely that they contribute to the vasoactive effects of their parent molecules. 
Concentrations of 15S-HEPE and 18S-HEPE also changed markedly postprandially. Specifically, we 
observed 6.4 fold increases in 15S-HEPE concentration in response to the EPA meal and a 2.3 fold 
increase in response to the DHA meal (non-significant). 18S-HEPE concentration also increased 7.3 
fold in response to EPA and 7.2 fold in response to the DHA meal. It should be noted that the mean 
18S-HEPE concentration reached 7.27ng/ml after the EPA meal compared to 3.74ng/ml after the DHA 
meal. The similarity in percentage increases but differences in concentration at 4 hours, were 
attributed to one individual having raised levels of 18S-HEPE at baseline for EPA treatment. Curiously, 
the acute changes observed for 18S-HEPE concentrations fell out of significance for treatment*time 
effects in our study despite the large changes in concentration in response to EPA and DHA meals. This 
lack of significance was likely due to very large variances in the data due to huge inter-individual 
differences in responsiveness.  Specifically, in the greatest responder we observed blood levels of 18S-
HEPE by close to 100 fold, whereas in some individuals there was no increase in the concentration of 
this compound acutely. This observation alone warrants further investigation as 18S-HEPE acts as pre-
cursor for the E-series resolvins described in section 1.9.4 and inter-individuals variation in the 
production of this compound may have consequences for human health. It is of note that to the best 
of our knowledge, specific biological activity has not been discerned for 15S-HEPE and 18S-HEPE. Given 
that the bioactivity of these compounds has been scarcely explored, the possibility remains that the 
lack of documented bioactivity is as much a product of a lack of exploration as an actual lack of 
bioactivity. Currently, it is difficult to discern how changes in these compounds may affect vascular 
tone postprandially or indeed other aspects of human health. 
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We also observed highly significant increases in the DHA derived diol 19, 20 DiHDPA concurrent with 
treatment. Interestingly, this metabolite has been indicated in the promotion of angiogenesis (186). 
In the long term, this effect may contribute to DHA’s effect on cardiovascular progression and further 
work is warranted to investigate these possibilities. However, there is currently little evidence to 
suggest 19, 20 DiHDPA contributes to the short term effects on vascular tone of its parent molecule. 
As indicated in section 1.9, the DHA derived epoxide, 19, 20 EpDPE, is noted as being a particularly 
efficacious vasodilator. Keeping in mind that 19, 20 DiHDPA is derived from 19, 20 EpDPE, the marked 
and highly significant increase in concentration of 19, 20 DiHDPA in response to the DHA meal is likely 
reflective of increases in 19, 20 EpDPE concentrations. However, the concentration of 19, 20 EpDPE 
fell beyond the limit of detection in our analysis, therefore no data is available for this metabolite.  
With regards, to changes in concentration of the diol derivative of 19, 20 EpDPE, postprandial 
concentrations of 19, 20 DiHDPA increased by 127% relative to baseline. Modest increases were seen 
in response to EPA treatment, however, this change did not reach significance when compared to 
control. Results from the human serum metabolome project suggest that the molar ratio of 19, 20 
EpDPE  to 19, 20 DiHDPA is in the range of 1 in 8 (187). This ratio is reflective of previous studies which 
have indicated that the concentration of the DHA derived epoxides in blood is below 0.1µM or beyond 
the limit of detection (187, 188). These estimates put the serum concentration of 19, 20 EpDPE in the 
low picomolar range, which may explain why this compound fell beyond the limit of detection in our 
analysis.  
As noted, given that the epoxide derived diol 19, 20 DiHDPA was detectable in our sample and doubled 
in response to DHA consumption, it is highly likely that this is reflective of changes in 19, 20 EpDPE 
concentration. Accordingly, any assumption that these DHA epoxides are not present, does not change 
acutely and/or do not contribute to the lipidome’s effects on vascular tone postprandially should be 
interpreted with due caution. When interpreting these results it is also worth noting that soluble 
epoxide hydrolase (sEH), the enzyme that generates these diols from their epoxide derivatives, has 
shown slightly lesser affinity for the DHA derived epoxides when compared to the EPA derived 
epoxides (189). In our study we showed that the molar ratio of 17, 18 EpETE and 14, 15 EpETE to their 
diol counterparts was roughly 1:1 post EPA meal consumption. Assuming these ratios remain broadly 
consistent for the EpDPEs and DiHDPAs, we would expect a doubling in concentration of 19, 20 EpDPE. 
It should be noted that this assumption is based on the assumption that the CYP450 enzymes have 
equal propensity for EPA and DHA. As mentioned, it has been previously observed that human sEH 
has a relatively low KM for 19, 20 EpDPE when compared to other fatty acid epoxides, and an 
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intermediate KCAT which might infact suggest that we see more than a doubling of the DHA derived 
epoxides postprandially (189).  
In summary, it is likely that the concentration of the DHA derived epoxides increase postprandially. 
Given their increased capacity to illicit vasodilation relative to their EPA counterparts this increase may 
explain the observation that the DHA meal improved AI to a greater degree than the EPA meal. 
Unfortunately, we were unable to detect 19, 20-EpDPE or other DHA derived epoxides in our plasma 
samples due to the low concentration of these compounds in plasma. Given these considerations, and 
the likely contribution of these DHA derived epoxides to the parent nutrient’s effect on vascular tone 
and health, future work in this area would be well advised to consider utilisation of a combination of 
sample concentration and higher sensitivity methods in order to accurately quantify changes in the 
concentration of the DHA derived epoxides in response to acute or chronic DHA consumption. 
3.3.4.6. Bivariate correlations between EPA and DHA derived epoxide and 
diols and Augmentation Index 
 
We conducted a bivariate correlation between concentrations of the EPA and DHA epoxides and diols 
measured in our analysis and augmentation index, in order to investigate if changes in the 
concentration of these compounds were correlated with changes in AI (see table 3.3.3.7). 
Our analysis showed that 17, 18-DiHETE and 19, 20-DiHDPA acid were significantly negatively 
correlated with Augmentation Index. As decreases in Augmentation Index are associated with 
decreases in vascular tone, these results tentatively link these compounds to decreases in vascular 
tone. It should be noted that it is unknown whether 17, 18-DiHETE or 19, 20-DiHDPA activity on 
vascular smooth muscle tone. We hypothesise a number of explanations for these observations. In 
the case of 19, 20-DiHDPA, it is likely that if this correlation is indicative of a genuine link between this 
molecule and improvements in vascular tone, that in this instance the increases in 19, 20-DiHDPA are 
indicative of increases in 19, 20-EDP (the parent molecule of 19, 20-DiHDPA which is responsible for 
the causation of improvements in vascular tone. In the case of 17, 18-DiHETE this correlation may be 
indicative of some yet undocumented bioactivity. Previous indications have suggested that the diol 
derivatives can have similar capacities to induce dilation of blood vessel as their parent epoxides (190), 
so this possibility is not without precedent. It is worth noting that generally the epoxides have been 
shown to elicit a more potent vasodilatory response than the diols, and accordingly this hypothesis 
should be interpreted with due caution. The alternative explanation for these observations is that that 
these correlations are merely indicative of a correlation between the decreased AI values we saw in 
response to the EPA and DHA meal and do not indicative causation. It is also worth noting that we also 
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observed a significant negative correlation between EPA and DHA concentrations in our study, 
although the size of the correlation was decreased when compared to the diol metabolites. 
Interestingly, although nitrite did not change in our intervention it did correlate significantly with 
decreased AI measures in our analysis. Other investigations in this context have shown 
pharmacological modulation of NO metabolism to impact plasma nitrite levels, which in turn correlate 
with regional changes in vascular tone (191). These correlations are in line with this finding. Similarly, 
although we did not observe any significant changes in plasma H2S concentrations in response to our 
interventions we also observed a correlation for the novel vasodilator H2S with AI measures. 
In interpretation of these results, it should be noted that these correlations are, at best, a crude 
estimate of the contribution of these compounds to changes in vascular tone. The control of vascular 
tone is a complex process dependent on the nervous system and a plethora of chemical mediators of 
autocrine, paracrine, exocrine and endocrine origin and also exogenously produced compounds (drugs 
and xenobiotics). Accordingly, these correlations are not adequate for the purposes of establishing 
causation. Most notably the epoxide metabolites of EPA and DHA have been shown to be efficacious 
and robust modulators of vascular tone in a number of models in studies undertaken by a number of 
independent groups (131-134, 192). We feel the contribution of these compounds likely accounts for 
a sizable portion of DHA dependent changes in vascular tone. 
In summary, despite the limitations of this analysis, this data, in particular the correlations with the 
epoxide derived diols 19, 20-DiHDPA and 17, 18-DiHETE, provides some insight into the changes in 
vascular tone which have been observed in our study and others in response to DHA and EPA 
consumption. 
3.3.4.7. Summary  
Our results for serum glucose, triglyceride and NEFA levels did not suggest any differential effects for 
control EPA or DHA containing meals on these biomarkers. These results are consistent with the 
results for studies which investigated the inclusion of EPA or DHA (61) in high fat meals and also those 
which included mixed doses of EPA/DHA in high fat meals (58).  We observed changes in the 
concentration of EPA and DHA postprandially dependent on treatment, and increases in DPA 
independent of treatment, but no marked increases in any other plasma fatty acids.   
With references to our measurement of blood borne vasomediators, our study provided novelty in its 
investigation of the relative efficacy of EPA vs DHA to modulate a broad array of vasomediators in the 
postprandial state, these included H2S (previously uninvestigated in this context), nitrite as a marker 
of NO production and the vasoactive epoxy and diol derivatives of EPA and DHA. In short, using the 
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most reliable techniques clinically available, we did not observe changes in plasma H2S or nitrite levels 
dependent on meal consumption, or EPA or DHA inclusion in the meal. Accordingly, we were not able 
to establish a role for these vasomediators in contributing to EPA or DHA dependent changes in 
vascular tone. Finally, we were able to establish that EPA derived epoxides and diols and DHA derived 
diols change profoundly in the postprandial state in response to physiologically relevant doses of EPA 
and DHA. Although we were unable to qualify changes in the concentration of the DHA epoxides (due 
to analytes falling beyond the range of detection), given that the concentrations of the 19, 20-DiHDPA 
changed >2 fold in response to the DHA meal it is likely that changes in the concentration of the parent 
epoxide also occur. Bivariate correlations undertaken between these epoxy and diol metabolites 
linked 17, 18-DiHETE and 19, 20-DiHDPA to Augmentation Index measures (see 3.3.5.5 and 3.3.5.6 for 
a thorough discussion of these results). 
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Chapter 4 
Whole Blood Culture investigations on the impact of postprandial blood fat profile on the innate 
inflammatory response 
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Chapter 4 – Whole Blood Culture investigations on the impact 
of postprandial blood fat profile on the innate inflammatory 
response 
4.1. Introduction 
 
Whole blood culture (WBC) has been utilised in a number of human studies to measure leukocytic 
cytokine production in response to a range of treatment (193-195). Comparison of this methodology 
to responses in isolated monocytes and PBMCs have validated WBC as a reliable, and low cost, 
proximal measure of monocytic cytokine production (193). This approach also has the benefit of 
including a complex mixture of effector cells, including granulocytes, monocytes, lymphocytes and 
potentially other minor contributors to blood cytokine production including circulating endothelial 
progenitor cells and fibroblasts. Accordingly, this model is likely more physiologically comparable to 
the in-vivo heightened systemic inflammation observed in cardio-metabolic disease states, than one 
single monocytic cell line (such as THP-1) or PBMC isolation. 
In our model, we stimulated whole blood cytokine production with LPS. Stimulation of whole blood 
culture with LPS is known to induce cytokine signalling primarily through TLR4 (196), which plays a 
critical role in innate immunity and is known to be activated above normal, basal levels in obesity and 
cardiovascular diseases. Furthermore, certain free fatty acids, such as palmitic acid and oleic acid, all 
contained within the control meal (Table 2.6.3), are known to activate TLR4 signalling and increase 
inflammatory cytokine production (49). Given the integral role that inflammation plays in the 
pathology of obesity and cardiovascular disease, and the likely impact of the postprandial dyslipidemia 
on inflammation, our whole blood culture experiments were designed to investigate the impact our 
interventions had on cytokine production in cultures of whole blood taken at 4 hours postprandially.  
Previous experiments utilising this model have shown modest reductions in LPS stimulated IL-6 
production after 8 weeks of fish-oil consumption (3.1g per day of EPA and DHA, ratio of EPA:DHA not 
provided) (52). However, to the best of our knowledge, no studies have been undertaken which have 
investigated how acute changes to the lipidome, dependent on meal fat content, might impact whole 
blood LPS stimulated cytokine production responses. As mentioned previously in this thesis, we 
hypothesise that controlled investigation of the postprandial state (which is associated with 
‘heightened’ inflammation) is more likely to generate informative and physiologically relevant data on 
how individual dietary components such as EPA or DHA might exert their effects in-vivo given than 
investigation of the fasting state (which only represent approximately 25% of the day for individuals 
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who eat regular meals). Accordingly, we aimed to utilise this model in order to investigate how 
changes in the lipidome postprandially, after the consumption of EPA or DHA, might affect cytokine 
production in this whole blood culture model. This approach allowed us to assess the impact of the 
whole profile of lipids, and lipid derivatives, found in the blood postprandially in response to each 
treatment (a comprehensive overview of meal nutrient information and fat composition can be found 
in Section 3.6) in a physiologically relevant model of inflammation. A number of cytokines were 
measured in our model, including IL-6, IL-10, IL-1α, Il-4, IFN-ƴ, IL-1β, IL-8, MCP-1 and the growth 
factors epidermal growth factor (EGF) and VEGF. A more thorough review of these cytokines and 
growth factors, and their interplay with the conditions which arise in vascular dysfunction and 
cardiovascular disease is given in Section 1.3 and 1.6. 
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4.2. Materials 
All materials were obtained from Sigma (Dorset, UK) unless noted otherwise. 
4.3. Methods 
The main study design and blood sampling procedure are given in chapter 2, section 2.7.5. Here the 
specific details of the whole blood culture and analysis of cytokines and growth factors are given.   
4.3.1. Whole blood culture 
LPS stimulated whole blood culture was carried out as per Damsgaard et al (52). At 4 hours 
postprandially blood was drawn into a 6ml Lithium Heparin vacutainer for whole blood culture in order 
to investigate aspects of how the postprandial inflammatory response was modified by meal fat 
content. 6-well plates were pre-alliquoted with 200 µL of 10 µg/mL of LPS stock solution (final 
concentration 1µg/mL LPS). Blood drawn at 4 hours was mixed with RPMI 1640 media supplemented 
with HEPES, L-glutamine and 0.05ug/ml of benzyl penicillin and streptomycin sulphate (Lonza 
Wokingham) in a ratio of 1:1 (4ml of blood to 4ml of media), mixed gently and subsequently 1.8ml 
was added to the well plates pre-alliquoted with LPS and RPMI 1640. The resulting solution was 
incubated for 24 hours at 37°C in a 5% CO2 incubator. At the end of the culture period, well contents 
were removed, transfer to three eppendorf tubes and centrifuged at 1000g for 4 minutes. The 
supernatant was removed and frozen at -20°C until analysis. 
4.3.2. Analysis of cytokine production in whole blood culture in 
response to intervention 
 
The production of cytokines and growth factors in the whole blood culture model was investigated via 
the Evidence Investigator (Randox Laboratories Ltd, County Antrim, Northern Ireland) in a cytokine 
and growth factor array (Cat No. EV3513). For VEGF which fell out of the range of analysis 
concentrations were determined by single ELISA kits (Sigma Aldrich, Dorset, United Kingdom). 
For the cytokine and growth factor array, 200µl of assay buffer and 100µl of samples are added into 
each biochip in the array. The biochips were then placed in a thermoshaker at 37°C at 370RPM for 60 
minutes. The biochips were subsequently rinsed twice using a washing buffer, followed by four two 
minute washes in wash buffer. 300µl of a conjugate solution was then added to each reaction well 
before placing the biochips in a thermoshaker at 4°C at 370 RPM for 60 minutes. Following this, 250µl 
of Luminol-EV701 and peroxide solution was added to each biochip before loading into the Evidence 
Investigator for analysis. 
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For the VEGF ELISA, pre-prepared standards and samples were added to wells and incubated for 150 
minutes at room temperature with gentle shaking. Standards and samples were then discarded and 
wells were washed 4 times with wash solution. 100µl of prepared biotinylated antibody was then 
added to each well and left to incubate for 60 minutes with gentle shaking. The solution was then 
discarded, and wells were washed as before. 100µl of streptavidin solution added to each well and 
left to incubate for 45 minutes with gentle shaking. The streptavidin solution was discarded after 
incubation, wells were washed as before and 100µl 3,3’,5,5’-tetramethylbenzidine solution was added 
and incubated for 30 minutes, before final addition of stop solution. Absorbance was subsequently 
read at 450nm. 
4.3.3. Statistical analysis 
The impact of meal fat composition on ex-vivo cytokine production was tested via 1-way ANOVA. Data 
was also subsequently tested to investigate the effect of a number of covariates on cytokine 
production in our model via use of ANCOVA. SPSS (version 22; Chicago, Illinois, USA) was used for all 
statistical analysis. Further to this, a summative score of inflammatory cytokine production was also 
generated in order to investigate the net effect of treatment on all inflammatory cytokines measured 
in our model. This summative score was generated by normalising data via use of z-scores which were 
generated by pooling responses to all treatments (see Fig 4.2.3.). 
 
Figure 4.2.3. Formula for generation of z-score 
 
Average z-scores for inflammatory cytokines were then summed as described to provide an indication 
of treatment effect on overall inflammatory cytokine production (see Figure 4.2.3.1.). This approach 
has previously been utilised in nutrition studies in order to elucidate the subtle effect of individual 
nutrients on related biological outcomes (197).  
 
Figure 4.2.3.1. Formula for investigative total inflammatory cytokine production score. 
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Finally, Pearson bivariate correlations were established between postprandial triglyceride 
concentrations and cytokine concentrations for control cultures alongside bivariate correlations 
between EPA and DHA concentrations and cytokine concentrations for all cultures. 
Outliers were identified by visual inspection of normal Q-Q Plots and by variance greater than +/- two 
standard deviations or between visit coefficient of variation falling above 30%. IL-6, IL-10, IL-1α, IL-4, 
IFN-ƴ, IL-1β, IL-8, MCP-1 and EGF were all analysed by Evidence Investigator Biochip arrays. Sample size 
for these investigations was n=20, but was reduced to n=18 due to removal of data for n=2 individuals 
due to presence of an outlier >2 SD from populational mean for one individual and due to average 
between visit coefficient of variations falling above 30% for another individual. Sample size for IL-8 
and MCP-1 was further reduced to n=17 and EGF (epidermal growth factor) to n=8, this was due to 
readings falling out of range of analysis for each of these analytes.  
VEGF was quantified via a single VEGF strip ELISA. Sample size for this analysis was n=19. One outlier 
was omitted due to a value falling >2 SD from population mean. 
4.4. Results 
 
One-way ANOVA showed no significant effect of treatment on WBC cytokine production, or total 
inflammatory cytokine production score (TICPS) (see table 4.3.1, Figure 4.3.2). Subsequent analysis 
was undertaken in order to correct for age and BMI levels as covariates via ANCOVA. BMI significantly 
influenced IL-6, IL-4 and IL-10 However, adjusted p-values did not reach significance for the effect of 
treatment on any individual cytokines following the age and BMI adjustment. 
For the TICPS although there was some evidence of a trend towards a reduced inflammatory z-score 
for EPA and DHA relative to control, no significant effect was evident. 
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Figure 4.3.2.a. Cytokine concentrations in the supernatant from 24-hour culture of whole blood drawn 4-
hour post-test meal consumption, data are presented as mean ± SEM. Continued, on following page. 
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Figure 4.3.2.b.  Cytokine concentrations in the supernatant from 24-hour culture of whole blood drawn 
4-hour post test meal consumption, data are presented as mean ± SEM. 
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ANOVA showed no statistically significant effect for treatment for any of the cytokines or growth factors 
measured. Furthermore, after adjustment for age and BMI by ANCOVA, treatment did not reach statistical 
significance.  
 
Cytokine P-non adjusted1 P-Age2 P-BMI3 P-adjusted4 
IL-6 0.83 0.67 .04* 0.83 
IL-8 0.58 0.74 0.32 0.58 
IL-1α 0.93 0.31 0.54 0.93 
MCP1 0.91 0.34 0.82 0.91 
IL-4 0.99 0.41 0.03* 0.99 
IFN-ƴ 0.90 0.50 0.37 0.90 
IL-1β 0.95 0.25 0.54 0.95 
IL-10 0.49 0.33 >0.01** 0.39 
EGF 0.39 0.22 0.94 0.37 
VEGF 0.97 0.09 0.05 0.40 
TICPS 0.98 0.71 0.11 0.97 
Table 4.3.1. P-values for ANOVA1 and between subject effects for ANCOVA after adjustment for Age2, BMI3 and Age and 
BMI4 for treatment effect on cytokine production and TICPS. 
 
Pearson bivariate correlations with plasma triglyceride, EPA and DHA concentrations. 
 
Pearson bivariate correlations showed no significant association between any of the cytokines or growth 
factors measured and postprandial triglyceride levels or EPA and DHA concentrations. 
 
Cytokine Pearson correlation 
with triglycerides  
P-
value 
Pearson correlation 
with EPA  
P-
value 
Pearson correlation 
with DHA  
P-
value 
IL-6 0.19 0.44 0.45 0.10 0.16 0.24 
IL-8 -0.33 0.20 -0.03 0.82 -0.05 0.73 
IL-1α 0.23 0.35 0.14 0.32 -0.05 0.71 
MCP1 -0.06 0.81 0.07 0.63 0.18 0.20 
IL-4 0.15 0.54 0.18 0.18 0.27 0.06 
IFN-ƴ -0.02 0.94 0.13 0.34 0.25 0.07 
IL-1β 0.02 0.93 0.04 0.79 0.04 0.80 
IL-10 -0.37 0.13 -0.23 0.10 -0.23 0.10 
EGF -0.26 0.54 -0.06 0.77 -0.34 0.11 
VEGF 0.12 0.61 0.03 0.80 0.03 0.80 
TICPS 0.05 0.84 0.19 0.18 0.23 0.09 
 
Table 4.3.2. Pearson bivariate correlation between postprandial triglyceride, EPA and DHA concentrations and cytokine 
concentrations. Bivariate correlations were established between postprandial triglyceride concentrations and cytokine 
concentrations for control cultures, whereas for bivariate correlations between EPA and DHA concentrations and cytokine 
concentrations data from all cultures was utilised. 
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4.5. Discussion 
 
This investigation was conducted to examine how postprandial alterations to the whole lipidomic 
profile, post consumption of EPA or DHA, impacts inflammatory cytokine production in a LPS 
stimulated whole blood culture model. The whole blood culture model was utilised as it is a 
physiologically relevant method for measuring whole blood cytokine production, which is thought to 
be reflective of mainly monocytic cytokine production (193), but also is dependent on contributions 
from  granulocytes, monocytes, lymphocytes and other minor contributors such as endothelial 
progenitor cells and fibroblasts.  
In these studies we were not able to establish a statistically significant effect of treatment on the 
production of any of the cytokines measured, however, some over-arching trends were noted. In 
particular it was noted that of the pro-inflammatory cytokines, IL-8 was 22% and 20% lower in 
response to the EPA and DHA meals when compared to control. Somewhat in contrast to this we also 
observed concurrent 20% and 10% decreases in the production of the anti-inflammatory cytokine IL-
10 in response to EPA and DHA. Concurrently, we also observed an 11% relative increase in production 
of MCP-1 in response to EPA treatment and an 11% relative increase in IFN-ƴ in response to DHA 
production. No other responses for any of the inflammatory cytokines differed markedly from control. 
With regards to comparisons with other investigations, one trial (n=15) has shown that a 30 day 3.4g 
EPA and DHA intervention lowers serum IL-10 levels (198). However, larger scale epidemiological 
investigations have shown positive correlations between total serum n-3 fatty acids and IL-10 
concentrations (199). Although it is difficult to compare the findings of our ex-vivo investigations with 
these in-vivo observations, our current understanding of EPA and DHA’s effect on innate immunity 
signalling cascades might be suggestive that these results indicating a dampening of TLR4 dependent 
LPS response. EPA and DHA have also been shown to modulate or have a differential effect on IL-8 
expression compared to other dietary fats in a number of contexts, including in epithelial cell lines 
(200), endothelial progenitor cells (201) and fibroblasts (202), with suggestions that DHA is more 
efficacious in mediating this effect (202). Given that our whole blood culture model would have 
accounted for a broad range of effector cells, including endothelial progenitor cells and fibroblasts, 
our data are somewhat supportive of these previous finding. It should be noted that in contrast to 
these studies we were not able to establish significance and our data did not suggest marked 
difference between EPA and DHA treatment in this regard. One other study has investigated the effect 
of mixed doses of EPA and DHA in this whole blood culture model. Specifically, this study involved a 
2x2 factorial 8 week intervention in which individuals (n=64) were randomised to either 5ml/day of 
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fish-oil (corresponding to 3.1g of n-3 PUFA of unknown EPA:DHA ratio) or olive oil. Within these 
groupings individuals also received instructions to consume either high or low linoleic acid spreads 
(52). In this study, after 8 weeks IL-6 levels were significantly lower in LPS stimulated whole blood 
culture from individuals randomised to the fish-oil treatment when compared to the olive oil 
intervention. In contrast, we were not able to establish a role for either EPA or DHA treatments in 
reducing IL-6 production in our model, however, it is possible that these effects are dependent on 
incorporation of EPA and DHA into PBMC membranes, which likely would not have occurred within 
the 4 hours post-consumption.  
In interpreting these results it is important to consider that production of these cytokines is a co-
ordinated, auto-regulatory process which, when functioning optimally, contributes to maintenance of 
a homeo-static environment. In this light, and in the context of our experiments, the observation of 
trends towards decreased IL-10 production alongside decreased IL-8 should not necessarily be 
considered diametrically opposed. Most likely, these changes are explained by some decrease in the 
inflammatory response to LPS stimulation  which leads to decreased production of inflammatory 
cytokines in the initial response to LPS, but also decreases in IL-10 production in the latter part of 
culture. 
With regards mechanisms for these trends, as mentioned, a plausible explanation for this observation 
is that EPA and DHA dampened the LPS response somewhere downstream of TLR4, causing diminished 
production of IL-8 during the initial response to LPS exposure, but also leading to diminished IL-10 
production during the latter stages of culture. It is important to remember that up-regulation of anti-
inflammatory cytokines, such as IL-10, is delayed in response to LPS in monocytes (203) and 
production of IL-10 is often a product of ERK1/2, p38 and NF-κB signalling (204). Accordingly, it is likely 
that a greater degree of the IL-10 produced in our investigation was in the latter half of the culture, 
whereas the pro-inflammatory cytokines would have been produced in the initial exposure to LPS. 
Appropriately designed time course experiments would be informative on how these treatments 
differentially affect cytokine production as a product of time and this information could in turn yield 
insight into the mechanistic workings of the treatments in our model. It is also important to consider 
the crosstalk between LPS induced ERK1/2 activation, the subsequent activation of eicosanoid 
synthesising enzymes and substrate availability. These considerations have important consequences 
for these experiments as substrate availability for eicosanoid production would have differed 
significantly in our model dependent on treatment. The amount and type of eicosanoids produced 
likely play a role in any immune function modulation dependent on EPA or DHA in this model. Finally, 
there are also a number of other target molecules in the TLR4 kinase cascade which could also play a 
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role in these responses. For example, a plausible effector molecule which could play a role is SOCS3, 
which is known to decrease JAK1 activity (involved downstream of ligand binding in the IL-10 signalling 
cascade) and MKK3 activity (involved downstream of ligand binding in the TLR-4/LPS signalling 
cascade). Notably, SOCS3 is known to be activated by DHA in a PPAR-ƴ dependent manner (205) and 
it is likely that EPA has similar although possibly diminished effects.  
We also saw a trend towards a decrease in VEGF (9%) and EGF (31%) production in response to DHA. 
VEGF is involved in neoangiogenesis and vasculogenesis and also in migration of vascular smooth 
muscle cells into the atheroma in later stage atherosclerosis (206) and is also chemotactic for 
macrophages and granulocytes (207, 208). Accordingly, it has a causal link to CVD. EGF is also 
implicated in migration of vascular smooth muscle cells into the atheroma, and activation of its 
receptor has been shown to cause vasoconstriction (209-211) and there are links between the 
abnormal vascular smooth muscle tone in type I and II diabetes and dysregulation of EGFR signalling 
(212).  
Previous reports have reported a number of interactions between EPA, DHA, their metabolites and 
VEGF signalling in a number of contexts. These have included reports of reduced expression in colon 
cancer cells in-vivo and in-vitro in response to DHA via a ERK1/2 dependent mechanism (213), 
decreased VEGF dependent cell migration in a HUVEC model in response to DHA via a GPR120, ERK1/2 
dependent mechanism (214), decreased VEGF dependent angiogenesis in Met-1 breast cancer models 
in response DHA epoxides and sEH inhibitors (215) and EPA but not DHA inhibited VEGF induced 
proliferation in bovine carotid artery endothelial cells (216). Accordingly, there are a number of studies 
reporting evidence of interactions between DHA and its metabolites with VEGF signalling and one 
study which suggests these effects extend to EPA but not DHA in a bovine endothelial cell model. 
There are also a number of lines of evidence that are supportive of this effect occurring through some 
modification of ERK1/2 phosphorylation state. Our data is suggestive of the possibility of these 
interactions involving some modification of VEGF expression in monocytes and possibly other blood 
borne cytokine producing cells. With regards to differences in EGF concentrations dependent on 
treatment, a previous study has shown changes in mesangial cell expression of EGF in response to 
DHA but not EPA (217). We are not aware of other studies which have investigated the differential 
effects of EPA and DHA in this context. It is plausible that the effect of treatment may reach 
significance with greater sample size (retrospective power calculation give a required n=20, at a power 
of 0.80 to distinguish the effect size observed as significant). Given the implications of EGF’s role in 
the development of dysfunction of the endothelium, abnormal smooth muscle cell tone, 
atherosclerosis and diabetes mellitus (218), future studies on these interactions may be warranted.  
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Despite a number of cytokines decreasing in response to EPA and DHA, we were not able to establish 
statistical significance for any of the 10 cytokines measured. In order to account for covariates which 
may have contributed to some of the variance in our analysis, we utilised ANCOVA which adjusted for 
BMI and age. We hypothesised that due to positive associations between increased BMI and 
inflammation (219, 220) that BMI may be a causal factor in inter-individual variations systematic 
innate immune response. Similarly, we hypothesised that links between aging and increased 
inflammation (221) may influence our data. However, after adjusting for BMI and age as covariates, 
treatment dependent changes in cytokine production, growth factor production or TICPS did not reach 
significance. BMI did emerge as modifier of response for IL-10 and IL-4 and IL-6 production (see Table 
4.3.1). However, BMI did not interact with treatment to a sufficient degree to impact significance in 
our adjusted ANCOVA model. Although this study was not designed to investigate these interactions, 
these results can be considered supportive of previous indications of associations between BMI and 
increased inflammation (219, 220), and might suggest that increased BMI is associated with functional 
changes in circulatory productions of these cytokines. 
We also investigated correlations between postprandial triglyceride, EPA and DHA concentrations and 
cytokine and growth factor production (see Table 4.3.2). This was undertaken as triglyceride rich 
lipoproteins have been shown to bind and modulate LPS activity (222) and we hypothesised that this 
may play a role in modulating LPS stimulated cytokine production in our model. Furthermore, we 
reasoned that if a significant impact of treatment was evident then absolute concentrations of EPA 
and DHA in plasma would be associated with the WBC cytokine response. Accordingly, this analysis 
was undertaking to see if postprandial triglyceride, EPA or DHA concentrations correlated with any 
changes in cytokine production. We did not show significant bivariate correlations between 
postprandial triglyceride, EPA or DHA concentrations for any of the variants analysed.  
With regards limitations of this study, it is worth noting that, as expected, there was significant 
difference in inter-individual responsiveness to LPS stimulated cytokine production and this likely 
played a part in mean responses to treatment falling outside of statistical significance. Previous 
investigations have shown that although individual cytokine production responses to LPS in this model 
are reproducible over long time periods, there are large inter-individual variations in response (193). 
In this regard our observations are consistent with previous investigations. This consideration also 
played a role in a lack of power to detect any significance in this study, which was originally powered 
to examine impact of treatment on vascular responses. Retrospective power calculations indicate that 
n numbers of 169, 99 and 76 would be required to detect significance at a power of 0.80 for the effect 
sizes observed for IL-8, IL-10 and VEGF analyses respectively. 
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Some other aspects of our experimental design may have contributed to the lack of significance in this 
analysis. Specifically, due to aspects of our trial design we were unable to run a baseline blood culture 
as a comparison. Although our experiments accounted for an appropriate control fat comparison, a 
baseline culture would have allowed us to completely rule out any interday differences in baseline 
cytokine concentrations or responsiveness of the effector cells in this model to LPS. We accounted for 
these concerns in our trial design by checking for signs or reports of infection at each visit before 
baseline measures and blood draws, along with checking medication usage with particular emphasis 
on any other medications which might affect nutrient absorption and metabolism, vascular function 
or immune function (see Annex 3). Despite this, the only way to fully account for potential interday 
variations in inflammatory status and responsiveness to LPS would have been to perform a baseline 
culture. Future experiments in this context would be well advised to perform a baseline culture to 
account for these factors.  
Other considerations for future work include investigation of concentrations of eicosanoid and other 
lipid mediators at baseline and in response to LPS exposure. Further to this, western blotting of targets 
downstream of TLR4 and the IL-10 receptor in an appropriate monocytic cell model may yield 
important information on mechanisms of any effects in monocytes, which are the major contributor 
to cytokine production in this model. As mentioned, a potential explanation for the dichotomy of our 
observation of decreased IL-8 production in response to EPA and DHA alongside decreased IL-10 
production is that the EPA and DHA effect the propagation of the signal downstream of the TLR4 and 
this dampens both initial inflammatory cytokine production in response to LPS and also the production 
of anti-inflammatory cytokines in the resolution phase of LPS exposure. Accordingly, it would be 
advisable to perform a time course analysis in order to see how the cytokine response varies as a 
product of both time and treatment.  
In conclusion, we were not able to show any modification of cytokine or growth factor production 
dependent on treatment, before or after adjustment for BMI and age, or dependent on postprandial 
triglyceride levels. However, it is plausible that some effects of treatment in particular for EPA and 
DHA’s effect on IL-8 and IL-10 and DHA’s effect on EGF and VEGF might reach significance with greater 
sample size (approximations put a sample size with 0.80 power in the order of magnitude of 2).  
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Chapter 5 – Impact of genotype on the postprandial response 
to EPA and DHA in a high fat meal - a pilot study 
 
5.1. Introduction 
As discussed throughout this thesis, there are numerous indications in the literature that suggest EPA 
and DHA have beneficial effects in the vasculature (40, 58-60, 79). Evidence suggests that EPA and 
DHA improve postprandial vascular reactivity (58) and this may contribute to improvement in the 
integrity of both peripheral and conduit arteries in the longer term which in turn, may contribute to 
improvements in cardiovascular health outcomes (40). However, there is a dearth of data from human 
investigations on the relative effects of EPA vs DHA in general, and on their effects in the postprandial 
state. Furthermore, it is also suggested that the postprandial and chronic response to EPA and DHA in 
the vasculature varies significantly according to genotype (46, 174). There is also a lack of information 
on the influence of genotype in the response to these dietary fats. Accordingly, in order to generate 
pilot data for future work investigating nutrient*genotype interactions which may affect inter 
individual responses to EPA and DHA in the vasculature, a candidate gene approach was taken. SNPs 
were initially identified on the basis of pre-existing data in the literature suggesting that interactions 
between mixed EPA and DHA supplementation and SNP genotype influence vascular responses or on 
the basis of significant theoretical links between SNP variation and change of function/efficiency of 
enzymes which may impact the vasculature response to EPA and DHA. Given our sample size, in order 
to produce meaningful data, we restricted our options to those with a minor allelic frequency of >10%. 
A list of the four SNPs to emerge is found below in Table 5.1.  
SNP Protein coded by gene BP upstream and downstream of SNP SNP 
location 
in gene 
Minor 
allele 
frequency 
rs1799983 eNOS …ATGA[G/T]CCCC… Exon 35% 
rs4673 NADPH Oxidase …GAAG[C/T]ACAT… Exon 31% 
rs1801282 PPAR-ƴ …TGAC[C/G]CAGA… Exon  9% 
rs1048943 CYP1A1 …GACC[A/G]TTGC.. Exon 4% 
Figure 5.1. SNPs selected for investigation in the F.O.F.A study. 
With regards to indications in the literature linking these SNPs to altered responses to EPA and DHA, 
the rs1799983 SNP (also known as the eNOS, Glu298Asp polymorphism) has been previously linked to 
alterations in the vasculature response to fish-oil (174, 223). Specifically, both males and female 
carriers of the homozygous for the ASP298 isoform have shown 2-fold greater improvement in 
measures of endothelium dependent vascular reactivity (FMD) in the postprandial state in response 
to a dose of 0.46g of EPA and 4.18g DHA alongside heparin infusion which was utilised to artificially 
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raise NEFA levels.  A cohort study, on a population of male and female individuals undergoing routine 
diagnostic cardiac catheterization for unclear chest pain (n=97), has also shown positive correlations 
between plasma n-3 fatty acid concentrations and FMD in GLU298 carriers, but not in ASP298 carriers 
(223). On a mechanistic level, the minor allelic variant of the ASP298 polymorphism has been linked 
to perturbations in normal vasoregulation, specifically increased coronary vascular resistance (224), 
and the development of endothelial dysfunction (225) independent of EPA and DHA. Our study aimed 
to investigate for the first time whether EPA or DHA rich meals differed in their capacity to alter 
vascular tone dependent on the rs1799983 SNP. We reasoned that these investigations would help 
expand the base of knowledge on these interactions as previous studies have not compared the 
individual effects of EPA vs DHA in this regard. 
NADPH Oxidase genotype was investigated as presence of the 242T allele has been demonstrated  to 
have a negative impact on vascular superoxide production (226). Specifically, the nucleotide change 
at this position gives rise to a histidine residue instead of a tyrosine residue in the expressed protein. 
The impact of this change in amino acid on enzyme functionality has been insufficiently evaluated, 
however, evidence is suggestive that it may confer an increased capacity for production of superoxide 
to NADPH oxidase. Interestingly, this SNP has been linked by meta-analyses with modest increases in 
risk of coronary artery disease in Caucasians (227). We hypothesized that given that reactive oxygen 
species are involved in the sequestering of NO, by reaction of superoxide with nitric oxide to produce 
peroxynitrite, it is possible that this genotype may play a role in bioavailability of NO. Although there 
isn’t existing evidence in the literature to suggest an interaction for this SNP with EPA or DHA, we 
reasoned that due to previous observations suggesting a role for NO in EPA and DHA’s effects in the 
vasculature (58), this SNP could theoretically influence vascular responsiveness to EPA or DHA. 
Accordingly, we investigated this SNP to see if vascular responsiveness to EPA and DHA may be 
influenced by a capacity of this SNP to impact oxidative stress dependent sequestering of NO.  
As discussed in Chapter 1, it is known that PPAR-ƴ plays a pivotal role in the metabolic response to 
EPA and DHA. Furthermore, the 2 allelic variants at position rs1801282 (the Pro12Ala polymorphism) 
in the gene coding for PPAR-ƴ have been shown to alter the serum triglyceride response in a 3 month 
n-3 fatty acid supplementation (228). Specifically, carriers of the ALA12(G:C)  polymorphism had 
greater triglyceride decreases in response to consumption of 2.4g per day of n-3 PUFA (ratio of 
EPA:DHA was not provided in the original study) than PRO12 carriers (C:C) in this 3 month intervention. 
Furthermore, the minor allelic variant has been shown to be  associated with greater degrees of 
postprandial hyper-triglyceridemia (229). Accordingly, the status of this polymorphism was 
investigated in order to see if the postprandial triglyceridemic responses to high fat meal consumption 
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were altered dependent on rs1801282 status by inclusion of EPA or DHA content of the intervention 
meals. 
Finally, given that the CYP1A1 rs1048943 SNP has been observed to contribute to differential 
production of EPA epoxymetabolites in in-vitro investigations (230), we reasoned that this SNP may 
impact in-vivo production of the EPA and DHA epoxymetabolites in our trial, for which we observed 
large inter-individual variation. Unfortunately, validation of genotyping for this SNP failed in our 
investigations. This data may in the future be utilised for retrospective genotyping pilot studies on the 
genetic contribution to variations in LC n-3 PUFA epoxide production. 
5.1. Materials 
 
Fully details of the study design can be found in Chapter 2, blood sampling procedure is described in 
section 2.7.5. 
All materials for genotyping were provided by LGC Genomics (Herts, United Kingdom) and Qiagen 
(Manchester, United Kingdom) unless otherwise noted. 
5.2. Methods 
5.2.1. Genomic DNA Isolation 
 
Genomic DNA was isolated from buffy coat samples generated at screening for the 26 individuals who 
completed the trial. DNA was isolated using the QIAamp DNA blood kit. In brief, 25 µL of a protease 
solution (QIAGEN Protease) was added to 1.5ml eppendorf tubes. 200 µL of buffy coat samples was 
then added to the protease solution. 200 µL of lysis buffer (QIAGEN Buffer AL) was then added and 
eppendorfs were briefly vortexed and then incubated at 56°C for ten minutes. 200 µL of ethanol was 
added after incubation and samples were once again vortexed. Subsequent to addition of ethanol, 
samples were applied to a QIAamp spin column and were centrifuged at 8000rpm and 14,000rpm for 
1 minute and 3 minutes respectively with wash buffers in order to remove impurities. Genomic DNA 
was then eluted from the column by incubating the column with 200 µL of elution buffer (10mM Tris-
HCl, 0.5mM EDTA, pH 9.0) before centrifugation at 8000rpm for 1 minute. Genomic DNA content was 
subsequently quantified by nanodrop and then stored at -20°C until use. 
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5.2.2. KASP Genotyping 
 
All DNA samples were genotyped via KASP genotyping. In short, KASP genotyping relies on polymerase 
chain reaction (PCR) process in a cyclical process in which genomic DNA is denatured, primers are 
annealed, and complement allele specific tails with FAM or HEX fluorescent tags are elongated 
dependent on which allelic variants are present. The end product of this process being exponential 
production of labelled DNA strands which can be measured by fluorescence in order to qualify 
genotype. Fluorescence is subsequently measured in order to qualify which allelic variant has been 
amplified and genotype is subsequently qualified via this process. 
Specifically, KASP Master Mix and KASP Primer Mix were thawed and vortexed. 300 µL of KASP Master 
Mix and 8.4 µL of KASP Primer Mix were mixed and made up to 600 µL with PCR grade water. 
 Isolated genomic DNA 5 µL (concentration >5ng/ml) for each individual was added to wells in a 96 
well plate. 5 µL of the previously prepared KASP Master and Primer Mix was subsequently added to 
each well. Plates were sealed with an optimally clear seal to prevent evaporation. Thermal cycling was 
conducted immediately, as described below in Table 5.2.2, was utilised to denature DNA and allow for 
subsequent cycles of annealing/elongation.  
Step Temperature Time Number of cycles per step 
1. Activation 94°C 15 min 1 
2. A)Denaturation 
B)Annealing/Elongation 
94°C 
61-55°C 
20 sec 
60 sec (drop 0.6°C per cycle) 
10 cycles 
3. A) Denaturation 
B)Annealing/Elongation 
94°C 
55°C 
20 sec 
60 sec 
26 cycles 
Table 5.2.2. Thermal cycling conditions. 
After thermal cycling plates were left to cool below 40°C and fluorescence was subsequently 
measured in each well in order to qualify genotype of each individual. 
5.2.3. Statistical Analysis 
 
The impact of genotype at baseline was assessed by 2-tailed heteroscedastic student t-tests 
(rs1801282 and rs1799983) or one-way ANOVA (rs4673) for BMI, serum total cholesterol, 
triglycerides, AI, PWV, RHI, DBP and SBP. For triglyceride, AI, PWV and RHI for each individual an 
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average value was taken from their three baseline (pre-meal) measures and used in the statistical 
analysis. BMI, serum total, and cholesterol values were taken from screening values. 
 In order to assess the impact of genotype on response to treatment, three-way repeated measures 
ANOVA were conducted for rs1799983 and rs4673. Three-way repeated measures ANOVA were not 
possible for rs1801282 due to unequal group sizes, accordingly for rs1801282 one-way repeated 
measures ANOVA were conducted on change scores. SPSS (version 22; Chicago, Illinois, USA) was used 
for all statistical analysis. 
5.3. Results 
5.3.1. Baseline vascular measures, blood pressure, markers of lipid 
metabolism and anthropometric measures as according to 
genotype 
2-tailed students T-test showed significant differences in baseline serum triglyceride concentrations 
dependent on rs1801282 genotype (p=0.041). Specifically, baseline triglyceride levels were 26% 
higher in rs1801282 12ALA (G:C) carriers when compared to 12PRO (C:C) carriers. None of the other 
variables investigated differed significantly by rs1801282, rs1799983 or rs4673 genotype in our 
analysis. 
 PPAR-ƴ - rs1801282 eNOS - rs1799983 NADPH oxidase - rs4673 
 C:C 
(Pro/Pro) 
(n=26) 
G:C 
(Pro/Ala) 
(n=3) 
G:G 
(Glu/Glu) 
(n=14) 
T:G 
(Glu/Asp) 
(n=12) 
C:C 
(Tyr/Tyr) 
(n=12) 
C:T 
(Tyr/His) 
(n=11) 
T:T 
(His/His) 
(n=3) 
Age (years) 44.9±1.2 45.7±2.2 44.4±1.7 45.7±1.3 44.4±1.8 44.6±1.4 48.1±1.1 
BMI (kg/m2) 27.0±0.8 28.8±1.1 - - - - - 
Total 
Cholesterol 
(mmol/L) 
5.71±0.19 6.93±0.29 - - - - - 
Triglycerides 
(mmol/L) 
1.74±0.14 2.19±0.09* - - - - - 
AI (%) - - 23.2±1.3 24.9±1.1 21.2±2.5 26.1±1.5 24.2±1.2 
PWV (m/s) - - 8.4±0.2 8.1±0.2 8.6±0.4 8.4±0.2 8.2±0.3 
RHI - - 2.50±0.14 2.32±0.09 2.25±0.22 2.45±0.12 2.39±0.14 
Diastolic BP 
(mmHg) 
- - 85±2  92±42 87±1  83±3  89±4  
Systolic BP 
(mmHg) 
- - 133±2 140±2 137±2  132±4  138±2 
 
Table 5.3.1. Baseline age, BMI, lipids and vascular measures as according to genotype.  
– variables not analysed as according to this genotype 
* significant difference from major allelic variant.  
Data are presented as mean ± SEM.  
BMI, Body mass index; AI, Augmentation Index; PWV, Pulse Wave Velocity; BP, Blood Pressure. 
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Figure 5.3.1.1. Mean serum triglyceride levels at baseline as according to PPAR-ƴ rs1801282 genotype. Data are presented 
as mean ± SEM. 
 
5.3.2. Postprandial triglyceridemic response to treatment according 
to PPAR-ƴ genotype 
 
The absolute triglyceride concentration at 0h and 4h according to genotype and treatment is given in 
Figure 5.3.2.1. One-way ANOVA undertaken on change scores showed that there were significantly 
greater increases in triglyceride concentrations in response to consumption of the EPA and control 
meals in Pro12Ala carriers (G:C) when compared to Pro12Pro carriers (C:C), p=0.02 and 0.007 
respectively. This effect did not reach significance for DHA, p=0.2, indicating that DHA treatment 
negated the effect of this genotype on postprandial triglyceridemia (see Figure 5.3.2.2.).  
With regards treatment effect sizes, triglyceride concentrations increased postprandially by 64% and 
69% in response to control and EPA treatments for the Pro12Ala carrier. In Pro12Pro carriers these 
increases were 30% and 40% respectively. In contrast, in response to the DHA treatment triglyceride 
levels increase by 33% in Pro12Pro carriers and by 54% in the Pro12Ala carriers. 
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Figure 5.3.2.1. Serum triglyceride levels at baseline and in response to treatment as according to PPAR-ƴ rs1801282 
genotype. Data are presented as mean ± SEM. 
 
 
Figure 5.3.2.2.  Mean change in serum triglyceride concentration from baseline dependent on treatment and rs1801282 
genotype. * indicates significant difference in change score when compared to major allelic variant (C:C). Data presented 
as mean ± SEM. 
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5.3.3. Vascular response as according to eNOS rs1799983 genotype 
 
Analysis did not show an interaction between intervention and the eNOS rs1799983 genotype for 
any of the vascular measures in our study. 
Specifically, by Repeated Measures Anova treatment*time*genotype interactions did not reach 
significance for PWV (p=0.54, F(2, 22) = 0.64, partial η2 = 0.14), PWA (p=0.79, F(2, 22) = 0.24, partial 
η2 = 0.08) or RHI (p=0.35, F(2, 20) = 1.09, partial η2 = 0.21) for the rs1799983 genotype. Accordingly, 
no post-hoc analysis was undertaken. 
Data for PWV, PWA and RHI are presented below in Figures 5.3.3.1, 5.3.3.2 and 5.3.3.3 respectively. 
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Figure 5.3.3.1. PWV response to treatment as according to eNOS rs1799983 genotype. Data presented as mean ± SEM. 
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Figure 5.3.3.2. AI response to treatment as according to eNOS rs1799983 genotype. Data presented as mean ± SEM. 
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Figure 5.3.3.3. RHI response to treatment as according to eNOS rs1799983 genotype. Data presented as mean ± SEM. 
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5.3.4. Vascular response as according to NADPH rs4673 genotype 
 
Analysis did not show an interaction between intervention and the NADPH rs4573 genotype on any 
of the vascular measures in our study. 
Treatment*time*genotype interactions did not reach significance for PWV (p=0.69, F(4, 8) = 0.58, 
partial η2 = 0.13), PWA (p=0.07, F(4, 8) = 3.33, partial η2 = 0.58) or RHI (p=0.73, F(4, 8) = 0.51, partial 
η2 = 0.12) for the rs4673 genotype. Accordingly, no post-hoc analysis was undertaken. 
Data for PWV, PWA and RHI are presented below in Figures 5.3.4.1, 5.3.4.2 and 5.3.4.3 respectively. 
 
 
 
 
Figure 5.3.4.1. PWV response to treatment as according to NADPH rs4673 genotype. Data presented as mean ± SEM. 
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Figure 5.3.4.2. AI response to treatment as according to NADPH rs4673 genotype. Data presented as mean ± SEM. 
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Figure 5.3.4.3. RHI response to treatment as according to NADPH rs4673 genotype. Data presented as mean ± SEM. 
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5.4. Discussion 
5.4.1. Baseline vascular measures, blood pressure, markers of lipid 
metabolism and anthropometric measures as according to 
genotype 
 
In our pilot analyses we investigated whether PPAR-ƴ rs1801282 genotype, eNOS rs1799983 genotype 
or NADPH rs4673 genotype influenced baseline vascular or plasma lipid measures. As mentioned, in 
our investigations we utilised a “candidate gene” approach and baseline status was investigated with 
a hypothesis driven approach in order to minimise the risk of type-1 errors. Accordingly, markers of 
lipid metabolism along with body weight and BMI were analysed dependent on PPAR-ƴ rs1801282 
genotype; whereas blood pressure and vascular measures were analysed dependent on eNOS 
rs1799983 genotype and NADPH rs4673 genotype. 
In this study, baseline serum triglyceride concentrations were significantly higher in rs1801282 ALA12 
(G:C) carriers when compared to PRO12 (C:C) carriers (see Table 5.3.1). However, we draw conclusions 
from our findings with caution given that we had only three participants in our rare allele group. 
Nevertheless this observation is consistent with a meta-analysis (n=52,998) which investigated the 
effect of this genotype on fasting triglyceride concentrations (231). We also observed higher total 
cholesterol levels in the ALA12 group; however, this effect fell just out of significance in our analyses. 
As before, this observation is consistent with previous findings from a meta-analysis (231), which 
indicate that there is an interaction between this genotype and fasting total cholesterol 
concentrations.  
Fasting vascular measures and blood pressure did not differ depending on eNOS rs1799983 genotype 
or NADPH rs4673 genotype in our analyses. With regards to the eNOS rs1799983 previous studies 
have observed that although lifestyle factors (smoking status) and dietary factors (plasma n-3 fatty 
acid concentrations) interact with rs1799983 to influence endothelial function (namely FMD), a 
relationship does not hold when considering only the impact of this genotype alone (223). With 
regards potential interactions between blood pressure and rs1799983, a previous cohort study of 
Caucasian women (n=18,436) did not show a relationship between this SNP and incident hypertension 
or progression of hypertension (232). Our investigations corroborate these observations and suggest 
that these previous findings also hold in males. It should be noted that although AI and RHI did not 
differ significantly depending on rs1799983 genotype, these measures tended to be improved in G:G 
carriers. However, this trend did not hold for PWV. 
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With regards, the NADPH rs4673 genotype a previous indication suggests that the rs4673 
polymorphism does not influence baseline endothelial dependent or independent vascular function 
(233). Similarly to the interactions with rs1799983 our results are corroborative of previous findings, 
and once again suggest that these findings hold in males aged 35-55 years who phenotypically are at 
an increased risk of CVD. 
5.4.2. Triglyceride response to treatment according to PPAR-ƴ 
genotype 
In our present study we demonstrated that after consumption of a high fat meal, postprandial changes 
in triglyceride concentrations responses vary dependent on PPAR-ƴ rs1801282 genotype (see Figure 
5.3.2.1). Further to this, DHA but not EPA seems to have a corrective effect in individuals who are 
heterogeneous for the minor allelic variant of rs1801282 (see Figure 5.3.2.2).  
A previous study has shown an interaction between this genotype and changes in serum triglyceride 
concentrations in response to a mixed n-3 fatty acid intake. Specifically, the previous demonstration 
which compared the effects of 2.4g of EPA and DHA per day to an olive oil control, showed that carriers 
of the ALA12(G:C)  polymorphism had greater triglyceride decreases than PRO12 carriers (C:C) in a 3 
month intervention (228). Although the ratio of EPA:DHA was not explicitly stated in the paper, 
information available elsewhere suggests that the ratio of EPA and DHA in the supplement used was 
1:1. Our work builds on these demonstrations by comparing the interaction of this genotype with 
plasma triglyceride levels in response to an EPA rich meal and DHA rich meal when compared to 
control fat in the context of the postprandial state. Our data suggests that the interaction of LC n-3 
PUFA and the ALA12 polymorphism is extended into the postprandial state and also that this effect 
may be dependent on DHA, rather than EPA. 
Another study has also demonstrated a greater propensity towards postprandial hyper-
triglyceridemia in ALA12 carriers when compared to PRO12 carriers (odds ratio, 7.6; p<0.001) (229).  
This study defined postprandial hyper-triglyceridemia as a >1.71mmol/L increase in plasma 
triglyceride levels postprandially, a quite marked increase in triglyceride levels. Our data, which 
showed a 64% (1.43 mmol/l) increase in triglyceride concentration in response to the control meal in 
ALA12 carriers as compared to a 30% (0.48mmol/l) increase in PRO12 homozygotes, supports this 
previous observation. It is also of note that baseline triglyceride concentrations in the ALA12 
individuals were 26% higher when compared to PRO12 carriers. As mentioned in section 5.4.1., this 
difference at baseline reached significance.  
In summary, our data demonstrates that inclusion of DHA in high fat meals significantly dampens the 
postprandial hyper-triglyceridemia after consumption of a high fat meal in rs1801282 ALA12 carriers. 
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Specifically, the control meal increased triglyceride concentrations postprandially by 20% more than 
the DHA meal. Although proper interpretation of these results is hampered by small sample sizes (n=3 
for ALA12 carriers and n=23 for PRO12 carriers), the consistency, size and significance of the responses 
warrants further investigation. In particular in the light of evidence that suggests that postprandial 
lipaemia is a highly significant CVD risk factor (234). It is thought that BMI, age and gender are among 
the most significant physiological determinants for postprandial lipaemia, however, genotypes that 
influence this response, and specifically those that may be modifiable dependent on dietary or lifestyle 
modification, are likely to be of wide spread public health relevance. 
When considering these results, it is worth noting that DHA is suggested to be a more effective PPAR-
ƴ activator than EPA and indeed other fatty acids (106, 114). It is also worth noting that this 
polymorphism codes for an amino acid in the ligand binding domain of PPAR-ƴ. Of particular 
importance are observations that have previously shown the ALA12 polymorphism to have an almost 
2 fold decreased affinity for the PPAR-ƴ promoter response element in electrophoretic mobility shift 
assay experiments (235). Another investigation which utilised thialozinediones to compare the activity 
of the PPAR-ƴ rs1801282 isoforms upon ligand binding suggest that the presence of the minor allelic 
variant may impact the effect of ligand binding on induction of PPAR-ƴ activity (236).  Our results are 
suggestive of DHA in part compensating for the impact of defective enzyme activity on the 
postprandial TG response. From a mechanistic standpoint it follows logically that DHA’s greater 
activation of PPAR-ƴ when compared to other fats, could play a role in compensating for the effect on 
the minor allelic variant on PPAR-ƴ promoter binding affinity. In short, given the impact of this 
polymorphism on PPAR-ƴ activity, and the significant role PPAR-ƴ plays in extracellular fat metabolism, 
and indeed triglyceride clearance, a plausible mechanism for this observation exists, which provides 
further support for future investigations of these interactions. 
In summary, this data provides a base for future investigations on the interactions between EPA and 
DHA with the rs1801282 polymorphism. From a theoretical standpoint, it plausible, given that DHA 
has been shown to be an effective activator of PPAR-ƴ and that PPAR-ƴ plays a role in lipid clearance, 
that DHA may play a greater role than EPA in contributing to increased LC n-3 PUFA dependent 
changes in triglyceride concentrations in ALA12 carriers when compared to PRO12 carriers (228). The 
possibility that this interaction could be leveraged to offer a therapeutic dietary strategy to overcome 
previously indicated increases in postprandial hyper-triglyceridemia in ALA12 carriers (229) is an 
interesting prospect. When considering that previous findings indicate an interaction between this 
SNP and modifications to basal triglyceride concentration in longer term n-3 PUFA interventions (228), 
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the potential impact of an interaction between this SNP and chronic DHA consumption on basal 
triglyceride concentration also warrants consideration. 
5.4.3. Vascular response to treatment as according to eNOS 
rs1799983 genotype 
 
In contrast with previous studies (174, 223, 237) we did not observe any differences in the vascular 
response to EPA and DHA when compared to control dependent on rs1799983 genotype, see Figures 
5.3.3.1 to 5.3.3.2. There are a number of factors which may in part explain these observations, 
including the power of the studies, differences in the vascular measures undertaken and differences 
in total n-3 dosage and indeed differences in the amounts of individual EPA and DHA ingested. 
With regards interactions between postprandial PWV measures and meal fat content, our results 
showed no impact for any treatment on PWV. Given that PWV is more dependent on physical changes 
in artery structure, rather than acute changes in artery diameter dependent on vascular tone, it is also 
likely that any interactions between meal fat content, genotype and changes in postprandial vascular 
tone are not measurable by PWV.  
Changes in AI and RHI also did not reach statistical significance for genotype*treatment interactions. 
With reference to eNOS rs1799983 genotype, a previous study showed a 2-fold greater improvement 
in FMD in response to an intervention similar in scope to the DHA arm of our study (150). Unpublished 
work in our lab has also suggested that the vasodilatory response to EPA and DHA in individuals 
carrying ASP298 may be greater than non-carriers (237). A cohort study has also shown interactions 
between plasma n-3 PUFA concentrations, rs1799983 and basal vascular reactivity as measured by 
FMD (223). There are a number of notable differences between our study and the previous studies 
which may explain the discrepancies observed. These differences include the measures involved (FMD 
in the previously published trial as compared to AI and RHI in our study), study design (the previously 
published trial utilised infused heparin to artificially raise NEFA levels and also utilised a meal design 
that differed significantly in meal fat composition), sample size and health status, age and gender of 
the study population. It is plausible that each of these differences contributed to the discrepancy 
between results.  
With regards to the measurements undertaken in our study, AI can be considered to be dependent 
on both endothelium dependent and independent changes in vascular tone and longer term 
mechanical changes to artery structure which influence arterial stiffness, whereas RHI can be 
considered a measure of an endothelial dependent measure of peripheral arterial tone. The FMD 
measure used in this previous study is considered the gold standard of endothelium dependent 
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measures of vascular reactivity. A number of physiological determinants distinguish this measurement 
from our measure of RHI. It is important to consider that FMD is measured via ultrasound, most 
commonly in the brachial artery, a major blood vessel, whereas RHI utilises measures of peripheral 
arterial tone in the tip of the index fingers, these measures are more dependent on the tone of the 
smaller arterioles of the fingertip than the FMD measure. The gross differences in structure and 
physiology of these blood vessels may well contribute to the discrepancy in observations between 
these studies, as may the difference in the responsiveness of these blood vessels to NO, n-3 epoxides 
and other vasomediators. The AI measurement also differs significantly to the FMD measure and it is 
also likely that these differences contribute to the discrepancy in these observations.  
Finally, with specific references to our study, it is worth noting that these investigations were designed 
as pilot studies and accordingly, the original study was more adequately powered than ours. 
Furthermore, our study investigated the vascular responses to EPA and DHA in individuals with a 
higher CVD risk profile than that of the previous study and our individuals were significantly older 
(mean age of 45 in our study vs 28 in original study). It is plausible that the contribution of any ‘subtle’ 
impact of rs1799983 genotype to the postprandial vascular response to DHA and EPA changes with 
age and the baseline reactivity of the vasculature (which would tend to decrease as CVD risk increases). 
In summary, we were unable to demonstrate a significant impact of this SNP on the vascular responses 
to EPA and DHA in the postprandial state. As noted this was a retrospective study, designed with the 
aim of generating pilot data, and accordingly was not sufficiently powered to generate definitive 
answers to these research questions. Also previous demonstrations of the interaction between 
rs1799983 and fish-oil intake in the literature have focused on younger populations (174, 223, 237). It 
is plausible that the effect for rs1799983 may hold in younger populations but not in older populations, 
or those with a higher CVD risk profile. This could be attributable to differences in basal vascular 
reactivity, which tends to worsen with increased CVD risk. Future work on rs1799983’s impact on EPA 
and DHA’s effect on postprandial vascular reactivity might consider investigating the effect of age on 
these interactions.  
 
 
 
5.4.4. Vascular response to treatment as according to NADPH oxidase 
rs4673 genotype 
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Our investigations of NADPH Oxidase rs4673 genotype were based on previous indications that the 
presence of the T allele at this position is associated with decreased superoxide production  (226). 
Accordingly, given the links between superoxide production and NO bioavailability, and the suggested 
links between the vascular response to fish-oil and NO (58), we investigated if this SNP may influence 
vascular responsiveness to fish-oil.  
In our investigation, we did not observe a relationship between rs3673 genotype and inter-individual 
vascular responsiveness to EPA or DHA when compared to control for PWV (Figure 5.3.4.1), AI (Figure 
5.3.4.2) or RHI measures (Figure 4.3.4.2). 
It is likely that the lack of effect for PWV is attributable to the lack of change in PWV in response to 
meal consumption. As mentioned, this in turn is likely due to the fact that PWV is more dependent on 
physical changes in artery structure, rather than acute changes in artery diameter dependent on 
vascular tone. As discussed in section 5.4.1, rs4673 genotype also had no effect on baseline PWV 
measures. AI and RHI, which are modifiable by NO bioavailability also did not change dependent on 
rs4673 genotype or for treatment*time*genotype interactions for rs4673. Only one other study has 
investigated rs4673 in this context, which has shown that rs4673 genotype does not impact forearm 
blood flow in response to acetylcholine in hypercholesterolemic individuals (233). 
Although we would emphasise prudency in interpretation of these data due to sample size 
considerations, in the absence of other data, the investigative work presented in this chapter does not 
support further investigations on the contribution of this SNP to inter-individual differences in vascular 
response to EPA or DHA. 
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5.4.5. Conclusion 
 
The scope of the investigative work in this chapter was to derive pilot data to inform future work. To 
this end, the data presented in this chapter have generated two main findings which may warrant 
further investigation.  
Previous investigations have suggested PPAR-ƴ rs1801282 minor allele carriers have a greater degree 
of postprandial hyper-triglyceridemia (229)  and that there is an interaction between this SNP, n-3 
PUFA intake and the degree by which n-3 PUFA intake reduces basal triglyceride concentrations in 
chronic interventions (228). Our data support the previous observation that minor allele carriers are 
subject to greater degrees of postprandial hyper-triglyceridemia. Furthermore, our data adds to the 
current evidence of interactions between this SNP and n-3 PUFA consumption by comparing the 
effects of meals high in EPA or DHA and by investigating the postprandial state, which is more 
physiologically relevant than the fasting state. Specifically our data suggests that inclusion of DHA in a 
high fat meal has a compensatory effect for the postprandial hyper-triglyceridemia associated with 
the minor allelic variant of rs1801282. In the context of LC n-3 fatty acid dependent modifications to 
blood lipid levels, it seems that increased DHA intake may be particularly beneficial to ALA12 carriers. 
This data, presents a new and novel perspective which should inform future research. Should these 
findings hold in larger populations these observations could potentially lead to better targeting and 
more efficacious therapeutic strategies for reduction of blood lipid levels in the proportion of the 
population (approximately 10%) that carries the minor allelic variant of this SNP. 
As discussed in section 5.4.3, we were unable to show any interaction between rs4673 and rs1799983, 
the EPA, DHA and control meals and AI, PWV and RHI. The main suggestion to come forward from this 
data is that future investigations on interactions between n-3 PUFA and rs1799983 should account for 
age as a variable which may alter the degree by which this SNP influences the interaction between 
EPA, DHA and vascular and endothelial function.  
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Chapter 6 
Conclusions and future directions of work 
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Chapter 6 – Conclusion 
6.1. Conclusion 
 
The first documentation of associations between LC n-3 PUFA and modifications to blood lipid profiles 
and decreased incidences of cardiovascular disease are over 40 years old (26). Since this initial 
observation, the effect of LC n-3 PUFA intake on CVD risk has been studied extensively, with evidence 
suggesting anti-arrhythmic (35), hypolipidemic (36-39), anti-inflammatory and plaque stabilising (41) 
and cholesterol profile modulating (42, 43) effects for LC n-3 PUFA. As they are usually consumed 
together in fish and or fish oil products, EPA and DHA have traditionally been grouped together in 
investigations of their effects on human health. However, evidence is emerging that they may have 
differential effects with specific reference to different effects on vascular tone and blood pressure. 
Specifically, chronic intervention studies have suggested a potential hypertensive effect for DHA but 
not EPA (40),  which corresponds with a capacity for DHA, but not EPA, to modulate fasting vascular 
tone (57).  
Although studies on dietary dependent changes to fasting vascular tone are meaningful and 
informative in their own regard, we hypothesise that changes in the postprandial state may be more 
important given that individuals spend the majority of the day in the postprandial state. Recent studies 
in this context have shown that mixed doses of EPA and DHA beneficially modulate postprandial 
vascular tone (58-60) and that DHA but not EPA reduces systemic vascular resistance in the 
postprandial state (61). However, it remains unknown how DHA and EPA compare with regards their 
capacity to induce these effects in the postprandial state in individuals at increased risk of CVD. 
The main finding of this thesis is that acute intake of a single dose (4.16g) of DHA modifies postprandial 
vascular tone to a greater degree than EPA in men 45-55 years of age at an increased risk of CVD. 
Although both treatments had some utility in this regard only the effect of the DHA treatment reached 
significance (p=0.04 as compared to 0.06 for EPA). The importance of these findings is significant, given 
that individuals spend the majority of the day in the postprandial state and the significant role of 
vascular reactivity in the pathogenesis of CVD. The significant effect observed for DHA, by current 
estimates would correlate with a decrease in 10 year CVD risk from 3.25% to 2.83%, as according to 
estimates established between AI and ESC risk levels (9). The fact that new emerging technologies 
have been shown to have a capacity to produce high quality DHA from plant sources (238), underpins 
the relevance and importance of these investigations. Also of consideration is that these technologies 
may offer more affordable sources of DHA in the future, which will aid not only with research efforts 
which aim to elucidate the unique effects of these distinct dietary fats on human health, but also the 
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potential translatability of any observed effects. In the future, it may be possible that the EPA/DHA 
blend recommended to individuals may depend on the physiological target of interest. 
To the best of our knowledge, our study represents the most thorough profiling of changes to acutely 
modifiable vasomediators, including H2S, NO and the epoxy and diol metabolites of EPA and DHA, in 
response to EPA rich, DHA rich and control meals. Furthermore, our data is the first in-vivo indication 
of a link between changes in n-3 PUFA epoxide and diol metabolites to these changes in vascular 
reactivity. Other novel findings in this regard are the large variations and the sizable changes in the 
profile of n-3 PUFA epoxide and diol metabolites postprandially in response to physiological 
consumption of EPA and DHA. The large inter-individual variability in changes in the concentration of 
these compounds is an important finding, which is suggestive of inter-individual functional differences 
in either the CYP450 enzymes that generate the epoxides or the sEH enzymes that hydrolyse them, or 
both. Given the well documented capacity of these compounds to modulate vascular tone (131-134), 
a reduced capacity to produce the n-3 PUFA epoxides may have an impact on CVD outcomes. 
Qualifying the genetic variants that contribute to these effects may also aid in establishing which 
individuals respond the most beneficially to EPA and DHA consumption. Furthermore, given the 
ongoing attempts to develop new sEH inhibiting drugs to enhance the stability of these compounds 
(239), establishing the genetic variants that contribute to these large inter-individual differences may 
be important in establishing individuals who may respond the most to these drugs. The final 
consideration in this context is that individuals, who are particularly effective producers of the n-3 
PUFA epoxides, may be prone to adverse effects in response to sEH inhibiting drugs due to over 
production of the n-3 PUFA epoxides.  
Our investigation was also novel both in its investigation of H2S production in the postprandial state 
and in response to EPA and DHA, and in its utilisation of a reliable proximal measure of NO production 
to investigate EPA and DHA dependent changes in NO production in the postprandial state. Our 
findings suggest that neither NO or H2S play a role in mediating the effects of an acute dosage of EPA 
or DHA on vascular tone in the postprandial state. 
Our analysis of markers of glucose and lipid metabolism in our whole study population, indicate no 
differential effect for EPA or DHA in modulating the glucose, triglyceride or NEFA response and are 
consistent with previous observations in the literature. Likewise our analysis of plasma fatty acid 
profiles were as expected and indicated that concentrations of EPA and DHA increased, approximately 
1.4 fold and 2 fold respectively, upon consumption. Of note, upon investigation of interactions 
between genotype and the lipidemic response, our data suggested a previously undocumented 
beneficial effect of DHA consumption on postprandial triglyceridemia in carriers of the minor allelic 
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variant of PPAR-ƴ rs1801282. As noted in Chapter 5 this work was undertaken as part of a pilot study 
and further work is required to establish if this effect holds in a larger population. 
Finally our LPS stimulated whole blood culture investigations were not able to determine a significant 
differential effect of EPA, DHA or control on IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, MCP-1, VEGF, EGF 
production or summative score of total inflammatory cytokine production. We also we were not able 
to establish any significant associations between postprandial triglyceride, EPA or DHA concentrations 
and cytokine concentrations in whole blood culture. As discussed in chapter 4, due to the high inter-
individual variance in WBC responses it is likely that this investigation was underpowered and also it 
would be of benefit to conduct a baseline culture of blood to account for any effect of interday 
variation in LPS stimulated cytokine production. These considerations may have contributed to the 
lack of significance in this investigation. 
6.2. Future work 
 
Our observations suggest that DHA is a more potent modulator of postprandial vascular tone than 
EPA. Due to the fact that individuals spend a large proportion of the day in the postprandial state, we 
hypothesise that this capacity of DHA to modulate vascular tone may impact CVD risk. This data may 
also be indicative of chronic habitual intake of DHA, having different effects to chronic habitual intake 
of EPA. To date there have been no adequately powered, long term clinical trials of the effect of DHA 
consumption on hard CVD outcomes. The lack of long term studies in this context is in part explained 
by economic considerations, due to the expense of the currently commercially available oils high in 
DHA. This fact has ramifications for the cost of running an adequately powered trial and also for the 
translatability of any findings of such a trial, as the high cost of DHA rich oils is a barrier to the 
commercial viability of these products. This consideration impacts the likelihood of commercial 
funding for this research and also the likelihood for the public to utilise these products.  However, 
given the emergence of GM technologies that have the capacity to produce high quality DHA oils from 
plant sources at lower costs, studies on the long term effects of DHA supplementation are likely to be 
of warrant in the near future. Our data supports the hypothesis that dietary DHA has unique and 
beneficial effects in the vasculature, different to those of EPA. Accordingly, we feel our data adds 
support for the justification of adequately powered long term studies on the effect of DHA on hard 
CVD outcomes. 
More immediately feasible studies on soft outcomes in this context could include investigation of the 
longer term effects of DHA doses of between 0.5g to 4.0g per day on haemodynamic and vascular 
outcomes measures, including BP, FMD and AI in both hyper-triglyceridemic and hypertensive 
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populations, when compared to appropriate control fat treatments. Alongside these investigations 
parallel exploration of the genetic determinants of inter-individual variation in LC n-3 PUFA epoxide 
and diol production are advisable as these genetic determinants of changes in LC n-3 PUFA epoxide 
and diol concentrations may in turn influence inter-individual differences in BP and vascular responses 
to LC n-3 PUFA. In these studies, the interaction between the genes that influences LC n-3 PUFA 
epoxide and diol production and changes in BP and vascular responses should also be conducted. 
This work would be well advised to also investigate if long term DHA supplementation modifies 
postprandial responses to high fat challenge meals both with and without DHA inclusion. 
Investigations in this context should consider that postprandial changes in the concentration of these 
compounds may be more pronounced than the long term changes in concentration due to the 
efficiency of sEH in hydrolysing the epoxide derivatives of EPA and DHA. Once again, due to the fact 
that individuals spend the majority of the day in the postprandial state, investigation of the genetic 
determinants of changes in the concentration of these bioactive LC n-3 PUFA epoxide derivatives in 
the postprandial state may be informative of some of the longer term differences in inter-individual 
responsiveness to these dietary fats. Specifically, variation in the capacity to produce the LC n-3 PUFA 
epoxide compounds in response to LC n-3 PUFA consumption may correspond with variations in 
reductions to BP or improvement in vascular tone, in particular in response to DHA. Information on 
the genetic determinants of inter-individual variation in changes to circulatory concentrations of the 
LC n-3 PUFA epoxides in response to LC n-3 PUFA consumption may be informative in the context of 
other conditions also. For instance, evidence suggests these compounds exert effects on a number of 
physiological and patho-physiological processes including, but not limited to, angiogenesis (215) and 
tumor growth (215). Genes of interest in these studies could include rs1048943 (CYP1A1) and tagging 
SNPs or SNPs which induce functional changes in genes coding for other enzymes in the CYP450 family, 
including CYP1A2, CYP2C19, CYP2C11, CYP2J2, CYP4A11, CYP4F2, CYP4B1 and CYP4F12 and others in 
the 2C/2J family which have been shown to act on LC n-3 PUFA (240).  
Finally, given the efforts to develop sEH inhibitors for use in a number of therapeutic indications (239), 
establishing the genetic component of variability in production of n-3 PUFA epoxide and diol may aid 
in selective targeting of these drugs. As mentioned, in section 6.1, these considerations may also aid 
in prediction of individuals who may react adversely to these drugs. 
The final recommendation for future research based on the results presented in this thesis, is a larger 
scale study studying interactions between the PPAR-ƴ rs1801282 minor allelic variant, DHA 
consumption and postprandial triglyceridemia and also fasting triglyceride levels. Based on our the 
effect size in our observations, while accounting for a high degree of variance in postprandial 
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triglyceride levels, a trial which prospectively carriers of the rs1801282 minor allelic variant would 
have 0.80 power to reliably detect an interaction between DHA and reductions in postprandial 
triglyceridemia with a sample size of n=17 in each group. This endeavour would require screening of 
an estimated n=90 individuals based on estimates of minor-allelic frequency in Northern European 
populations. However, it may be prudent to expand on these still modest sample sizes to account for 
the possibility that the putative effect of DHA in this context was inflated in our analysis due to small 
sample size. 
With regards investigations of the effects of EPA and DHA on whole blood culture production of 
cytokines, as discussed in chapter 4, future investigations utilising this model would be well advised 
to use sample sizes in the region of n=100 due to issues regarding inter individual variability in WBC 
responses. Furthermore, baseline cultures may aid in accounting for some non-treatment inter-day 
variations in cytokine production. 
6.3. Concluding remarks 
 
In conclusion, the major findings of this thesis support our hypothesis that DHA is a more efficacious 
modifier of post-prandial vascular reactivity than EPA. However, it is worth nothing that the EPA 
treatment also had some utility in it’s capacity to reduce the AI measure although the effect did not 
reach statistical significance (p=0.06). Furthermore, from these investigations it seems likely that these 
effects are mediated through the epoxide and diol metabolites rather than NO or H2S. 
This work also emphasises the importance of investigating how genotype influences responsiveness 
to EPA and DHA. 
The findings of this thesis are likely to be of growing importance as high quality and affordable EPA 
and DHA supplements become available due to the utilisation of emerging recombinant plant 
technologies. Our research extends our knowledge of the differential and unique effects of EPA and 
DHA in the vasculature and sets the scene for future research on the longer term individual effects of 
EPA and DHA consumption in this context. 
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Annex 1 – List of prohibited medications 
 
Ca2+-channel blockers 
Adalat Capsules (Nifedipine), Adalat LA (Nifedipine), Adipine XL (Nifedipine) ,Amlodipine (Amlodipine) ,Angitil 
SR (Diltiazem), Beta-Adalat (Atenolol, Nifedipine), Calchan MR (Nifedipine), Cardene (Nicardipine), Cardene SR 
(Nicardipine), Cardioplen XL (Felodipine), Coracten XL (Nifedipine), Diltiazem (Diltiazem), Dilzem XL (Diltiazem), 
Exforge (Amlodipine, Valsartan), Fortipine LA (Nifedipine), Istin (Amlodipine), Lercanidipine, Motens 
(Lacidipine), Nicardipine (Nicardipine), Nifedipine (Nifedipine), Nimotop (Nimodipine), Plendil (Felodipine), 
Prescal (Isradipine), Securon I.V. (Verapamil), Securon SR (Verapamil), Sevikar (Amlodipine, Olmesartan), 
Slozem (Diltiazem), Syscor MR (Nisoldipine), Tarka (Trandolapril, Verapamil), Tenif (Atenolol, Nifedipine), 
Tensipine MR (Nifedipine), Tildiem LA (Diltiazem), Triapin (Felodipine, Ramipril), Univer (Verapamil), Valni XL 
(Nifedipine), Verapamil (Verapamil), Vertab SR (Verapamil), Viazem XL (Diltiazem), Zanidip (Lercanidipine), 
Zemtard XL (Diltiazem), Zolvera (Verapamil). 
 
α-blockers 
Baratol (Indoramin), Cardura XL (Doxazosin), Carvedilol (Carvedilol), Combigan (Brimonidine, Timolol), 
Combodart (Dutasteride, Tamsulosin hydrochloride), Contiflo XL (Tamsulosin), Doralese (Indoramin), 
Doxazosin (Doxazosin), Eucardic (Carvedilol), Flomaxtra XL (Tamsulosin), Hypovase (Prazosin), Hytrin 
(Terazosin), Indoramin (Indoramin), Labetalol (Labetalol), Opilon (Moxisylyte), Pinexel PR (Tamsulosin), 
Raporsin XL (Doxazosin), Rogitine (Phentolamine), Tabphyn MR (Tamsulosin), Tamsulosin (Tamsulosin), 
Terazosin (Terazosin), Trandate (Labetalol), Xatral XL (Alfuzosin). 
Antibiotics 
Beta Lactam Medicines 
Amoxicillin, Amoxicillin + clavulanic acid, Ampicillin, Benyathine benzylpenicillin, Benzylpenicillin, Cefalexin, 
Cefazolin, Ceftriaxone, Cloxacillin, Phenoxymethylpenicillin, Procaine benzylpenicillin, Cefotaxime, Ceftazidime, 
Imipenem + cilastatin. 
Other antibacterials 
Azithromycin, Chloramphenicol, Ciprofloxacin, Doxycycline, Erythromycin, Nitrofurantoin, Spectinomycin, 
Sulfamethoxazole + trimethoprim, Clindamycin, Vancomycin. 
Thiazolidinediones 
Rosiglitazone, Pioglitazone, Troglitazone. 
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Liver enzyme inducing drugs 
Barbiturates, Carbamazepine, Phenytoin, Primidone, Ritonavir, Sulfinpyrazone, St. John’s wort. 
β-blockers 
Acebutolol (Acebutolol), Atenolol (Atenolol), Azarga (Brinzolamide, Timolol), Beta-Adalat (Atenolol, 
Nifedipine), Beta-Cardone (Sotalol), Betagan (Levobunolol), Celectol (Celiprolol), Celiprolol (Celiprolol), 
Combigan (Brimonidine, Timolol), Corgard (Nadolol), Cosopt (Dorzolamide, Timolol), Co-tenidone (Co-
tenidone), DuoTrav (Timolol, Travoprost), Emcor (Bisoprolol), Eucardic (Carvedilol)Ganfort (Bimatoprost, 
Timolol), Inderal Injection (Propranolol), Inderal LA (Propranolol), Kalten (Amiloride, Atenolol, 
Hydrochlorothiazide), Labetalol (Labetalol), Levobunolol, Lopresor (Metoprolol), Metoprolol (Metoprolol), 
Nebilet (Nebivolol), Nyogel (Timolol), Prestim (Bendroflumethiazide, Timolol maleate), Propranolol 
(Propranolol), Sectral (Acebutolol), Slow-Trasicor (Oxprenolol), Sotacor (Sotalol), Syprol (Propranolol), Tenif 
(Atenolol, Nifedipine), Tenoret 50 (Atenolol, Chlortalidone, Co-tenidone), Tenoretic (Atenolol, Chlortalidone, 
Co-tenidone), Tenormin (Atenolol), Teoptic (Carteolol), Timolol (Timolol), Timoptol-LA (Timolol), Trandate 
(Labetalol), Trasicor (Oxprenolol), Trasidrex (Co-prenozide, Cyclopenthiazide, Oxprenolol), Viskaldix 
(Clopamide, Pindolol), Visken (Pindolol), Xalacom (Latanoprost, Timolol maleate). 
ACE Inhibitors 
Accupro (Quinapril), Accuretic (Hydrochlorothiazide, Quinapril), Capoten (Captopril), Capozide (Captopril, Co-
zidocapt, Hydrochlorothiazide), Captopril (Captopril), Carace 10 Plus (Hydrochlorothiazide, Lisinopril), Coversyl 
Arginine (Perindopril), Coversyl Arginine Plus (Indapamide, Perindopril), Enalapril (Enalapril), Enalapril + 
hydrochlorothiazide (Enalapril, Hydrochlorothiazide), Fosinopril (Fosinopril), Gopten (Trandolapril), Innovace 
(Enalapril), Innozide (Enalapril, Hydrochlorothiazide), Lisinopril (Lisinopril), Lisinopril + hydrochlorothiazide 
(Hydrochlorothiazide, Lisinopril), Perdix (Moexipril), Perindopril (Perindopril), Quinapril (Quinapril), Ramipril 
(Ramipril), Tanatril (Imidapril), Tarka (Trandolapril, Verapamil), Triapin (Felodipine, Ramipril), Tritace (Ramipril), 
Vascace (Cilazapril), Zestoretic 20 (Hydrochlorothiazide, Lisinopril), Zestril (Lisinopril). 
Lipid lowering medication 
Statins 
Lescol XL (Fluvastatin), Lipitor (Atorvastatin), Lipostat (Pravastatin), Pravastatin (Pravastatin), Crestor 
(Rosuvastatin), Fluvastatin, Simvastatin (Simvastatin), Zocor (Simvastatin). 
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Annex 2 – Dietary Restrictions 
 
All participants partaking in the dietary intervention assessments in the trial were provided with the 
following guidelines on dietary restrictions. Adherence to these restrictions was subsequently 
checked at the beginning of the assessment visit. 
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Annex 3 – Pre-assessment health check, 24 hour diet recall 
and restriction adherence checks 
 
 
 
 
 180 | P a g e  
 
 
 
 
 
 
 
 
 181 | P a g e  
 
 
 
 
 
 
 
 
 182 | P a g e  
 
 
 
 
 
 
 
 
 183 | P a g e  
 
Annex 4 - Supplementary Data 
 
Plasma fatty acids as % of total lipid weight at baseline and in response to treatment 
 
Table A) Plasma fatty acids from total lipids (% weight) at baseline and in response to treatment. Data is presented as 
mean±SEM. 1Indicates significant effect for time by Repeated Measures Anova, 2Indicates significant effect for treatment 
by Repeated Measures Anova, 3Indicates significant effect for time*treatment effect by Repeated Measures Anova.* 
indicates a significant difference in change from baseline when compared to control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fatty 
acid 
Control meal 
(0h) 
Control meal 
(4h) 
EPA meal 
(0h) 
EPA meal 
(4h) 
DHA meal 
(0h) 
DHA meal 
(4h) 
16:0 23.33±0.48 23.63±0.37 23.07±0.39 23.24±0.30 23.21±0.42 23.08±0.37 
16:12 2.09±0.10 1.85±0.09 2.27±0.14 1.99±0.12 2.05±0.10 1.86±0.09 
18:0 7.45±0.17 7.46±0.19 7.39±0.18 7.07±0.13 7.59±0.23 7.19±0.17 
18:1 24.94±0.50 25.57±0.52 25.61±0.47 25.56±0.44 25.53±0.34 25.57±0.34 
18:2n6 26.43±0.47 26.00±0.66 25.73±0.62 25.31±0.52 25.76±0.62 25.30±0.59 
18:3n32 0.66±0.04 0.75±0.03 0.59±0.04 0.74±0.03 0.70±0.06 0.76±0.04 
18:3n6 0.51±0.05 0.46±0.05 0.45±0.04 0.48±0.04 0.53±0.05 0.45±0.04 
20:3n62 1.58±0.06 1.47±0.06 1.68±0.07 1.56±0.05 1.57±0.05 1.46±0.05 
20:4n62 6.54±0.30 6.09±0.31 6.44±0.27 6.17±0.22 6.33±0.25 6.01±0.19 
20:5n3123 0.78±0.05 0.86±0.11 0.87±0.07 2.03±0.19* 0.90±0.06 1.23±0.03 
22:5n3 0.27±0.03 0.26±0.03 0.27±0.03 0.20±0.03 0.23±0.03 0.24±0.03 
22:6n3123 1.61±0.08 1.65±0.10 1.68±0.07 1.92±0.08 1.70±0.0 2.90±0.16* 
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Figure b. Representative calibration curve for nitrite analysis. 
 
Figure c. Standard curve for H2S quantification via SDB derivatisation. 
 
 
 
 
y = 1.405x
R² = 0.9932
0
20
40
60
80
100
120
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0
N
it
ri
te
 c
o
n
ce
n
tr
at
io
n
 (
in
 n
M
)
AUC
R² = 0.9937
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0 1000 2000 3000 4000 5000 6000 7000
Fl
u
o
re
se
n
ce
 (
A
U
C
)
H2S concentration (in nM)
